

Tobacco: preventing uptake, promoting quitting and treating dependence: update

[K] Evidence review for cessation and harm reduction treatments

NICE guideline <number>

Evidence reviews underpinning recommendations 1.12.1 to 1.12.6, 1.12.13 to 1.12.17, 1.14.19, 1.22.1 to 1.22.2, 1.22.14, and research recommendations in the NICE guideline

June 2021

Draft for Consultation

*These evidence reviews were developed
by PH-IGD*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2021. All rights reserved. Subject to [Notice of rights](#).

ISBN:

Contents

Cessation and harm reduction treatments	5
Review questions	5
Smoking cessation treatments.....	6
Review question	6
Introduction	6
PICO table.....	6
Methods and process	8
Identification of public health evidence	10
Summary of public health studies included in the evidence review	11
Economic evidence	24
Summary of studies included in the economic evidence review.....	25
Economic model.....	58
Summary of the evidence	74
Harm reduction treatments.....	84
Review question	84
Introduction	84
PICO table.....	84
Methods and process	85
Identification of public health evidence	86
Summary of public health studies included in the evidence review	86
Economic evidence	86
Economic model.....	87
Summary of the evidence	87
The committee's discussion of the evidence.....	87
Review questions	87
Overall discussion of evidence across multiple reviews.....	96
Recommendations supported by this evidence review	99
References for cessation and harm reduction treatments	100

1 Cessation and harm reduction treatments

2 Review questions

- 3 This evidence report covers one review question with subsections.
- 4 What are the most effective and cost effective means of smoking cessation (including e-
- 5 cigarettes^a)?
 - 6 i. Are e-cigarettes effective for cessation at 1-<6 months compared with e-cigarettes
 - 7 without nicotine (hereafter 'placebo e-cigarettes'), usual care or NRT?
- 8 Are e-cigarettes effective and cost effective for smoking harm reduction?

^a E-cigarettes refer throughout to any type of e-cigarette which contains nicotine unless stated otherwise.

1 Smoking cessation treatments

2 Review question

- 3 What are the most effective and cost effective means of smoking cessation (including e-
4 cigarettes^b)?
- 5 i. Are e-cigarettes effective for cessation at 1-<6 months compared with e-cigarettes
6 without nicotine ('placebo e-cigarettes'), usual care or NRT?

7 Introduction

- 8 Electronic cigarettes (e-cigarettes) are a relatively new technology. Commonly used
9 pharmacotherapies for cessation include NRT, varenicline and bupropion. The relative
10 effectiveness of these treatments compared with e-cigarettes is unclear and may affect
11 patient choice.
- 12 The main aim of this review is to establish which interventions are the most effective and cost
13 effective for cessation at 6 months. The review will also separately consider the effectiveness
14 of e-cigarettes for shorter term cessation (1-<6 months; question 1a.i.) to compare with the
15 longer term results.
- 16 A Network Meta-Analysis (NMA) conducted by Thomas 2020^c has been used for part of this
17 review in order to provide information on relative effectiveness of smoking cessation
18 treatments. This will allow judgements to be made about which treatments are likely to be
19 most effective. The version of Thomas (2020) that was considered by the NICE guideline
20 committee was based on a draft version of the manuscript dated July 2019. That version is
21 yet to undergo a full peer and editorial review process in line with the NIHR Journals Library
22 Policy.
- 23 Behavioural interventions are not the focus of this review question, which considers
24 pharmacological treatments, NRT and e-cigarettes. Behavioural intervention-only arms were
25 classed as "no drug treatment", along with arms where no intervention was given. Therefore
26 the "no drug treatment" class represents a variety of different situations. There are also no
27 "drug + behavioural intervention" nodes in the NMA, as the additive effect of behavioural
28 interventions are not under investigation.
- 29 For most included studies, behavioural interventions are equal across arms with the only
30 difference being the drug intervention. However, some studies investigated behavioural plus
31 drug intervention vs no intervention. In these cases, the effect of the drug + behavioural
32 intervention is attributed solely to the drug in the NMA

33 PICO table

- 34 The following table summarises the protocol for this review.

^b E-cigarettes refer throughout to any type of e-cigarette which contains nicotine.

^c Kyla H Thomas, Michael N. Dalili, Jose A. Lopez-Lopez, Edna Keeney, David Philipppo, Marcus R Munafo et al. (2020) How do smoking cessation medicines compare with respect to their neuropsychiatric safety: a systematic review, network meta-analysis and cost effectiveness analysis. Health Technology Assessment 2020; in review.

1 **Table 1: PICO inclusion criteria**

Criteria	Detail
Population	Anyone aged 18 and over who smokes and wants to stop smoking. Excluded: People who do not smoke Pregnant and breastfeeding women People aged 17 and under People who want to stop using smokeless tobacco but not smoking.
Interventions	Relative effectiveness: Elements to be included in the NMA: • Varenicline • Bupropion • NRT single mode (use of either long-acting or short-acting NRT only) • NRT multi-mode (use of both a long-acting and short-acting NRT) • E-cigarettes (containing nicotine) • No intervention or usual care • E-cigarettes without nicotine ("placebo e-cigarettes"). These may be used as monotherapy or in combination with each other or with behavioural support. Short follow-up: E-cigarettes
Comparator	Relative effectiveness: Other interventions in the NMA Short follow-up: Placebo e-cigarettes, usual care, NRT. Excluded: Therapies not licensed in the UK. Alternative and complementary therapies. Psychotherapies (unless included as co-treatment with an included smoking cessation therapy). Therapies that are either smoked or contain tobacco.
Outcomes	Critical outcomes Cessation: Smoking status at 6 months follow-up. Measured as abstinence from smoking (relative risk). Where continuous abstinence is presented, this is preferred over point-prevalence abstinence. Point prevalence measures will only be used where no continuous measure is reported. Only biochemically validated measures will be accepted (i.e. saliva cotinine / carbon monoxide validation). Important outcomes • Adverse or unintended (positive or negative) effects of e-cigarettes when used for cessation or harm reduction at any time point, including: ◦ Adverse effects such as headaches, nausea, throat irritation or dry mouth.

Criteria	Detail
	Health-related quality of life of using e-cigarettes for cessation or harm reduction (using validated patient-report measures, for example EQ-5D).

1 NMA: Network Meta-Analysis, NRT: Nicotine Replacement Therapy

2 For full details see the clinical review protocol in appendix A.

3 Methods and process

4 This evidence review was developed using the methods and process described in
5 [Developing NICE guidelines: the manual](#). Methods specific to this review question are
6 described in the review protocol in appendix A, and the methods chapter for this guideline.

7 Declarations of interest were recorded according to NICE's 2018 conflicts of interest policy.

8 Included studies and tobacco organisations

9 The following studies included in the NMA had a link to tobacco organisations:

- 10 • Rose (2013): Funded by Philip Morris. Comparing bupropion + NRT long/short vs NRT
11 long/short; varenicline + NRT long/short vs no drug treatment; varenicline + NRT
12 long/short vs bupropion + NRT long/short.
- 13 • Caldwell (2014): Nicotine mouth spray provided by Nicovum. Study was not funded by
14 Nicovum. Comparing NRT long / short vs NRT long & short.

15 The following study included in other parts of this review had a link to tobacco organisations:

- 16 • Cravo (2016) compared the adverse events of e-cigarettes to continued smoking. This
17 study was funded by Fontem ventures.

18 Protocol deviations

19 A deviation from protocol has been made. The protocol stated that where biochemically
20 validated measures were available, these would be preferred to self-reported measures.
21 Self-reported measures would only be used where no validated measure is reported. This
22 review will now exclude self-reported measures of smoking and only use validated
23 measures. This is because self-report may show an underestimation in smoking prevalence
24 and also an overestimation of abstinence due to reporting bias. While self-report measures
25 have been accepted in some other reviews in this guideline due to paucity of data, this
26 review contains a large number of studies, and so the restriction is judged to be reasonable.
27 In addition, the work being undertaken by Thomas (2020) includes only studies with validated
28 outcomes.

29 The NMA undertaken by Thomas (2020) investigated several different cessation outcomes.
30 The cessation outcome that the committee decided to use for this review was *all bioverified
31 abstinence*, defined as bioverified abstinence by any definition reported at 6 months. Where
32 studies reported more than one cessation outcome, continuous/sustained abstinence was
33 preferred, followed by prolonged abstinence, 30-day PPA, 7-day PPA and any other
34 abstinence. This outcome was chosen as it balanced making good use of data by including a
35 large number of studies with rigour by preferencing types of cessation known to be more
36 robust. As this does not necessarily use the longest available follow up reported by the study,
37 this is also a deviation from the protocol.

38 Risk of bias

- 39 • This review addresses an intervention question. Only randomised studies are eligible for
40 inclusion in this review. Question 1a.i of this review was conducted by NICE. The

evidence, which was all randomised, was assessed using the Cochrane Risk of Bias 2.0 tool, according to the NICE Manual.

- The part of this review conducted by Thomas (2020) (relative effectiveness, adverse events) used *Cochrane Risk of Bias (ROB) tool*, rather than the *Cochrane ROB 2.0 tool* recommended by NICE. As such, assessments of overall risk of bias of studies in this review were revised to align with judgments that would be derived from the use of the preferred tool as follows:
 - High risk of bias: The Cochrane ROB checklist contains a judgement for high risk of bias in at least one domain, or unclear risk for multiple domains in a way that substantially lowers confidence in the result.
 - Some concerns: The Cochrane ROB checklist contains a judgement for unclear risk in at least two domains, but not to be at high risk of bias for any domain.
 - Low risk of bias: The Cochrane ROB checklist contains no judgements of high risk of bias for any domain and is at unclear risk of bias in no more than one domain.
 - All GRADE ratings start at 'high' and are downgraded as appropriate.
 - Assessments for Risk of Bias in GRADE were drawn from the RoB tool assessment.
- See appendix F for full GRADE tables.
- See Methods document for details of rationale for GRADE judgements.

Classes of intervention

Interventions were grouped into classes as selected by the committee:

- E-cigarettes: any e-cigarette device which includes nicotine
- Long-acting or short-acting NRT: use of either long- or short-acting NRT. Long-acting NRT is made up of patches. Short-acting NRT is made up of gum, nasal spray, mouth spray, lozenge, sublingual tablet or inhalator.
- Long-acting and short-acting NRT: contemporaneous use of long- and short-acting modes of NRT in one treatment period.
- Varenicline: a single intervention class, as NICE guideline recommendations do not differentiate by dosage.
- Bupropion: a single intervention class, as NICE guideline recommendations do not differentiate by dosage.
- Placebo: placebo version of the active intervention.
- No drug treatment: arms where no intervention was given, or arms with counselling or behavioural intervention only.
- Waitlist: participants waiting for treatment.
- Usual care: as described by the paper. This could be various treatments dependent on what the usual care in the context involves and so will encompass a range of care.
- Combination treatments:
 - Combinations of two or more included interventions were also eligible (for example, e-cigarettes + NRT long/short). Not every possible combination appears in the results, as some were not investigated by any studies.

Subgroup analysis

Data was sufficient for subgroup analysis according to mental illness, as stated in the protocol.

After analysing all studies together (see the full NMA results, Appendix J), studies of people with mental illness were identified. For pairwise analysis (see forest plots in Appendix E), the full forest plots are subgrouped by mental health studies and studies of the general population. The exception to this is where the main analysis and the mental health

1 populations analysis required two different models (random effects and fixed effects). In this
2 case the two are presented in separate forest plots with the relevant model applied.

3 Minimal Important Differences (MIDs)

4 The following MIDs were applied to the outcomes in this review.

5 **Table 2: Minimal Important Differences (MIDs) agreed**

Outcome	Importance	MID
Abstinence from smoking	Critical	Statistical significance
Adverse events of mortality	Important	Statistical significance
All other adverse events	Important	Default (RR 0.8-1.25)
Health-related quality of life (HRQoL) measures	Important	Published MIDs if available for individual measure, otherwise default.

6 Identification of public health evidence

7 Included studies

8 Section 1a of this review is made up of two separate parts:

- 9 1. relative effectiveness of treatments for cessation at 6 month follow-up
- 10 2. effectiveness of e-cigarettes for cessation at shorter follow-up of more than 1 month but
- 11 less than 6 months.

12 *Relative effectiveness at 6 month follow-up*

13 The studies identified for inclusion in the Thomas (2020) NMA and which reported the
14 outcome of interest (abstinence) were considered (n = 197). Studies investigating cessation
15 from smokeless tobacco (n = 9) were removed. A total of 188 RCTs from Thomas (2020)
16 were included. Of these, 13 were in populations with mental health conditions and so were
17 included in the subgroup analysis. Rerun searches were carried out in November 2019.
18 1,137 items were identified. Twenty-six were requested for full-paper assessment. Four met
19 the inclusion criteria for the NMA (none were in populations with mental health conditions).
20 Additional rerun searches were carried out in July 2020. 1,382 articles were identified. Three
21 studies were requested for full-paper assessment, none of these met the inclusion criteria for
22 this review. A total of 192 studies were therefore included in the overall NMA for this review.

23 The NICE surveillance review for the Tobacco Update was checked. Four systematic reviews
24 were consulted to check lists of included studies. Two studies were identified which matched
25 the inclusion criteria (Bullen 2013, Caponnetto 2013) – these were already included in the
26 Thomas (2020) NMA. A study which was ongoing at the time of the surveillance review
27 (Hajek 2019) was not included by the Thomas (2020) study because it did not report
28 bioverified abstinence at 6 months.

29 *Adverse events*

30 Nine RCTs were identified which provided data on adverse events of e-cigarettes compared
31 to any of the interventions included in the NMA. The only comparisons used in the studies
32 were NRT, placebo e-cigarette, and no drug treatment (definitions as per the above section
33 on 'classes of intervention'). Rerun searches were not conducted for this part of the review
34 because the committee did not believe there to be substantial new evidence that would
35 change the current results.

1 **Relative effectiveness at short follow-up**

2 Thomas (2020) identified 814 papers for inclusion in their wider review. Follow-up length was
3 not a criterion for exclusion from this list, and so any studies investigating the relative
4 effectiveness of e-cigarettes at 1-6 months follow-up would be included in this list. The full list
5 of 814 papers was obtained and sifted at title and abstract stage. 13 papers from this search
6 with potential to answer this review question were ordered for full-text review. Six studies met
7 the inclusion criteria for this review.

8 The surveillance review for the Tobacco Update was also consulted. References were
9 searched alongside the sift of the Thomas (2020) studies. One ongoing study – now
10 published – identified in the surveillance review had already been identified.

11 Of the six studies meeting the inclusion criteria for this section of the review, two were also
12 included in the NMA. Three were not included in the NMA due to follow-up times of less than
13 6 months, and one due to not measuring bioverified abstinence at 6 months. All six are
14 RCTs, as specified in the review protocol. Only effectiveness data was used from these
15 papers, as adverse event data from the Thomas (2020) review – which includes these
16 studies and studies with longer follow-up – was used to assess adverse events of e-
17 cigarettes. Rerun searches were not conducted for this part of the review because the
18 committee did not believe there to be substantial new evidence that would change the
19 current results.

20 **Excluded studies**

21 Studies excluded from the review and reasons for their exclusion are provided in appendix G
22 for the short follow-up outcome, and for rerun searches.

23 **Summary of public health studies included in the evidence review**

24 **Relative effectiveness at 6 months**

25 192 studies were included for the NMA for cessation at 6 months (see [references](#)), with a
26 total sample size of 92,067. Studies reported on ten active treatments (see Table 3) in
27 addition to placebo, waiting list, usual care, and no drug treatment arms. Numbers of studies
28 investigating each intervention or intervention combination are recorded below:

29 **Table 3: Number of studies investigating each intervention or intervention**
30 **combination in the NMA**

Intervention	Number of studies investigating this intervention
NRT long/short acting	116 Ahluwalia 2006 Andrews 2016 Anthenelli 2016A Anthenelli 2016B Areechon 1988 Aubin 2008 Baker 2006 Baker 2016 Baldassarri 2018 Binnie 2007 Blondal 1997 Blondal 1999 Bullen 2013 Caldwell 2014

Intervention	Number of studies investigating this intervention
	Caldwell 2016 Chan 2011 Cinciripini 1996 Cooney 2007 Cooney 2009 Cooper 2005 Cooperman 2017 Covey 2007 Cummins 2016 Cunningham 2016 Daughton 1991 Daughton 1998 Daughton 1999/TNSG 1991 Dautzenberg 2001 De Dios 2012 Ehram 1991 Evins 2007 Fagerstrom 1982 FernandezArias 2014 Fiore 1994A Fiore 1994B George 2008 Gifford 2004 Glavas 2003B GlaxoSmithKline 2009 Glover 2002 Gourlay 1995 Gross 1995 Hall 1985 Hall 1987 Hall 2006 Hanioka 2010 Harackiewicz 1988 Hays 1999 Herrera 1995 Heydari 2012 Hjalmarson 1984 Hjalmarson 1994 Hjalmarson 1997 Horst 2005 Hughes 1999 Hughes 2003 Hurt 1990 Jamrozik 1984 Jensen 1991 Jorenby 1999 Kalman 2006 Kalman 2011 Killen 1997 Killen 1999 Kornitzer 1995

Intervention	Number of studies investigating this intervention
	Leischow 1996
	Lerman 2004
	Lerman 2015
	Lewis 1998
	Llivina 1988
	Malcolm 1980
	Mori 1992
	Nakamura 1990
	Niaura 1994
	Niaura 1999
	Nides 2018
	Okuyemi 2007
	Perng 1998
	Piper 2009
	Pirie 1992
	Puska 1995
	QuilezGarcia 1989
	Ratner 2004
	Reid 2008
	Richmond 1993
	Richmond 1994
	Rohsenow 2017
	Rose 2013
	Sachs 1993
	Schneider 1983A
	Schneider 1983B
	Schneider 1995
	Schneider 1996
	Schnoll 2010
	Schnoll 2010A
	Schnoll 2010B
	Segnan 1991
	SelmaBozkurtZincir 2013
	Sharma 2018
	Shiffman 2009
	Shiffman 2019
	Stapleton 1995
	Steinberg 2009
	Sutherland 1992
	Swanson 2003
	Tonnesen 1993
	Tonnesen 1999
	Tonnesen 2000
	Tonnesen 2006
	Tønnesen 2012
	Tulloch 2016
	Uyar 2007
	Vial 2002
	Wallstrom 2000
	Westman 1993
	Wong 1999

Intervention	Number of studies investigating this intervention
NRT long&short acting	12 Blondal 1999 Bonevski 2018 Caldwell 2014 Caldwell 2016 Cooney 2009 Hand 2002 Heydari 2013 Joseph 2004 Kornitzer 1995 Puska 1995 Stein 2013 Stockings 2014
Bupropion	44 Ahluwalia 2002 Anthenelli 2016A Anthenelli 2016B Aryanpur 2016 Aubin 2004 Cinciripini 2013 Collins 2004 Covey 2007 Cox 2012 Dalsgarð 2004 Eisenberg 2013 Evins 2001 Evins 2005 Ferry 1992 Fossati 2007 Gonzales 2001 Gonzales 2006 Haggsträm 2006 Hall 2002 Hall 2011 Hatsukami 2004 Hertzberg 2001 Holt 2005 Jorenby 1999 Levine 2010 McCarthy 2008 Myles 2004 Nides 2006 Piper 2007 Piper 2009 Schmitz 2007 SelmaBozkurtZincir 2013 Siddiqi 2013 Simon 2009 SMK20001 Swanson 2003 Tashkin 2001

Intervention	Number of studies investigating this intervention
	Tonnesen 2003 Tonstad 2003 Uyar 2007 Wagena 2005 Zellweger 2005 Zernig 2008 ZYB40005
Varenicline	41 Anthenelli 2013 Anthenelli 2016A Anthenelli 2016B Ashara 2019 Aubin 2008 Baker 2016 Bolliger 2011 Carson 2014 Chengappa 2014 Cinciripini 2013 Cinciripini 2018 De Dios 2012 Dogar 2018 Ebbert 2014 Ebbert 2015 Ebbert 2017 Eisenberg 2016 Gonzales 2006 Gonzales 2014 Heydari 2012 Hughes 2011 Koegelenberg 2014 Lerman 2015 Nahvi 2014 Nakamura 2007 Niaura 2008 Nides 2006 Ramon 2014 Rennard 2012 Rigotti 2010 Rohsenow 2017 SelmaBozkurtZincir 2013 Stein 2013 Steinberg 2011 Tashkin 2011 Tonstad 2006 Tsai 2007 Tulloch 2016 Wang 2009 Westergaard 2015 Williams 2012
E-cigarette	4 Bullen 2013

Intervention	Number of studies investigating this intervention
	Caponnetto 2013 Halpern 2018 Holliday 2019
Bupropion + NRT long/short acting	10 Covey 2007 George 2008 Jorenby 1999 Kalman 2011 Piper 2007 Piper 2009 Rose 2013 Schnoll 2010 Swanson 2003 Winhusen 2014
Bupropion + NRT long&short acting	2 Evins 2007 Steinberg 2009
Varenicline + NRT long/short acting	3 Koegelenberg 2014 Ramon 2014 Rose 2013
Varenicline + bupropion	2 Cinciripini 2018 Ebbert 2014
E-cigarette + NRT long/short acting	2 Baldassarri 2018 Walker 2019

1 Possible intervention combinations where there were no studies identified:

- 2 • E-cigarette + NRT long&short acting
- 3 • E-cigarette + bupropion
- 4 • E-cigarette + varenicline
- 5 • Varenicline + NRT long&short acting
- 6 • Any combination of three treatments

7 Although nine studies were identified which reported on adverse events of e-cigarettes, only

8 four of these met the inclusion criteria for the NMA, due to having shorter follow-up than 6

9 months.

10 **Risk of bias**

11 Of the studies included in the NMA, 44 were judged to be at low risk of bias. There were

12 some concerns about 89 studies, and 59 studies were at high risk of bias:

Low risk	Some concerns	High risk
Ahluwalia 2002	Blondal 1997	Andrews 2016
Ahluwalia 2006	Carson 2014	Areechon 1988
Anthenelli 2013	Chengappa 2014	Aryanpur 2016
Anthenelli 2016A	Cinciripini 1996	Aubin 2008
Anthenelli 2016B	Cinciripini 2013	Baker 2006
Ashara 2019	Collins 2004	Baker 2016
Aubin 2004	Cooper 2005	Baldassarri 2018

Low risk	Some concerns	High risk
Blondal 1999	Cox 2012	Binnie 2007
Bolliger 2011	Dalsgarð 2004	Bonevski 2018
Bullen 2013	Daughton 1991	Caldwell 2014
Caldwell 2016	Daughton 1998	Chan 2011
Campbell 1983	Daughton 1999/TNSG 1991	Cooney 2007
Caponnetto 2013	Dautzenberg 2001	Cooperman 2017
Cinciripini 2018	Ehrsam 1991	Covey 2007
Cooney 2009	Eisenberg 2013	Cummins 2016
Dogar 2018	Eisenberg 2016	Cunningham 2016
Ebbert 2014	Evins 2001	Ebbert 2017
Ebbert 2015	Evins 2005	FernandezArias 2014
Glover 2002	Evins 2007	Gifford 2004
Gonzales 2006	Fagerstrom 1982	Gross 1995
Hays 1999	Ferry 1992	Hall 1985
Hjalmarson 1997	Fiore 1994A	Hall 2002
Kornitzer 1995	Fiore 1994B	Hall 2006
Lerman 2004	Fossati 2007	Halpern 2018
Lewis 1998	De Dios 2012	Hand 2002
McCarthy 2008	George 2008	Harackiewicz 1988
Myles 2004	Glavas 2003B	Hatsukami 2004
Nahvi 2014	GlaxoSmithKline 2009	Hertzberg 2001
Piper 2007	Gonzales 2001	Heydari 2012
Ramon 2014	Gonzales 2014	Heydari 2013
Rennard 2012	Gourlay 1995	Holliday 2019
Rigotti 2010	Haggsträm 2006	Holt 2005
Schneider 1996	Hall 1987	Horst 2005
Schnoll 2010A	Hall 2011	Hughes 1999
Segnan 1991	Hanioka 2010	Jensen 1991
Shiffman 2019	Herrera 1995	Joseph 2004
Simon 2009	Hjalmarson 1984	Leischow 1996
Stapleton 1995	Hjalmarson 1994	Levine 2010
Steinberg 2011	Hughes 2003	Llivina 1988
Tonnesen 1993	Hughes 2011	Nakamura 1990
Tonnesen 1999	Hurt 1990	Nakamura 2007
Tønnesen 2012	Jamrozik 1984	Okuyemi 2007
Tonstad 2006	Jorenby 1999	Ratner 2004
Walker 2019	Kalman 2006	Reid 2008
	Kalman 2011	Richmond 1993
	Killen 1990	Schnoll 2010B
	Killen 1997	SelmaBozkurtZincir 2013
	Killen 1999	Sharma 2018
	Koegelenberg 2014	Siddiqi 2013
	Lerman 2015	Steinberg 2009
	Malcolm 1980	Stockings 2014
	Mori 1992	Swanson 2003
	Niaura 1994	Tulloch 2016
	Niaura 1999	Uyar 2007
	Niaura 2008	Vial 2002
	Nides 2006	Winhusen 2014
	Nides 2018	Wong 1999
	Perng 1998	Zernig 2008

Low risk	Some concerns	High risk
	Piper 2009 Pirie 1992 Puska 1995 QuilezGarcia 1989 Richmond 1994 Rohsenow 2017 Rose 2013 Sachs 1993 Schmitz 2007 Schneider 1983A Schneider 1983B Schneider 1995 Schnoll 2010 Shiffman 2009 SMK20001 Stein 2013 Sutherland 1992 Tashkin 2001 Tashkin 2011 Tonnesen 2000 Tonnesen 2003 Tonnesen 2006 Tonstad 2003 Tsai 2007 Wagena 2005 Wallstrom 2000 Wang 2009 Westergaard 2015 Westman 1993 Williams 2012 Zellweger 2005	ZYB40005

1 **Table 4: Risk of bias in studies included in the NMA, by sources of bias**

Source of bias	High risk	Some concerns	Low risk
Selection bias (random sequence generation)	1	89	102
Selection bias (allocation concealment)	4	102	85
Performance bias (participant and treatment administrator blinding)	43	73	76
Detection bias (blinding of outcome assessors)	18	84	90
Attrition bias (incomplete outcome data)	17	57	118
Reporting bias (selective reporting)	2	37	153
Other biases (adherence issues, lack of validation)	3	10	179

2

1 Of the studies included, 44 were judged to be at low risk of bias. There were some concerns
 2 about 89 studies, mainly due to unclear reporting on several the risk of bias domains. Fifty-
 3 nine studies were at high risk of bias for the outcome of cessation, due to being at high risk
 4 of bias in one or more of the domains (random sequence generation, allocation concealment,
 5 blinding of participants / personnel, blinding of outcome assessor, incomplete outcome data,
 6 selective reporting).

7 Adverse events

8 The Thomas (2020) group also conducted an NMA for serious adverse events, which
 9 included observational data. This is not included in the protocol for this review.

10 The randomised controlled trials included in this review investigated adverse events of e-
 11 cigarettes compared with any other included intervention at any time point. See table 4 for
 12 more detail. The studies reported results are reported as number of participants, not number
 13 of events.

14 **Table 5: Summary of adverse event data**

Adverse event	Studies reporting	E-cigarettes are compared with:
Abnormal Dreams	n = 3 Baldassarri 2018 Cravo 2016 Tseng 2016	• No drug treatment • NRT • Placebo e-cigarette
Anxiety	n = 2 Baldassarri 2018 Cravo 2016	• No drug treatment • NRT
Arrhythmia	n = 1 Cravo 2016	• No drug treatment
Cardiovascular Death	n = 3 Bullen 2013 Hajek 2019 Tseng 2016	• NRT • Placebo e-cigarette
Chronic Obstructive Pulmonary Disease (COPD)	n = 1 Bullen 2013	• NRT • Placebo e-cigarette
Death (All Causes)	n = 4 Bullen 2013 Cravo 2016 Hajek 2019 Tseng 2016	• No drug treatment • NRT • Placebo e-cigarette
Depression	n = 1 Hajek 2019	• NRT
Discontinued Treatment due to Adverse Events (AEs)	n = 2 Carpenter 2017 Tseng 2016	• No drug treatment • Placebo e-cigarette
Dry Mouth	n = 1 Cravo 2016	• No drug treatment
Fatal Stroke	n = 1 Tseng 2016	• Placebo e-cigarette
Fatigue	n = 3 Baldassarri 2018	• No drug treatment • NRT

Adverse event	Studies reporting	E-cigarettes are compared with:
	Cravo 2016 Tseng 2016	• Placebo e-cigarette
Headache	n = 7 Baldassarri 2018 Carpenter 2017 Cravo 2016 Hajek 2019 Lee 2018 Masiero 2018 Tseng 2016	• No drug treatment • NRT • Placebo e-cigarette
Hospitalisation	n = 2 Bullen 2013 Hajek 2019	• NRT • Placebo e-cigarette
Insomnia	n = 4 Baldassarri 2018 Cravo 2016 Masiero 2018 Tseng 2016	• No drug treatment • NRT • Placebo e-cigarette
Irritability	n = 1 Cravo 2016	• No drug treatment
Nausea	n = 7 Baldassarri 2018 Carpenter 2017 Cravo 2016 Hajek 2019 Lee 2018 Masiero 2018 Tseng 2016	• No drug treatment • NRT • Placebo e-cigarette
Non-fatal Myocardial Infarction (MI)	n = 2 Bullen 2013 Hajek 2019	• NRT • Placebo e-cigarette
Non-fatal Stroke	n = 1 Bullen 2013	• NRT • Placebo e-cigarette
Palpitations	n = 4 Baldassarri 2018 Bullen 2013 Lee 2018 Tseng 2016	• NRT • Placebo e-cigarette
Pruritus	n = 1 Baldassarri 2018	• NRT
Serious Adverse Events	n = 6 Bullen 2013 <i>Caponnetto 2013</i> Cravo 2016 Hajek 2019 <i>Lee 2018</i> <i>Tseng 2016</i>	• No drug treatment • NRT • Placebo e-cigarette
Skin Rash	n = 2 Cravo 2016	• No drug treatment • NRT

Adverse event	Studies reporting	E-cigarettes are compared with:
	Lee 2018	
Sleep Disorders	n = 2 Cravo 2016 Hajek 2019	- No drug treatment - NRT
Suicidal Ideation	n = 1 Hajek 2019	NRT
Transient Ischemic Attack	n = 2 Bullen 2013 Hajek 2019	- NRT - Placebo e-cigarette
Unstable Angina	n = 1 <i>Bullen 2013</i>	- NRT - Placebo e-cigarette
Withdrew from study due to Adverse Event (AE)	n = 3 <i>Carpenter 2017</i> Cravo 2016 <i>Tseng</i>	- No drug treatment - Placebo e-cigarette

1 *Italics denotes 0 events in both arms, therefore not included in analysis*

2 Mental health subgroup – relative effectiveness

3 In addition to the main analysis of the effectiveness of the treatments in the general
4 population, a subgroup analysis was conducted for studies in populations with mental health
5 conditions.

6 Thirteen studies in populations with mental health conditions were identified (see Table 5).
7 These formed a connected network.

8 Possible interventions where there were no studies identified;

- 9 • E-cigarettes
- 10 • Waitlist

11 Of the interventions included, possible combinations where there were no studies identified:

- 12 • NRT long/short acting + varenicline
- 13 • Bupropion + varenicline
- 14 • NRT long & short acting with any other active treatment
- 15 • Any combinations of three treatments

16 **Table 6: Details of mental health studies in subgroup analysis**

Study	Participants studied	Comparisons	Risk of bias
Anthenelli 2013	Smokers with current or past depression (major depressive disorder)	- Varenicline - Placebo	Low risk
Anthenelli 2016B	Smokers with psychiatric disorders	- Varenicline - Bupropion - NRT long / short acting - Placebo	Low risk
Baker 2006	Smokers with a non-acute psychotic disorder	- NRT long / short acting - Usual care	High risk
Chengappa 2014	Smokers with bipolar disorder	- Varenicline - Placebo	Some concerns

Study	Participants studied	Comparisons	Risk of bias
Evins 2001	Smokers with schizophrenia	• Bupropion • Placebo	Some concerns
Evins 2005	Smokers with schizophrenia or schizoaffective disorder depressed type	• Bupropion • Placebo	Some concerns
Evins 2007	Smokers with schizophrenia	• NRT long/short acting • Bupropion + NRT long & short acting	Some concerns
George 2008	Smokers with schizophrenia or schizoaffective disorder	• NRT long/short acting • Bupropion + NRT long / short acting	Some concerns
Hall 2006	Smokers with unipolar depression	• NRT long / short acting • No drug treatment (brief contact control)	High risk
Hertzberg 2001	Male veteran smokers with PTSD	• Placebo • Bupropion	High risk
Horst 2005	Smokers with a diagnosis of schizophrenia or schizoaffective disorder who successfully quit tobacco use after 90 days (open label phase)	• NRT long / short acting • Placebo	High risk
Stockings 2014	Inpatient psychiatric patient smokers	• NRT long & short acting • Usual care	High risk
Williams 2012	Smokers with schizophrenia/schizoaffective disorder	• Varenicline • Placebo	Some concerns

- 1 Sensitivity analysis by risk of bias was not undertaken. This is because Thomas (2020)
- 2 concluded that removing high risk of bias studies from the NMA did not change the results.

3 Relative effectiveness at short follow-up

- 4 Six studies were identified which reported the effectiveness of e-cigarettes for cessation vs.
- 5 comparators defined in the protocol (placebo e-cigarette, usual care, or NRT) at more than
- 6 one but less than 6 months. A brief summary of these studies is in Table 6.

7 Table 7: Summary of e-cigarette studies for short follow-up

Study	Population	Intervention	Comparator	Outcome(s)
Baldassarri 2018	Smokers 18+ years old, 1+ CPD	E-cigarette (second generation) (24mg/ml, 2.4% nicotine), plus NRT patch plus counselling.	Non-nicotine e-cigarette (second generation) plus NRT plus counselling.	Validated smoking abstinence (point prevalence) (eCO ≤6ppm) at 8 weeks.
RCT	40 participants	People smoking 10+CPD received higher dose NRT patch than those smoking ≥10.	8 week duration.	
USA, outpatient smoking clinic				

Study	Population	Intervention	Comparator	Outcome(s)
		8 week duration.		
Bullen 2013 RCT New Zealand, community setting	Smokers 18+, 10+CPD for past year 657 participants	E-cigarette (first generation) (16mg/ml, 1.6% nicotine) plus Quitline referral. 1 week pre-quit date, 12 weeks post-quit date.	1. Non-nicotine e-cigarette (second generation) plus Quitline referral 2. NRT patch (21mg/24hr) plus Quitline referral 1 week pre-quit date, 12 weeks post-quit date.	Validated smoking abstinence (continuous) (eCO ≤10ppm) at 1 month and 3 months.
Hajek 2019 RCT UK, stop smoking services	Adult smokers 886 participants	E-cigarette (second generation) (18mg/ml, 1.8% nicotine) plus behavioural support. 4 weeks behavioural support, e-cig until e-liquid finished.	NRT of choice plus behavioural support. 4 weeks behavioural support, up to 3 months NRT.	Validated smoking abstinence (point prevalence) (eCO <8ppm) at 4 weeks.
Halpern 2018 RCT USA, workplace setting	Employed smokers 18+ 2012 participants	E-cigarette (generation unclear) (10-15mg/ml, 1.0-1.5% nicotine) plus usual workplace care plus text messaging service. 6 months e-cigarette duration.	Usual workplace care plus text messaging service. Unclear duration.	Validated smoking abstinence (continuous) (usual care: cotinine <20ng/ml; e-cig <20ng/ml and if positive, blood carboxyhaemoglobin level <4%) at 1 month and 3 months.
Lee 2018 RCT USA, preoperative clinic [not included in NMA]	Smokers of >2 CPD, presenting to preoperative clinic 30 participants	E-cigarette (first generation) decreasing dose (4.5% to 2.4% to 0%) plus brief counselling, brochure, referral to Quitline. 6 weeks duration.	NRT patch decreasing dose (21mg/day [for smokers of >10CPD] to 14mg/day to 7mg/day to 0mg/day) plus brief counselling, brochure, referral to Quitline. 6 weeks duration.	Validated smoking abstinence (point prevalence) (eCO ≤10ppm) at 8 weeks.
Masiero 2018 RCT	Adults 55+ years, ≥10 CPD for past 10 years	E-cigarette (second generation) (8mg/ml, 0.8%	Non-nicotine e-cigarette (second generation) plus	Validated smoking abstinence (continuous)

Study	Population	Intervention	Comparator	Outcome(s)
Italy, screening programme, outpatient [not included in NMA]	210 participants	nicotine) plus telephone counselling 1 week pre-quit date, 11 weeks post-quit date.	telephone counselling 1 week pre-quit date, 11 weeks post-quit date.	(eCO ≤5ppm) at 3 months.

1 CPD: Cigarettes per day

2 See appendix D for full evidence tables.

3 Studies were combined into meta-analysis for e-cigarettes vs placebo e-cigarette (abstinence at 1-<3 months and 3-<6 months) and for e-cigarettes vs NRT (abstinence at 1-<3 months).
4
5 There were no clear differences between studies in presence of mental illness,
6 cardiovascular disease, COPD, diabetes, heavy smoking (defined as smoking more than 20
7 cigarettes per day [CPD] at baseline), previous quit attempts or the generation of e-cigarette
8 used. Therefore, subgroup analysis was not possible for this section of the review.

9 Sensitivity analysis removing studies at high risk of bias was not able to be conducted for e-
10 cigarettes vs placebo e-cigarette (abstinence at 1-<3 months) despite serious inconsistency
11 because neither study was at high risk of bias.

12 Economic evidence

13 Included studies

14 3576 records were assessed against the eligibility criteria for review question (RQ) 6.1a.

15 3409 records were excluded based on information in the title and abstract for RQ 6.1a. Both
16 reviewers assessed all of the record. The level of agreement between the two reviewers was
17 100%.

18 The full-text papers of 166 documents were retrieved and assessed and 13 studies were
19 assessed as meeting the eligibility criteria for RQ 6.1a. Both reviewers assessed all of the
20 full texts. The level of agreement between the two reviewers was 100%. For RQ 6.1a, 13
21 studies were included.

22 One of the studies included (Li, 2019) was identified by a member of committee. Although
23 the study was published after completion of the cost effectiveness searches it was agreed it
24 should be included because it covered an intervention for which no other cost effectiveness
25 evidence had been identified.

26 Excluded studies

27 154 full text documents were excluded for this question. The documents and the reasons for
28 their exclusion are listed in Appendix G – Excluded studies. Documents were excluded for
29 the following reasons: ineligible study design (n=44), ineligible year (n=36), ineligible
30 intervention (n=29), ineligible outcomes (n=15), ineligible country (n=14), ineligible
31 comparator (n=6), ineligible language (n=4), ineligible patient population (n=4), paper not
32 found (n=1), and ineligible setting (n=1). The selection process is shown in Appendix G.
33

1

2 **Summary of studies included in the economic evidence review**3 **Varenicline interventions**

4

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Annemans 2015 (Belgium) Economic analysis: Cost-utility analysis (CUA) Population: Current smoker willing to quit Population size: 1,000 (hypothetical) Time horizon: Lifetime (100 years or dead) Study aim: To evaluate the cost-effectiveness of re-treatment with varenicline compared with	Minor limitations ^b	Partly applicable ^c	Similar model to Kautianen (2017) but in a Belgium context	Total population costs (€): Not reported Total cost per person (€): Not reported Currency & cost year: EUR (€); 2013	Total population QALYs: Not reported QALYs per person: Not reported % abstinent at 12 months 1st attempt (2nd attempt): Varenicline 21.1% (20.1%) Bupropion 15.7% (15.7%) NRT 14.9% (14.9%) Placebo 9.3% (3.3%)	Incremental costs (total population) (€): 2QA varenicline compared with: 2QA NRT - 275,000 2QA bupropion - 118,000 2QA placebo - 316,000 1QA varenicline - 237,000 Incremental costs per person (€):	Incremental QALYs (total population): 2QA varenicline compared with: 2QA NRT 74 2QA bupropion 63 2QA placebo 193 1QA varenicline 111 Incremental QALYs per person: <u>CALCULATE BY YHEC</u> ^d	Incremental cost per QALY (€): 2QA varenicline dominates all other interventions. This means it is both less costly and results in better health outcomes than each comparator.	Both one-way univariate analyses and probabilistic sensitivity analysis (PSA) were performed. Univariate sensitivity analyses found discount rates, cost of NRT and relative risks of smoking related diseases in long term quitters were the most influential parameters. However, changes to these parameters did not affect the conclusions. PSA indicated that the conclusions are robust. For every treatment

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
other smoking cessation interventions Intervention ^a: 2QA varenicline: 1QA with varenicline followed by varenicline re-treatment in case of failure or relapse Comparators ^a: 2QA NRT: 1QA with NRT followed by NRT re-treatment in case of failure or relapse 2QA bupropion: 1QA with bupropion followed by bupropion re-treatment in case of failure or relapse 2QA placebo: 1QA with placebo followed by placebo re-						<u>CALCULATE D BY YHEC</u> ^d 2QA varenicline compared with: 2QA NRT - 275 2QA bupropion - 118 2QA placebo - 316 1QA varenicline - 237	2QA varenicline compared with: 2QA NRT 0.074 2QA bupropion 0.063 2QA placebo 0.193 1QA varenicline 0.111 Incremental LYs (total population): Compared with 2QA varenicline 2QA NRT 56 2QA bupropion 48 2QA placebo 146		comparison, the PSA results confirmed that varenicline significantly dominated comparators.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
treatment in case of failure or relapse 1QA varenicline: 1QA with varenicline followed by 1QA with placebo							1QA varenicline 84		
Data sources									
Health outcomes: Abstinence rates were derived from Cahill et al. (2013) as well as RCTs. Second line treatment efficacy for NRT and bupropion conservatively used the same value as first line treatment due to lack of evidence. Quality-of-life weights: Utility weights for health states are from published data sources. These are the same as those reported in a previous BENESCO model (Annemans et al., 2009). Cost sources: Hospitalization costs of smoking-related diseases were obtained from the Belgium TCT database Annual follow-up costs were taken from literature. Drug costs were taken from the RIZIV/INAMI database and the CBIP. All cost prior to 2013 were inflated.									
Abbreviations: ICER: Incremental cost-effectiveness ratio; LY: Life years NRT: Nicotine replacement therapy; QA: quit attempt; QALY: Quality-adjusted life year									
a) The length of treatment is not specified within the study. A 12-week treatment length is assumed in line with the cost per intervention.									
b) The model includes all important, and relevant, costs and outcomes. It is assumed that the first and second quit attempts for NRT and bupropion cessation have equal efficacy; however, varying this in PSA did not change the conclusions. The model considers only five smoking related diseases keeping co-morbidities to a minimum. Finally, the impact of possible adverse events is not considered									
c) The interventions considered are relevant to the UK context, but caution is required when transferring the results of the study given the difference in prices and healthcare systems between the UK and Belgium.									
d) Assumed to be incremental costs/QALYS (total population) divided by population size (1000).									

1

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Athanasakis 2012 (Greece) Economic analysis:	Minor limitations ^a	Partly applicable ^b	Similar model to Knight (2012) but in a Greek context	Total population costs (€, thousands): Varenicline (12 weeks)	Total population QALYs: Varenicline (12 weeks) 11,610,664	Incremental costs (total population) (€, thousands):	Incremental QALYs (total population): Varenicline (12 weeks)	Incremental cost per QALY: Varenicline dominates all other	Both probabilistic sensitivity analysis (PSA) and deterministic sensitivity analysis (DSA)

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Cost-utility analysis (CUA) Population: Individuals making a single quit attempt Population size: 819,709 (hypothetical) Time horizon: Lifetime Study aim: To evaluate the cost-effectiveness of a 12-week course of varenicline for smoking cessation Intervention: Varenicline (12 weeks) Comparator(s): Bupropion (12 weeks) NRT (12 weeks)				15,485,564 Bupropion (12 weeks) 15,654,958 NRT (12 weeks) 15,711,867 Unaided cessation 15,883,032 Total cost per person: <u>CALCULATE D BY YHEC^c</u> Varenicline (12 weeks) 18,891 Bupropion (12 weeks) 19,098 NRT (12 weeks) 19,167 Unaided cessation 19,376	Bupropion (12 weeks) 11,582,961 NRT (12 weeks) 11,582,803 Unaided cessation 11,541,803 QALYs per person: <u>CALCULATE D BY YHEC^c</u> Varenicline (12 weeks) 14.2 Bupropion (12 weeks) 14.1 NRT (12 weeks) 14.1 Unaided cessation 14.1 % abstinent at 12 months:	Varenicline (12 weeks) compared with: Bupropion (12 weeks) -169,394 NRT (12 weeks) -226,302 Unaided cessation -397,468 Incremental costs per person (€): <u>CALCULATE D BY YHEC^e</u> ^eVarenicline (12 weeks) compared with: Bupropion (12 weeks) -207 NRT (12 weeks) -276	compared with: Bupropion (12 weeks) 27,703 NRT (12 weeks) 27,861 Unaided cessation 68,861 Incremental QALYs per person: <u>CALCULATE D BY YHEC^e</u> Varenicline (12 weeks) compared with: Bupropion (12 weeks) 0.034 NRT (12 weeks) 0.034 Unaided cessation	interventions and unaided cessation. Cost per additional quitter (strategy costs only) (€): Varenicline vs. bupropion 2,659 Varenicline vs. NRT 1,015	were performed. For an implicit €30,000 threshold, varenicline was cost-effective for 82.3%, 86.6%, and 85.2% of the Monte-Carlo iterations versus bupropion, NRT, and unaided cessation respectively. DSA found utilities after smoking-related events, the discount rate, costs of events, and effectiveness of varenicline to be of significant influence but did not change the conclusions. Varenicline remained dominant in a shorter timeframe of 20 years.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Unaided cessation				Intervention costs per person ^a: NR Currency & cost year: EUR (€); 2011	Varenicline (12 weeks) 22.4% Bupropion (12 weeks) 15.4% NRT (12 weeks) 15.4% Unaided cessation 5%	Unaided cessation -485	0.084		

Data sources

Health outcomes: 1-year quit rates from two head to head RCTs, pooled in analysis by Nides (2008) for varenicline and bupropion. 1-year quit rates for NRT taken from 2 meta-analyses of trials, and for unaided cessation taken from Foulds et al. **Quality-of-life weights:** Utility weights for health states are taken from various published data sources, baseline utilities from Fiscella and Franks. **Cost sources:** Medication cost were taken from the Greek National Formulary, the cost of a physician's visit was based on official social security tariff and healthcare costs are taken from recent economic evaluation in the Greek healthcare setting.

Abbreviations: DSA: Deterministic sensitivity analysis; ICER: Incremental cost- effectiveness ratio; NRT: Nicotine replacement therapy; PSA: Probabilistic sensitivity analysis; QALY: Quality-adjusted life year

- (a) The model includes all important, and relevant, costs and outcomes. Some parameter values are taken from published data sources without detailed methodology on how these were derived.
- (b) The interventions considered are relevant to the UK context, but caution is required when transferring the results of the study given the difference in prices and healthcare systems between the UK and Greece.
- (c) Assumed to be total population costs/QALYS divided by population size (819,709).
- (d) Intervention costs included 12 weeks of medication and the cost of a single physicians visit at the initiation of treatment. These figures were not reported.
- (e) Assumed to be incremental costs/QALYS (total population) divided by population size (819,709).

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Coward 2014 (Canada) Economic analysis: Cost-utility analysis (CUA) Population: Smokers between the age of 18 and 35, who are newly diagnosed with Crohn's disease (CD) and are naïve to antitumor necrosis factor (anti-TNF) ^a Population size: Not reported Time horizon: 5 years Study aim: to evaluate the cost-effectiveness of a 12-week course of varenicline for	Major limitations ^e	Partly applicable ^f	None	Total population costs: Not reported Total cost per person (CAD\$) (95% CI): Varenicline (12 weeks) 55,614 (52,755 – 58,474) NRT + counselling 58,878 (56,050 – 61,706) NRT 59,540 (56,732 – 62,347) Counselling 61,029 (58,246 – 63,812) No program 63,601 (60,865 – 66,337)	Total population QALYs: Not reported QALYs per person (95% CI): Varenicline (12 weeks) 3.70 (3.68 – 3.73) NRT + counselling 3.69 (3.66 – 3.72) NRT 3.69 (3.66 – 3.71) Counselling 3.68 (3.65 – 3.71) No program 3.67 (3.64 – 3.69) % abstinent at 12 months: Varenicline (12 weeks)	Incremental costs per person (CAD\$): <u>CALCULATE D BY YHEC</u> ^g Varenicline (12 weeks) compared with: NRT + counselling - 3,264 NRT - 3,926 Counselling - 5,415 No program - 7,987	Incremental QALYs per person: <u>CALCULATE D BY YHEC</u> ^g Varenicline (12 weeks compared with:) NRT + counselling 0.01 NRT 0.01 Counselling 0.02 No program 0.03	Incremental cost per QALY: Varenicline dominated all other interventions Cost savings (5 years) compared with no program: Varenicline (12 weeks) \$16,116,169 NRT + counselling \$9,530,069 NRT \$8,194,286 Counselling \$5,189,782	Probabilistic sensitivity analysis was conducted to account for variation in effectiveness of smoking cessation programs. Varenicline remained the most cost-effective strategy until its effectiveness was reduced below 17.7%. In addition, a 10% decrease in anti-TNF effectiveness among smokers and a 0.3 decrease in utilities for flares leading to surgery and the health state "surgery" were assessed. The finding did not substantially change results.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
smoking cessation for patients with CD Intervention: Varenicline (12 weeks) Comparator(s): NRT ^b + counselling ^c NRT Counselling No program ^d				Intervention costs per person (CAD\$): Varenicline (12 weeks) 293.33 NRT + counselling 458.58 NRT 267.78 Counselling 190.80 No program 0.00 Currency & cost year: CAD (\$); 2013	27.87% NRT + counselling 18.17% NRT 15.95% Counselling 10.96% No program 3.00%				
Data sources									
Health outcomes: Effectiveness data was taken from published data sources. Quality-of-life weights: Utility estimates were derived from Gregor (1997). Cost sources: Drug costs relating to CD were taken from the Alberta Blue Cross Interactive Drug Benefit List. Drug costs relating to smoking cessation were taken from published data sources. Surgery cost were taken from studies but the studies were not referenced.									
Abbreviations: CD: Crohn's disease; NRT: nicotine replacement therapy; QALY: quality adjusted life years									
a) This is not described by the author. Anti-TNF drugs are used to treat CD. It is assumed to mean a person who has not received an anti-TFN previously.									
b) A nicotine patch is used; however, the dose and length of use is not specified.									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
c)	Individual counselling once a week for six weeks led by a healthcare professional.								
d)	Recommendation to quit smoking without any direct counselling or prescription of smoking cessation medication.								
e)	The study focused on CD population and did not consider long-term health states relating to smoking. Effectiveness data for smoking cessation interventions is taken from multiple source without the use of meta-analysis. Some parameter values are taken from published data sources without detailed methodology on how these were derived. Utilities relating to CD health states were not varied for smokers and non-smokers.								
f)	The interventions considered are relevant to the UK context, but caution is required when transferring the results of the study given the difference in prices and healthcare systems between the UK and Canada.								
g)	Assumed to be costs/QALYS per person for varenicline (12 weeks) subtract comparator costs/QALYs per person.								

1

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Hagen 2010 (Norway)	Minor limitations ^b	Partly applicable ^c	None	Total population costs (kr): Not reported	Total population LYs: Not reported	Incremental costs per person (kr): Compared with placebo	Incremental LYs per person: Compared with placebo	Incremental cost per LY (kr): Compared with placebo	Both one-way and probabilistic sensitivity analysis was conducted. Results are most sensitive to changes in age (20 to 80), the price of varenicline (0 to 2,324), average healthcare expenses per person per year (0 to 60,000) and choice of discount rate (0 to 0.08). However, changes to these parameters will not bring the
Economic analysis: Cost-effectiveness analysis (CEA)				Total cost per person (kr): Varenicline 863,650	LYs per person: Varenicline 14.74	NRT 4,141	NRT 0.02	NRT 207,050	
Population: Current smoker of the Norwegian population				Bupropion 859,706	Bupropion 14.69	Bupropion 5,729	Bupropion 0.09	Bupropion 63,656	
Population size: Not reported				NRT 858,118	NRT 14.62	Varenicline 9,672	Varenicline 0.14	Varenicline 69,086	
Time horizon: Lifetime (100 years or dead)				No treatment 853,977	No treatment 14.60			Net health benefit: Compared with placebo	
				Intervention costs per	Efficacy in relative risks (95%)			Varenicline 0.121	

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Study aim: to evaluate the effectiveness and cost-effectiveness of varenicline, bupropion and nicotine replacement therapy for smoking cessation Intervention ^a: Varenicline Comparators ^a: Bupropion NRT No treatment				person (kr) ^d: Varenicline (105 days) 2,456 Bupropion (56 days) 1,103 NRT (90 days) 3,150 Annual healthcare cost ^e (kr): 45,544 Last year of life 73,306 Currency & cost year: NOK (kr); 2009	CI): NRT vs placebo 1.58 (1.50 – 1.66) Bupropion vs NRT 1.45 (0.50 – 4.18) Varenicline vs bupropion 1.46 (1.18 – 1.81)			Bupropion 0.079 NRT 0.012	ICER above the willingness to pay per life year of NOK 500,000. Probabilistic sensitivity analysis showed varenicline was the optimal choice when willingness to pay per life year was above NOK 116,000.
Data sources									
Health outcomes: Efficacy estimates were taken from a systematic review (no further details as this was in Norwegian). Quality-of-life weights: N/A. Cost sources: Cost data used from published data sources.									
<i>Abbreviations: CI: Confidence interval; ICER: Incremental cost-effectiveness ratio; LY: Life years; NRT: Nicotine replacement therapy; QALY: quality-adjusted life years</i>									
a) The dosage and treatment length for the intervention and comparators is not specified in the study. Length of treatment is specified when calculating costs; however, it is unclear whether the same length of treatment is used when calculating efficacy.									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
b)	The model includes all important, and relevant, costs and outcomes. The study calculates LYs but not QALYs. Only health states necessary to capture costs and health effects of being dead or alive are considered. The model did not consider long-term health states relating to smoking								
c)	The interventions considered are relevant to the UK context, but caution is required when transferring the results of the study given the difference in prices and healthcare systems between the UK and Norway.								
d)	It is assumed that patients treated with varenicline and bupropion will have one visit to a GP in order to get a prescription. NRT is available over-the-counter.								
e)	It is assumed that annual healthcare costs are the same for smokers and non-smokers, and that healthcare costs are constant across age. A higher healthcare cost is applied to the last year of life for all persons, a cost of dying. This assumption was investigated in sensitivity analysis. A scenario analysis was constructed where smokers had higher annual health care costs than ex-smokers and where annual costs varied across age. This did not affect the conclusions.								

1

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Hettle, 2012 (Europe)	Minor limitations ^b	Partly applicable ^c	Similar population and interventions to Wilson, 2012 but in three different countries	Total population costs (€): Austria Varenicline 17,730,771 Austria Placebo 16,970,528 Germany Varenicline 32,278,318 Germany Placebo 31,423,185 Hungary Varenicline 6,110,250 Hungary Placebo 5,771,339	Total population QALYs (millions): Austria Varenicline 5,316 Austria Placebo 5,172 Germany Varenicline 5,243 Germany Placebo 5,098 Hungary Varenicline 4,511	Incremental population costs (varenicline versus placebo, payer) (€): Austria 760,243 Germany 855,133 Hungary 338,911 Incremental population costs (varenicline	Incremental population QALYs (varenicline versus placebo): Austria 144.1 Germany 145.8 Hungary 106.5 Incremental QALYs per person (varenicline	Incremental cost per QALY gained (varenicline versus placebo) (€): Payers perspective: Austria 5,278 Germany 5,867 Hungary 3,183 Societal perspective: In all countries, varenicline	Results from the deterministic sensitivity analysis showed marginal changes in ICER across all settings. The probabilistic sensitivity analysis found that in all scenarios and countries, varenicline remained cost-effective under a threshold of €12,500 per QALY gained.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Cohort of 1,000 patients with history of CVD problems Time horizon: Lifetime (65 years) Study aim: To evaluate the cost-effectiveness of varenicline plus counselling as a smoking cessation Intervention: Varenicline plus counselling ^a Comparator(s): Placebo plus counselling ^a				Intervention cost of per person (€): Austria Varenicline 17,730,771 Placebo 16,970,528 Germany Varenicline 32,278,318 Placebo 31,423,185 Hungary Varenicline 6,110,250 Placebo 5,771,339 Total costs per person (€): <u>CALCULATE D BY YHEC</u> ^d Austria Varenicline 17,731 Placebo 16,971 Germany	Placebo 4,405 QALYS per person: <u>CALCULATE D BY YHEC</u> ^d: Austria Varenicline 5.32 Placebo 5.17 Germany Varenicline 5.24 Placebo 5.10 Hungary Varenicline 4.51 Placebo 4.41 % abstinent at 12 months: Varenicline 19.2% Placebo 7.2%	versus placebo, societal) (€): Austria -1,631,857 Germany -1,517,876 Hungary -231,063 Incremental costs per person(vare nicline versus placebo, payer) (€): <u>CALCULATE D BY YHEC</u> ^e Austria 760 Germany 855 Hungary 339 Incremental costs per person	versus placebo): <u>CALCULATE D BY YHEC</u> ^e: Austria 0.14 Germany 0.15 Hungary 0.11	plus counselling was cost saving with positive incremental QALYs so dominant over placebo plus counselling	

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
				Varenicline 32,278 Placebo 31,423 Hungary Varenicline 6,110 Placebo 5,771 Currency & cost year: EUR (€); 2010		(varenicline versus placebo, societal) (€): <u>CALCULATE D BY YHEC</u> £ Austria -1,632 Germany -1,518 Hungary -231			

Data sources

Health outcomes: % Abstinence rates after 52 weeks ^c from double-blind placebo RCT **Quality-of-life weights:** Numerous published studies from both included countries and countries not included in the study. **Cost sources:** Numerous country dependent published sources used, generally from national data registries, national tariff schemes and published studies.

Abbreviations: CHD: Chronic heart disease; CVD: Cardio-vascular disease; PVD: Peripheral vascular disease; QALY: Quality-adjusted life-year;

(a) Counselling was 12 weekly clinic visits lasting a maximum of 10 minutes, plus a single telephone call 3 days after the quit date

(b) Unclear whether all data is taken from the best sources

(c) European (Austria, Germany and Hungary) setting, so care is needed when using these results in a UK setting

(d) Calculated by total costs/QALYs over population size of 1000

(e) Calculated by total incremental costs/QALYs over population size of 1000

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Huber, 2018 (Germany) Economic analysis: Cost-utility analysis (CUA) Population: Current smokers in Germany Population size: Not reported Time horizon: Lifetime Study aim: To evaluate the cost-effectiveness of Varenicline as a smoking cessation Intervention: Varenicline (12 weeks)^a	Major limitations ^b	Partly applicable ^c	None	Total population costs (€): Not reported Total lifetime cost per person (€): Not reported Intervention cost of per person (€): Varenicline 293 Zero investment - Currency & cost year: EUR (€), 2015	Total population QALYs: Not reported Lifetime QALYs per person: Not reported Risk ratio versus usual care: Varenicline 2.27	Incremental costs per smoker (€): Prospective scenario 1^d: Zero investment - Varenicline -0.02 Prospective scenario 2^e: Zero investment - Varenicline -0.25	Incremental QALYs per smoker: Prospective scenario 1^d: Zero investment - Varenicline 0.0002 Prospective scenario 2^e: Zero investment - Varenicline 0.0031	Lifetime incremental cost-effectiveness ratio per QALY gained (€): Prospective scenario 1^d: Varenicline Dominant (-77.81) versus zero investment Prospective scenario 2^e: Varenicline Dominant (-77.80) versus zero investment	There was no sensitivity analysis that focussed solely on varenicline. The only analysis included other, non-drug comparators like a financial incentive, with no breakdown of individual interventions.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Comparator(s): Zero investment									
Data sources									
Health outcomes: Taken from systematic review, studies with self-reported abstinence were excluded (only studies with biochemical testing were included) Quality-of-life weights: NR Cost sources: Varenicline treatment cost calculated from German pharmacy pricing. Smoking-related disease costs were not reported.									
<i>Abbreviations: CHD: Coronary heart disease; EQUIPTMOD: European study on quantifying utility of investment in protection from tobacco model; QALY: Quality-adjusted life-year;</i>									
(a) Dosage not reported. Treatment was made up of starter kit then maintenance.									
(b) Study setting is Germany so care is needed when using results in a UK context. The comparators are not clear.									
(c) There was no sensitivity analysis. Data sources were unclear.									
(d) In prospective scenario 1, varenicline uptake was increased by 1% causing 57,915 more quit attempts (ie a population of 57,915 analysed).									
(e) In prospective scenario 2, varenicline uptake was increased to UK levels (by 14.49%) causing 839,188 more quit attempts (ie a population of ~800.000 analysed).									

1

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Kautiainen 2017 (Finland)	Minor limitations ^b	Partly applicable ^c	Similar model to Annemans (2012) but in a Finnish context	Total population costs (€, millions): 2QA varenicline 2,605 2QA bupropion 2,645	Total population QALYs: 2QA varenicline 1,835,400 2QA bupropion 1,831,805 2QA NRT	Incremental costs (total population) (€, millions): Compared with 2QA varenicline 2QA bupropion 40.1	Incremental QALYs (total population): Compared with 2QA varenicline 2QA bupropion -3,595 2QA NRT	Incremental cost per QALY (€): 2QA varenicline dominates all other interventions	Both one-way univariate analyses and probabilistic sensitivity analysis were performed. Univariate sensitivity analyses found discount rates, cost of NRT and
Economic analysis: Cost-utility analysis (CUA)									
Population: Current smoker willing to make a quit attempt									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Population size: 116,533 (hypothetical) Time horizon: Lifetime (100 years or dead) Study aim: To evaluate the cost-effectiveness of re-treatment with varenicline compared with other smoking cessation interventions Intervention ^a: 2QA varenicline: 1QA with varenicline followed by varenicline re-treatment in case of failure or relapse Comparators ^a: 2QA NRT: 1QA with NRT followed by NRT				2QA NRT 2,618 2QA unaided 6,660 1QA varenicline 2,633 Total cost per person (€): <u>CALUCLATE</u> <u>D BY YHEC</u> ^d 2QA varenicline 22,354 2QA bupropion 22,687 2QA NRT 22,466 2QA unaided 57,151 1QA varenicline 22,594 Currency & cost year:	1,831,175 2QA unaided 1,823,452 1QA varenicline 1,829,742 QALYS per person: <u>CALUCLATE</u> <u>ED BY YHEC</u> ^d 2QA varenicline 15.8 2QA bupropion 15.7 2QA NRT 15.7 2QA unaided 15.6 1QA varenicline 15.7 % abstinent at 12 months 1st	2QA NRT 12.7 2QA unaided 54.9 1QA varenicline 27.6 Incremental costs per person (€): <u>CALUCLATE</u> <u>D BY YHEC</u> ^e Compared with 2QA varenicline 2QA bupropion 344 2QA NRT 109 2QA unaided 471 1QA varenicline 237	-4,225 2QA unaided -11,948 1QA varenicline -5,658 Incremental QALYs per person: <u>CALUCLATE</u> <u>D BY YHEC</u> ^e Compared with 2QA varenicline 2QA bupropion -3,595 2QA NRT -4,225 2QA unaided -11,948 1QA varenicline -5,658		relative risks of smoking related diseases in long term quitters were the most influential parameters. However, changes to these parameters did not affect the conclusion that 2QA varenicline dominates all other interventions. Significant uncertainty related to varenicline retreatment efficacy was investigated by varying the parameter +/- 20%. At the lower limit, 2QA varenicline vs 2QA bupropion gave an ICER of 4,550€/QALY and vs NRT it was 1,584€/QALY. Probabilistic sensitivity

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
re-treatment in case of failure or relapse 2QA bupropion: 1QA with bupropion followed by bupropion re-treatment in case of failure or relapse 2QA unaided: 1QA unaided followed by a subsequent unaided attempt in the case of failure or relapse 1QA varenicline: 1QA with varenicline followed by 1QA with placebo				EUR (€); 2013/2014	attempt (2nd attempt): Varenicline 21.1% (20.1%) Bupropion 15.7% (15.7%) NRT 14.9% (14.9%) Unaided 5% (5%)				analysis indicated that the conclusions are robust. Compared with 2QA NRT, 2QA varenicline is 99.9% cost-effective at a willingness to pay threshold of 5,000€ per QALY.
Data sources									
Health outcomes: First line treatment efficacies were derived from the Cochrane systematic review (Cahill et al., 2013). Second line treatment efficacy for varenicline was from a RCT. Second line treatment efficacies for NRT and bupropion conservatively used the same value as first line treatment due to lack of evidence. Quality-of-life weights: Utility weights for health states are from published data sources. Cost sources: Unit costs were taken from Kapiainen et al., Finnish version of NordDRGs and pharmaceuticals pricing board (PPB)									
Abbreviations: ICER: Incremental cost-effectiveness ratio; NRT: Nicotine replacement therapy; QA: quit attempt; QALY: Quality-adjusted life year									
a) The length of treatment is not specified within the study. A 12-week treatment length is assumed in line with the cost per intervention.									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
b)	The model includes all important, and relevant, costs and outcomes. It is assumed that the first and second quit attempts for NRT, bupropion and unaided cessation have equal efficacy. In addition, the varenicline re-treatment efficacy estimate is based on only one RCT.								
c)	The interventions considered are relevant to the UK context, but caution is required when transferring the results of the study given the difference in prices and healthcare systems between the UK and Finland.								
d)	Assumed to be total population costs/QALYS divided by population size (116,533).								
e)	Assumed to be incremental costs/QALYS (total population) divided by population size (116,533).								

1

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Knight 2012 (Belgium) Economic analysis: Cost-utility analysis (CUA) Population: Current smokers willing to quit with pharmacological agent Population size: 168,239 (hypothetical) Time horizon: Lifetime Study aim:	Minor limitations ^b	Partly applicable ^c	Similar model to Athanasakis (2012) in a Belgium context	Total population costs (millions): Varenicline (12 + 12 weeks) plus brief counselling: €1,946 Varenicline (12 weeks) plus brief counselling: €1,941 Bupropion (12 weeks) plus brief counselling: €1,957	Total population QALYs (millions): Varenicline (12 + 12 weeks) plus brief counselling: 3.102 Varenicline (12 weeks) plus brief counselling: 3.097 Bupropion (12 weeks) plus brief counselling: 3.089	Incremental costs (total population) (€): Compared with varenicline (12 weeks) plus brief counselling Varenicline (12+12 weeks) plus brief counselling 6,000,000 Bupropion (12 weeks) plus brief counselling 16,000,000	Incremental QALYs (total population): Compared with varenicline (12 weeks) plus brief counselling Varenicline (12+12 weeks) plus brief counselling 5,000 Bupropion (12 weeks) plus brief counselling -8,000	Incremental cost per QALY (€): Varenicline (12 weeks) plus brief counselling vs. varenicline (12+12 weeks) plus brief counselling 1,101 The extended course of varenicline dominates all other interventions	Probabilistic sensitivity analysis was used to investigate the stability of the ICER when comparing the extended and non-extended course of varenicline. The extended course had an ICER below 30,000 € per QALYS 81.7% of the time. 30.9% of the time the extended course dominated the non-extended course.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
To evaluate the cost-effectiveness of an extended 12+12-week course of varenicline for smoking cessation Intervention: Varenicline (12+12 weeks) plus brief counselling ^a Comparator(s): Varenicline (12 weeks) plus brief counselling Bupropion (12 weeks) plus brief counselling Brief counselling alone				Brief counselling alone: €1,973 Total cost per person (€): <u>CALCULATE D BY YHEC</u>^e Varenicline (12+12 weeks) plus brief counselling 11,566 Varenicline (12 weeks) plus brief counselling 11,537 Bupropion (12 weeks) plus brief counselling 11,632 Brief counselling alone 11,727	Brief counselling alone: 3.081 QALYS per person: <u>CALCULATE D BY YHEC</u>^e Varenicline (12+12 weeks) plus brief counselling 3.102 18.43 Varenicline (12 weeks) plus brief counselling 18.41 Bupropion (12 weeks) plus brief counselling 18.36 Brief counselling alone 18.31 % abstinent at 12	Brief counselling alone 32,100,000 Incremental costs (total population) (€): <u>CALCULATE D BY YHEC</u>^f Compared with varenicline (12 weeks) plus brief counselling Varenicline (12+12 weeks) plus brief counselling 35.7 Bupropion (12 weeks) plus brief counselling 95.1 Brief counselling alone 190.8	Brief counselling alone -15,000 Incremental QALYs (total population) : <u>CALCULATE D BY YHEC</u>^f Compared with varenicline (12 weeks) plus brief counselling Varenicline (12+12 weeks) plus brief counselling 0.03 Bupropion (12 weeks) plus brief counselling -0.05 Brief counselling alone -0.09		

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
				Intervention costs per person ^d: Varenicline (12+12 weeks) plus brief counselling 547.52 Varenicline (12 weeks) plus brief counselling 382.14 Bupropion (12 weeks) plus brief counselling 288.23 Brief counselling alone 205.08 Currency & cost year: EUR (€); 2011	months: Varenicline (12+12 weeks) plus brief counselling 27.7% Varenicline (12 weeks) plus brief counselling 22.9% Bupropion (12 weeks) plus brief counselling 15.9% Brief counselling alone 9.3%				

Data sources

Health outcomes: 1-year quit rates reported in Knight et al. (2012). **Quality-of-life weights:** Utility weights for health states are as published in Annemans et al. (2009). **Cost sources:** Publicly available costs from the national institute for health insurance (RIZIV/INAMI), published hospital costs for the appropriate All Patient Refined Diagnosis Related Group and two published studies; Annemans et al. (2009) and Muls et al. (1998). Costs were inflated to 2011 price where necessary.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Abbreviations: BENESCO: Benefit of smoking cessation on outcomes; ICER: Incremental cost-effectiveness ratio; NRT: Nicotine replacement therapy; QALY: Quality-adjusted life year									
(a) The extended 12+12 weeks course of varenicline was only available to those who had remained abstinent after the initial 12-week period. Brief counselling consists of 12 GP visits within the first 12 weeks for each intervention. Subjects in the (12+12 weeks) intervention group received an additional 5 brief counselling GP visits in the following 12-week period.									
(b) The model includes all important, and relevant, costs and outcomes. Some parameter values are taken from previous BENESCO model(s) without detailed methodology on how these were derived. In addition, there were differences in the quantity of brief counselling with more sessions offered to the Varenicline 12+12 weeks intervention group if they remained abstinent after the initial 12 weeks.									
(c) The interventions considered are relevant to the UK context, but caution is required when transferring the results of the study given the difference in prices and healthcare systems between the UK and Belgium.									
(d) Starter pack was at quitters own expense for both varenicline and bupropion and not include in the cost. Treatment following the starter pack were included plus GP visits.									
(e) Assumed to be total population costs/QALYS divided by population size (168,239).									
(f) Assumed to be incremental costs/QALYS (total population) divided by population size (168,239).									

1

2

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Linden, 2010 (UK)	No limitations	Partly applicable ^c	None	Total lifetime population costs (€): Varenicline 5,170,773,916 Bupropion 5,185,427,331 Unaided cessation 5,213,398,246	Total lifetime population QALYs: Varenicline 4,161,579 Bupropion 4,156,728 Unaided cessation 4,149,094	Lifetime incremental costs (€): Varenicline versus bupropion: Cost-saving Varenicline versus unaided cessation: Cost-saving	Lifetime population incremental QALYs: Varenicline versus bupropion: 4,851 Varenicline versus unaided cessation: 12,485	Lifetime incremental cost-effectiveness ratio per QALY gained (€): Varenicline dominates both bupropion and unaided cessation (lower total costs and	The 20-year time horizon found ICER per QALYs of €8,791 and €7,791 for varenicline versus bupropion and unaided cessation respectively. The deterministic sensitivity analysis found that even with major changes of
Economic analysis: Cost-utility analysis (CUA)									
Population: Current Finnish smokers making a single quit attempt									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Population size: (229,301) Time horizon: 20 years and lifetime Study aim: To evaluate the cost-effectiveness of Varenicline as a smoking cessation Intervention: Varenicline (12 weeks) plus single physician visit ^{a,b} Comparator(s): Bupropion (7 weeks) plus single physician visit ^{a,b} Unaided cessation				Intervention cost of per person (€): Varenicline 386.47 Bupropion 229.92 Unaided cessation - Total lifetime cost per person (€): <u>CALCULATED BY YHEC ^d</u> Varenicline 22,550 Bupropion 22,614 Unaided cessation 22,736 Currency & cost year: EUR (€); 2006 (apart from healthcare sub-index of	Lifetime QALYs per person: <u>CALCULATED BY YHEC ^e</u> Varenicline 18.15 Bupropion 18.13 Unaided cessation 18.09 % abstinent at 12 months: Varenicline 22.5% Bupropion 15.7% Unaided cessation 5%		Lifetime incremental QALYs per person: <u>CALCULATED BY YHEC ^f</u> Varenicline versus bupropion: 0.02 Varenicline versus unaided cessation: 0.05	higher total QALYs)	the input values, varenicline remained dominant below the ICER threshold of £30,000 (€33,200) over a lifetime horizon. The probabilistic sensitivity analysis found that, when the willingness-to-pay threshold was €10,000, varenicline was cost-effective compared with bupropion (unaided cessation) 65% (80%) of the time.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
				Finnish cost-of-living index, 2007)					
<i>Abbreviations: ICER: Incremental cost-effectiveness ratio; QALY: Quality-adjusted life-year</i>									
(a) Dosage was not reported for either varenicline or bupropion									
(b) Patients had a single physician visit at the initiation of treatment									
(c) Study setting is Finland so care is needed when using results in a UK context									
(d) Calculated by total cost of intervention and treatment over population of 229,301									
(e) Calculated by total QALYs of intervention over population of 229,301									
(f) Calculated by total incremental QALYs over population of 229,301									

1

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Lock, 2011 (UK)	Minor limitations ^c	Directly applicable	None	Total population costs: Not reported	Total population QALYs: Not reported	Incremental costs per person (varenicline versus placebo) (€): <u>CALCULATED BY YHEC</u> ^d	Incremental QALYs per person (varenicline versus placebo): <u>CALCULATED BY YHEC</u> ^e	Incremental cost-effectiveness ratio per QALY gained (€): Varenicline versus placebo 4,478	There was limited sensitivity analysis around the UK model. At an implicit threshold of €30,000 per QALY gained, varenicline has a high probability of being cost-effective when compared with placebo.
Economic analysis: Cost-utility analysis (CUA)				Intervention cost per person (€): Varenicline 914	QALYs per person: Varenicline 5.78	740 per person	0.16 per person		
Population: Current cigarette smokers with COPD				Placebo 723	Placebo 5.62				
Population size: Not reported				Total cost per person (€): Varenicline 14,978	% abstinent at 12 months: Varenicline 18.6%				
Time horizon:									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
28 years, with mean starting age of 57 Study aim: To evaluate the cost-effectiveness of Varenicline as a smoking cessation Intervention: Varenicline (12 weeks) plus booklet and counselling ^{a,b} Comparator(s): Placebo (12 weeks) plus booklet and counselling				Placebo 14,238 Currency & cost year: EUR (€); 2010	Placebo 5.6%				
Data sources									
Health outcomes: % Abstinence rates after 52 weeks from a 27-centre double-blind placebo RCT ^c Quality-of-life weights: Estimated according to the UK EQ-5D tariff, taken from previous model of natural history and economic impact of COPD (Borg et al, 2004) Cost sources: Numerous cost sources used, prices inflated to 2010 levels and GDP converted to EUR at 2010 exchange rates when necessary. 'Whenever possible, state-specific costs are derived from peer-reviewed publications containing country-specific sources'.									
<i>Abbreviations: COPD: Chronic obstructive pulmonary disease; QALY: Quality-adjusted life year;</i>									
(a) Dosage was 1 mg by mouth twice daily for 12 weeks, though first week was 0.5mg once daily for 3 days, 0.5mg twice daily for 4 days									
(b) Persons were given an educational booklet on smoking cessation and brief (≤10 mins) counselling sessions at a weekly clinic visit. Further clinic visits and telephone calls were made during the 40-week follow-up period									
(c) Limited sensitivity analysis									
(d) Calculated by total cost for varenicline minus total cost for placebo									
(e) Calculated by total QALYs for varenicline minus total QALYs for placebo									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Von Wartburg 2014 (Canada) Economic analysis: Cost utility analysis (CUA) Population: Adult smokers who are assumed to make a quit attempt within the next 30 days Population size: 1,275,481 (hypothetical) Time horizon: Lifetime Study aim: to estimate the cost-effectiveness of an extended (12+12 weeks) course of	Minor limitations ^c	Partly applicable ^d	Similar model to Knight (2012) in a Canadian context	Lifetime costs (CAD\$, millions) – Payer perspective ^e Varenicline (12 weeks) 25,369 Varenicline (12+12 weeks) 25,426 Bupropion 25,510 NRT 25,705 Unaided cessation 25,746 Lifetime costs (CAD\$, millions) – Societal perspective ^f Varenicline (12 weeks) 98,739	Lifetime QALYs: Varenicline (12 weeks) 15,398,000 Varenicline (12+12 weeks) 15,413,000 Bupropion 15,376,000 NRT 15,374,000 Unaided cessation 15,342 1-year quit rates ^d: Varenicline (12+12 weeks) 27.7% Varenicline (12 weeks) 22.9%	Lifetime population costs (CAD\$, millions) – Payer perspective Varenicline (12+12 weeks) 12 weeks 56 Bupropion 140 NRT 336 Unaided cessation 376 Lifetime population costs (CAD\$) – Societal perspective	Incremental population QALYs: vs varenicline (12+12 weeks) Varenicline (12 weeks) -15,000 Bupropion -37,000 NRT -39,000 Unaided cessation -71,000 Incremental QALYs per person vs varenicline (12+12 weeks) <u>CALCULATED BY YHEC</u>ⁱ Varenicline	Incremental cost per QALY (CAD\$) – Payer perspective ^h Varenicline (12 + 12 weeks) vs varenicline (12 weeks): 3,758 Varenicline (12 + 12 weeks) dominated all the other interventions. Incremental cost per QALY – Societal perspective Varenicline (12 + 12 weeks) was dominant compared with all the other options.	Probabilistic sensitivity analysis (PSA) showed that varenicline (12+12 weeks) had a 95% probability of being cost-effective at a willingness to pay threshold of CAD\$30,000 per QALY compared with varenicline (12 weeks) and 100% compared with the other interventions (from the payer perspective).

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
varenicline using the Benefits of Smoking Cessation on Outcomes (BENESCO) model Intervention: Varenicline ^a (12 + 12 weeks) Smoking cessation for 12 weeks plus additional 12 weeks of Varenicline maintenance for quitters Comparator ^b: Varenicline (12 weeks) for smoking cessation plus 12 weeks placebo maintenance for quitters Bupropion (12 weeks) for				Varenicline (12+12 weeks 98,902 Bupropion 99,902 NRT 100,177 Unaided cessation 101,730 Currency & cost year: CAD (\$); 2009	Bupropion 15.9% NRT 15.4% Unaided cessation 5%	(vs varenicline 12+12 weeks) Varenicline (12 weeks) 645 Bupropion 1,807 NRT 2,082 Unaided cessation 3,635 Lifetime costs per person (CAD\$) – Payer perspective (vs varenicline 12 weeks) CALCULATED BY YHEC ⁱ Varenicline (12+12 weeks) 43.9	(12 weeks) -0.012 Bupropion -0.029 NRT -0.031 Unaided cessation -0.056		

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
smoking cessation						Bupropion 109.8			
Nicotine replacement therapy (NRT) (12 weeks) for smoking cessation						NRT 263.43			
Unaided cessation: no further description was provided						Unaided cessation 294.8			
						Lifetime costs per person (CAD\$, millions) – Societal perspective (vs varenicline 12+12 weeks) <u>CALCULATED BY YHECⁱ</u>			
						Varenicline (12 weeks) 505.7			
						Bupropion 1,416.7			
						NRT 1632.3			

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
						Unaided cessation 2849.9			
Data sources									
Health outcomes: 1-year quit rates were derived from a mixed treatment comparison of 3 RCTs (Knight 2010) and for NRT were taken from a meta-analysis by Silagy, 2004. Quality-of-life weights: These were taken from published literature but no further details were given. Cost sources: Costs associated with smoking-related morbidities were taken from published literature but were not described. Costs of interventions were taken from Pharmastat, Public Claim Data for Québec Abbreviations: CUA: Cost-utility analysis; NRT: Nicotine replacement therapy; PSA: Probabilistic sensitivity analysis; QALY: Quality-adjusted life year; RCT: Randomised controlled trial									
a) All Varenicline cessation and maintenance doses were 1mg taken twice daily.									
b) Details on the dose of bupropion was not provided. NRT comprised of chewing gum, transdermal patches, nasal spray, inhalers and tablets, doses were not provided.									
c) The study was based on multiple RCTs. When required, conservative assumptions were made.									
d) The interventions considered appear relevant to the UK context, but caution is required in transferring the results of this study given the differences in prices between Canada and the UK.									
e) Cost components of the payer perspective included intervention costs (drug costs and a single GP visit) and healthcare resources to treat smoking related comorbidities (lung cancer, stroke, coronary heart disease, chronic obstructive pulmonary disease and asthma)									
f) The cost components for the wider societal perspective included all those for the payer perspective and the following indirect costs: productivity benefits from improved health & reduced absenteeism, reduced tax from tobaccos sales, cost savings from reduced second-hand smoker and smoke related fires.									
g) 1-year quit rates for Varenicline (12+12 weeks), Varenicline (12 weeks) and Bupropion were derived from a mixed treatment comparison of 3 RCTs which established abstinence through self-reported non-smoking and exhaled CO readings < 10 parts per million; the 1-year quit rates for NRT was obtained from a meta-analysis which confirmed abstinence through a combination of self-reported non-smoking and CO readings.									
h) Cost-effectiveness driven by efficacy rates which result in a higher ratio of non-smoker to smokers and fewer smoking related comorbidities/deaths.									
i) Calculated by total incremental costs/QALYs over population size of 1,275,841									

1

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Wilson, 2012 (Europe)	Minor limitations ^b	Partly applicable ^c	Similar population and intervention s to Hettle,	Total population costs (€): Belgium	Total population QALYs (millions): Belgium	Incremental population costs (varenicline versus	Incremental QALYs (varenicline versus placebo):	Incremental cost-effectiveness ratio per QALY gained	The one-way sensitivity analysis determined that assumptions on
Economic analysis:									

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Cost-utility analysis (CUA) Population: Three groups: patients with CHD, patients with a history of stroke, patients with PVD Population size: Cohort of 1,000 patients with history of CVD problems Time horizon: Lifetime (65 years) Study aim: To evaluate the cost-effectiveness of Varenicline plus counselling as a smoking cessation Intervention: Varenicline plus counselling^a			2012 but in four different countries	Varenicline 34,812,609 Placebo 33,828,993 Spain Varenicline 25,984,405 Placebo 25,239,643 Portugal Varenicline 28,201,146 Placebo 27,451,663 Italy Varenicline 26,581,362 Placebo 25,706,868 Total costs per person (€): <u>CALCULATE D BY YHEC^d</u> Belgium Varenicline 34,813 Placebo 33,829 Spain	Varenicline 5311 Placebo 5150 Spain Varenicline 5154 Placebo 5010 Portugal Varenicline 5231 Placebo 5091 Italy Varenicline 5296 Placebo 5135 QALYs per person: <u>CALCULATE D BY YHEC^d</u> Belgium Varenicline 5.31 Placebo 5.15 Spain	placebo, payer) (€): Belgium 983,615 Spain 744,762 Portugal 749,483 Italy 874,494 Incremental population costs (varenicline versus placebo, societal) (€): Belgium -1,434,061 Spain -1,017,494 Portugal -1,493,532 Italy -1,210,496 Incremental costs per	Belgium 160.7 Spain 144.6 Portugal 139.9 Italy 161.0 Incremental QALYs (varenicline versus placebo): <u>CALCULATE D BY YHEC^e</u> Belgium 0.16 Spain 0.14 Portugal 0.14 Italy 0.16	(varenicline versus placebo) (€): Payer's perspective: Belgium 6,120 Spain 5,151 Portugal 5,357 Italy 5,433 Societal perspective: In all countries, varenicline plus counselling was cost saving with positive incremental QALYs, so dominant	cost parameters did not exhibit a strong influence on outcomes. It also found time horizon had no significant influence. The probabilistic sensitivity analysis found that all countries had an ICER between willingness to pay thresholds of €4,000 and €10,000 per QALY gained (ie. at a threshold of €10,000, there is 100% probability that varenicline is cost effective when compared with placebo in all countries).

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Comparator(s): Placebo plus counselling ^a				Varenicline 25,984	Varenicline 5.15	person (varenicline versus placebo, payer) (€): <u>CALCULATE D BY YHEC ^f</u>			
				Placebo 25,240	Placebo 5.01				
				Portugal Varenicline 28,201	Portugal Varenicline 5.23				
				Placebo 27,452	Placebo 5.09				
				Italy Varenicline 26,581	Italy Varenicline 5.30				
				Placebo 25,707	Placebo 5.14				
				Intervention cost of per person (€): Belgium Varenicline 519 Placebo 272	% abstinent at 12 months:^e Varenicline 19.2%				
					Placebo 7.2%				
				Spain Varenicline 682 Placebo 321					
				Portugal					

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
				Varenicline 665 Placebo 372 Italy Varenicline 575 Placebo 225 Currency & cost year: EUR (€), 2010		Portugal -1,494 Italy -1,210			

Data sources

Health outcomes: % Abstinence rates after 52 weeks ^c from a single double-blind placebo RCT. **Quality-of-life weights:** Numerous country dependent published sources used, generally published studies. **Cost sources:** Numerous country dependent published sources used, generally published studies.

Abbreviations: CHD: Coronary heart disease; CVD: Cardio-vascular disease; ICER: Incremental cost-effectiveness ratio; PVD: Peripheral vascular disease; QALY: Quality-adjusted life-year;

(a) Counselling was 12 weekly clinic visits, plus a single telephone call 3 days after the quit date

(b) Unclear whether all data is taken from the best sources

(c) European (Spain, Italy, Portugal and Belgium) setting, so care is needed when using these results in a UK setting

(d) Calculated by total population cost/QALYs over population size of 1,000

(e) Abstinence data taken from a multi-centre, randomised, double-blind, placebo-controlled trial, and the same data is used for each country.

(f) Calculated by total incremental costs/QALYs over population size of 1000

E-cigarette interventions

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Li 2019 (UK) Economic analysis: Cost-effectiveness analysis (CEA) Population: Adult smokers who sought help to quit Sample size (RCT): 886 Cohort size (lifetime model): 1000 Time horizon:	Minor limitations ^b	Directly applicable	A randomised control trial (RCT) was conducted with 12-month costs and effectiveness reported as the primary analysis. Following this, a Markov model was used to project lifetime cost-effectiveness.	Total population costs: Not reported Total cost per participant (SE) (£) ^c: 12-Month EC 1174 (147) NRT 1116 (163) Lifetime EC 3184 (169)	Total population QALYs: Not reported QALYs per participant (SE): 12-Month EC 0.886 (0.008) NRT 0.882 (0.009) Lifetime EC 24.14 (0.31)	Estimated incremental costs (£) ^f: 12-Month 11 Lifetime 9	Estimated incremental QALYs ^f: 12-Month 0.010 Lifetime 0.14	Estimated incremental cost per QALY (£) ^f: EC compared with NRT 12-Month 1,100 per QALY gained Lifetime 65 per QALY gained	Cost-effectiveness acceptability curves estimated the probability of EC being cost-effective in comparison with NRT to be: 12-month 87% at £20,00/QALY and 90% at £30,00/QALY Lifetime ^g 85% at both 20,000/QALY and 30,000/QALY thresholds.

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
12-month and lifetime Study aim: To evaluate the cost-effectiveness of e-cigarettes as a smoking cessation aid used in routine stop smoking services Intervention: E-cigarette (EC) + behavioural support ^a Comparator: Nicotine replacement therapy (NRT) + behavioural support ^a				NRT 3175 (161) Currency & cost year: GBP (£); 2015/16	NRT 24.28 (0.31) % abstinent at 12 months ^{d, e}: EC 18.0% NRT 9.9%				

Study	Limitations	Applicability	Other comments	Costs	Effects	Incremental cost	Incremental effects	Economic analyses outcomes	Uncertainty
Data sources									
Health outcomes: 1-year quit rates were used directly from RCT. Quality-of-life weights: EQ-5D utility values were based on a study of Health Survey for England data, with a sample size of 13,241. Cost sources: Costs were source from the NHS, NICE, PSSRU and government publications. <i>Abbreviations: EC: E-cigarette; ICER: Incremental cost-effectiveness ratio; NRT: Nicotine replacement therapy; QALY: Quality-adjusted life year; RCT: Randomised control trial; SE: Standard error</i> a) All participants were offered six weekly behavioural support sessions at their local stop smoking services (SSS) as per standard practice, with the second session on the target quit date. b) The lifetime model did not take into consideration the possible long-term effects of using EC on health and personal finance due to lack of evidence. The RCT had a 35% missing data level which make cost-effectiveness less certain. The 6-month recall period for self-reported health-care services use could potentially cause recall bias. QALYs were derived based on smoking status, and were not disease specific. c) Total costs include treatment costs, smoking cessation costs and health-care costs. Treatment costs consist of training and delivery costs. For NRT, supplies were provided for up to 3 months, as per usual practice. For EC, the 'One Kit' device and a 30-ml bottle of e-liquid was provided. Participants were instructed to obtain further e-liquid themselves although one additional 10-ml bottle of e-liquid could be requested if requires. d) Carbon monoxide (CO)-validated. e) 1-year quit rates were applied to the first cycle of the lifetime model. An annual relapse rate of 10% was applied for the following 10 years and abstinence was subsequently assumed to be permanent. f) Incremental costs and incremental QALYs were estimated using regression adjusting for baseline covariates and their respective baseline values. A generalized linear regression model controlled for utility value at baseline, age, gender, study site, entitlement of free prescriptions and FTCD at baseline. g) While the ICERs are lower over a lifetime horizon, uncertainty analysis shows a lower chance of being cost-effective. The author does not explain the reasoning. However, it is assumed that this is due to the use of wider confidence intervals for the long-term data.									


1 Economic model

2 The economic model used to assess the cost-effectiveness of smoking cessation
3 interventions was an adapted version of the model previously used to inform NICE guidelines
4 on smoking cessation [NG92]

5 Model Structure

6 It uses the same structure as was developed in the original NG92 model (8), considering
7 long-term epidemiological data in order to capture the lifetime complications associated with
8 six long-term smoking-related illnesses (Figure 1). A similar model structure has been used
9 in past cost-effectiveness models for smoking interventions (PHG10, PHG45).

10 **Figure 1: Model structure**



11 * LC = lung cancer, CHD = coronary heart disease, MI = myocardial infarction, COPD = chronic obstructive
12 pulmonary disease, asthma = asthma exacerbation.

11

12

13 The Markov model includes annual cycles where smokers have a probability of quitting (and
14 becoming 'former smokers') and former smokers have a probability of relapsing. People
15 from either the 'smoker' or 'former smoker' health state can move to the 'dead' health state.
16 The model doesn't include benefits for tobacco harm reduction.

17 The model includes six smoking related comorbidities: lung cancer (LC), coronary heart
18 disease (CHD), myocardial infarction (MI), stroke, chronic obstructive pulmonary disease
19 (COPD), and asthma. It uses published literature sources to establish the prevalence of LC,
20 CHD, MI, stroke and COPD, and incidence of asthma, for smokers and non-smokers by age
21 and gender. Each comorbidity has an associated NHS treatment cost and disutility. These
22 costs and disutilities are applied based on prevalence and incidence rates for each cycle and
23 summed to estimate lifetime costs and QALYs across all cycles.

24 The model calculates the average lifetime costs, lifetime QALYs, and subsequent cost-
25 effectiveness across all populations between the ages of 12 and 100. Age 12 was selected
26 as this was assumed to be the earliest age that someone would take up smoking.

27 Model inputs

28 This section outlines the model inputs that have been used to populate the economic model
29 and also highlights any area in which there are data gaps. Where required targeted searches
30 were carried out to identify new data to update parameter values in the existing NG92 model.

Numerous parameters remained the same as in the original model, since either the same source was found, or no better or more recent source was found.

Effectiveness estimates

Intervention effectiveness (relative risks of smoking abstinence at 6 months) was sourced from NICE evidence review K (5).

The PHAC were interested in comparing the cost-effectiveness of each intervention versus one another and versus a comparator, and therefore the incremental economic analysis included placebo as an intervention option.

The majority of RCTs informing the NMA (180 out of 189) included behavioural support in both intervention and control arms. The type of behavioural support offered was consistent within trials (i.e. equivalent for placebo and intervention arms) but was not consistent across RCTs.

To be consistent with the annual cycle lengths included in the economic model, probabilities of smoking cessation at 6-months were converted to probabilities of smoking cessation at 12-months, accounting for smoking relapse between these two time points. Long term relapse curves were used to adjust probabilities providing quit rate at one year (Figure 2). Relapse after 12 months was included as part of the natural rate of smoking cessation that was applied in the model. The rate was set equal to 2%, and incorporates both the expected number of people who quit smoking and relapse from smoking annually.

All RRs were obtained from the NMA results in Table 20 of NICE evidence review K. The RRs and absolute probabilities of quitting at 6-months and 12-months are outlined in Table 7.


Table 7: Intervention effectiveness

Intervention	RR of abstinence vs. placebo @ 6-months mean (95% CI)	P (quit) 6-months	P (quit) 12-months
Placebo	N/A	11.49%	9.84%
NRT I/s	1.83 (1.67, 2.01)	21.03%	18.00%
NRT I&s	2.71 (2.10, 3.40)	31.14%	26.66%
Bupropion	1.73 (1.52, 1.95)	19.88%	17.02%
Varenicline	2.27 (2.01, 2.55)	26.08%	22.33%
E-cigarettes	2.25 (1.33, 3.58)	25.85%	22.14%
Bupropion & NRT I/s	1.93 (1.50, 2.46)	22.18%	18.99%
Bupropion & NRT I&s	3.51 (1.77, 5.59)	40.33%	34.53%
Varenicline & NRT I/s	2.58 (1.68, 3.70)	29.64%	25.38%
Varenicline & Bupropion	2.75 (1.73, 4.05)	31.60%	27.05%
E-cigarettes & NRT I/s	2.93 (1.52, 4.80)	33.67%	28.82%

24

Figure 2: Relapse rate from Coleman et al. (2010)

25



1

2 **Intervention costs**

3 The cost of behavioural support (£82.96) was applied equally to both the placebo arms and
 4 each intervention arm. This was because the majority of studies informing the NICE NMA
 5 included some form of behavioural support in both the intervention and placebo arms.

6 All combination therapies were assumed to incur the sum of costs for each of the included
 7 pharmacotherapies. A single cost of behavioural support was then added to the summed
 8 cost of the combination therapy.

9 The total costs of each combination therapy in addition to behavioural support were as
 10 follows: bupropion + NRT I/s £175.94; bupropion + NRT I/s £231.23; varenicline + NRT I/s
 11 £292.74; varenicline + bupropion £287.94; E-cigarettes + NRT I/s £131.84.

12 The total cost of each of the included interventions, the components used to calculate the
 13 costs and the sources are summarised in Table 8.

14 **Table 8 Intervention costs (NHS/PSS)**

15

Intervention	Total cost	Components	Unit Costs (per dose)	Source
Behavioural support (applies to placebo and all other interventions)	£82.96	Total of 5.35 behavioural support sessions through LSSS. Sessions 1-2 assumed to last 30 minutes, with all subsequent sessions lasting 20 minutes. Total session number derived as a weighted mean trial arm.	N/A	Li et al (2020) (15)
NRT I/s*	£48.88	Weighted average: NRT patch (23.5%), NRT Lozenge (17.74%), NRT gum (31.48%), NRT Spray (10.15%), NRT Inhalator (17.27%)	NRT patch=£54.84 NRT lozenge=£26.93 NRT gum=£47.89 NRT spray=£50.63 NRT inhalator=£63.71	Weightings: Prescription Cost Analysis (2018) (16) Unit costs: Table 2
NRT I&s*	£104.17	100% receive long acting NRT patch plus a weighted average cost across short acting NRT. Weightings for short acting NRT= gum (25.45%),	NRT patch=£54.84 NRT gum=£47.89	Weightings: Updated NICE NMA (5)

		spray (50.72%), any (18.09%), inhalator (5.74%).	NRT spray=£50.63 NRT inhalator=£63.71 NRT any short acting=£43.56	Unit costs: Table 2
Varenicline	£160.88	500 micrograms take once daily for 3 days, 500 micrograms twice daily for 4 days, and 1mg twice daily for 11 weeks.	£0.98 [for both 500 microgram & 1mg]	Drug costs and dosage (BNF online 2020) (7)
Bupropion	£44.10	150mg daily for 1 week, then 150mg twice daily for 8 weeks	£0.70	(BNF online 2020) (7)
E-cigarettes	£0.00	E-cigarettes are not currently licenced by the NHS and therefore all costs are assumed to be incurred OTC for the base case analysis.		
Bupropion & NRT I/s*	£92.98	Cost of bupropion plus cost of NRT I/s.		
Bupropion & NRT I&s*	£148.27	Cost of bupropion plus cost of NRT I&s.		
Varenicline & NRT I/s*	£209.76	Cost of varenicline plus cost of NRT I/s.		
Varenicline & Bupropion	£204.98	Cost of varenicline plus cost of bupropion.		
E-cigarettes & NRT I/s*	£48.88	Cost of e-cigarettes plus cost of NRT I/s.		

1

2 **Private costs**

3 Intervention costs were also assigned for private purchases of e-cigarettes which are not
4 currently provided by NHS, and for NRT products available OTC.

5 For the base case analysis, the private cost of e-cigarettes included all costs previously
6 reported for e-cigarettes obtained from Li et al. (2020), that is a cost per person equal to
7 £35.81 including starter packs and extra refill bottles. For the scenario analysis 48% of costs
8 were assumed to be incurred via prescription, whilst 52% were purchased OTC.

9 The private costs of NRT included costs for the 52% of NRT products purchased OTC, the %
10 being informed by the study by Hajek et al. (2019). As there was no information on dose and
11 type of NRT purchased OTC, it was assumed prescribed and private unit costs would be
12 equivalent. Therefore, all costing was as described previously for each NRT intervention
13 classification in Table 8. The private costs for each intervention are reported in Table 9

14 **Table 9: Private costs (OTC)**

15

Intervention	Private costs (per person)
NRT I/s	£52.96
NRT I&s	£112.85
Bupropion	£0.00
Varenicline	£0.00
E-cigarettes	£116.14
Bupropion & NRT I/s	£52.96

Bupropion & NRT I&s	£112.85
Varenicline & NRT I/s	£52.96
Varenicline & Bupropion	£0.00
E-cigarettes & NRT I/s	£169.10

1

2 Comorbidity costs

3 The comorbidity costs were sourced from the same publications as were used in the original
 4 NG92 model. A pragmatic literature search in online databases was conducted which
 5 combined key terms and synonyms relating to each comorbidity combined with common
 6 search terms for healthcare costs and/or economic studies (for example, costs, healthcare
 7 costs, NHS costs, burden of illness, economic evaluation). The searches did not identify any
 8 relevant evidence from more recent publications. Each annual cost was inflated to 2019
 9 prices from the original source using the PSSRU H&CHS inflation indices^d. It was not
 10 possible to report overall costs for social care separately and, therefore, results are reported
 11 for NHS and personal social services as a whole.

12 The costs associated with each co-morbidity reflect on-going annual costs and are multiplied
 13 by the number of people with each co-morbidity each cycle. As the model estimates costs
 14 using a prevalence-based approach i.e. establishing the total proportion of smokers/ex-
 15 smokers in the population with a comorbidity at a certain time, the comorbidity costs
 16 represent an “average” cost per year for people with the comorbidity (see Table 10).

17 **Table 10: On-going annual comorbidity costs (NHS/PSS)**

18

Parameter	Cost	Source
Stroke	£5,618	NICE CG92 Full guideline (21) Inflated from 2007/08 to 2018/19 prices using PSSRU (2019) H&CHS indices (20)
Lung cancer	£10,772	Cancer Research UK (22) Inflated from 2012/13 to 2018/19 prices using PSSRU (2019) H&CHS indices (20)
MI	£1,135	Godfrey <i>et al.</i> (23) Inflated from 2011/12 to 2018/19 prices using PSSRU (2019) H&CHS indices (20)
CHD	£1,178	British Heart Foundation. Cardiovascular Disease Statistics (24) Inflated from 2012/13 to 2018/19 prices using PSSRU (2019) H&CHS indices (20)
COPD	£636	NICE NG115 Full guideline (previously CG101) Inflated from 2007/08 to 2018/19 prices using PSSRU (2019) H&CHS indices (20)

^d Personal Social Services Research Unit (PSSRU). Unit Costs of Health & Social Care 2015. Canterbury: University of Kent 2015.

Asthma exacerbation	£1,433	Leaviss <i>et al.</i> (2014) (25) Inflated from 2010/11 to 2018/19 prices using PSSRU (2019) H&CHS indices (20)
---------------------	--------	--

1

2 **Productivity costs**

3 The base case model was for a health and social care perspective. Productivity costs for
4 smokers and non-smokers were included in the model as part of a scenario analysis which
5 expanded the perspective to include wider societal costs. Full details of this can be found in
6 Report Q.

7 **Utilities**

8 Utility values are applied to smokers and former-smokers across each 1-year cycle in the
9 model by multiplying the relevant value by the proportion of people who are in each health
10 state across each annual cycle (i.e. the number of smokers and former smokers). In addition,
11 the utility values associated with each of the five comorbidities are used to calculate
12 disutilities. The disutilities are applied to the utilities of smokers and former smokers in the
13 model when they experience a comorbidity. Therefore, each disutility represented the
14 average annual disutility experienced per person per comorbidity.

15 It is possible to experience more than one comorbidity. When patients experience multiple
16 comorbidities at one time, it is not clear how this affects their quality of life. If each disease is
17 associated with a decrement in quality of life, would a person with two diseases experience
18 the sum of both decrements, only the decrement associated with the most severe
19 comorbidity or somewhere in between. The base analysis applies the disutility associated
20 with each comorbidity. Deterministic scenario analyses are used to explore the impact of
21 applying only the disutility associated with the most severe comorbidity. The utility inputs
22 included in the model are shown in Table 11.

23 **Table 11: Utility values**

24

Parameter	Utility value	Source
Stroke	0.48	Tengs and Wallace (28)
Lung cancer	0.61	Bolin <i>et al.</i> (2009) (29)
MI	0.80	Tengs and Wallace (28)
CHD	0.76	Stevanovic (30)
COPD	0.73	Rutten-van Molken <i>et al.</i> 2006 (31)
Asthma exacerbation*	0.729	For one week. Briggs <i>et al.</i> (2006) (32)
Smoker	0.8486	Vogl <i>et al.</i> (2012) (33)
Former smoker	0.8669	Vogl <i>et al.</i> (2012) (33)

25 *Assumed that disutility is incurred for 1 week

26

27 **Comorbidity epidemiology**

28

29 The model generates average (or 'expected') outcomes for specific baseline characteristics
30 (i.e. the outcomes are calculated for a person of a pre-specified age, gender and smoking
31 status). However, results are calculated for every possible baseline characteristic, and the

model then produces a 'weighted average' output, based on the known demographics of the assessed group. The specific parameters that varied by age group were smoking status, comorbidity prevalence and mortality risk. We were not able to identify age specific variables within the published sources so all other factors within the model were assumed to stay constant by age. The inputs required to inform the calculations of the prevalence of comorbidities by age, gender and smoking status are summarised in this section. Table 12 summarises the sources used for the prevalence of each comorbidity.

Table 12: Sources for prevalence of comorbidities

Prevalence	Source/notes
Stroke	Bhatnagar <i>et al.</i> (2015) (34)*
Lung cancer	Maddams <i>et al.</i> (2009) (35)*
MI	Health Survey for England (2017), Table 1: Prevalence of ever having any doctor-diagnosed MI by age and sex. (34)*
CHD	Townsend <i>et al.</i> (2012) (36). Assumed that 12 to 15-year olds had 0% prevalence. This assumption was made based on (i) the prevalence for the 16 to 24 age group was 0.1% (females) and 0.1% (males) and (ii) the younger age group (12 to 15) would have a lower risk for CHD than those aged 16 to 25. The youngest age group that data was available for was in people aged 16 to 24 years (0.1%)
COPD	Public Health England data set (not reported by gender). Assumed 12 to 15-year olds had 0.1% prevalence (given that the prevalence for the 16 to 24 age group 1.28% and the risk reduces with age). Data were only reported for ages as low as 16 to 24 years (1.28%)

Table 13 summarises the sources used for the relative risks by smoker, never-smoker and former smoker by gender. The pragmatic searches identified a new relevant source for the MI RR's, therefore Millet *et al.* (2018) was used as the source for this parameter in the updated model. All other RR values were retained from the original NG92 model. The between group differences in the intervention and comparator arms for the comorbidities are determined by smoking status based on the RR values. Each RR was obtained from a source in the published literature which applied an appropriate statistical technique to adjust for confounding factors which could also explain differences in comorbidity prevalence rates including age, sex, and disease risk factors.

Table 13: Sources for relative risks (RR) of comorbidities

Relative risks	Source/notes
Stroke	Myint <i>et al.</i> (2008) (40)
Lung cancer	Pesch <i>et al.</i> (2012) (41)
MI	Millet <i>et al.</i> (2018) (39)
CHD	Shields <i>et al.</i> (2013) (42)
COPD	Lokke <i>et al.</i> (2006) (43)

Asthma Exacerbation Inputs

The incidence of asthma exacerbations for smokers, short term (≤ 4 years) and long term quitters (> 4 years) follows the methods in the HTA report by Leaviss *et al.* 2014 where mortality associated with asthma exacerbation was assumed to equal all-cause mortality (i.e.

1 asthma exacerbations did not result in death). In addition, it was assumed that asthma
2 exacerbations were transient in nature and resolved within one year.

3 **Mortality epidemiology**

4 The mortality rates were obtained from Doll et al. (1994) which is an observational study with
5 40-year follow up using data the British doctors survey. The authors of the study have
6 published a more recent paper which provides 50-year follow-up (45). However, the 40-year
7 follow up data was used because it provided annual mortality by smoking habits at age of
8 death, which was not available in the 50-year follow up. The mortality rates from Doll et al.
9 (1994) were adjusted to reflect the general population mortality rates.

10

11 **Sensitivity analyses**

12 **Deterministic sensitivity analysis (DSA)**

13 Univariate deterministic sensitivity analyses were conducted for several key parameters in
14 the economic model. These included: intervention effectiveness (RR), the probability of
15 cessation at 12-months for placebo; the time horizon; intervention costs; the annual rate of
16 cessation and relapse; the discount rate for costs and QALYs; comorbidity costs; comorbidity
17 disutilities, and applying NHS intervention costs for e-cigarettes.

18

19 **Probabilistic sensitivity analysis**

20 Probabilistic sensitivity analysis was carried out to explore the impact of changing the value
21 of parameter inputs on the results produced by the model. In the base case model, a
22 weighted average of incremental costs and QALYs is obtained for one year age ranges i.e.
23 age 12, age 13, age 14...100. Incremental costs and QALYs across all population ages are
24 calculated as a weighted mean across all individual ages with weighting based on the
25 proportion of the UK population at each age individual.

26 To reduce the computational burden of the PSA, age categories were condensed from yearly
27 increments i.e. age 12, 13, 14, 15, ... , 100, to every ten years. To ensure the results of the
28 PSA were in alignment with the base case analysis, the youngest population age was set
29 equal to 12 (youngest age for the base case model) plus the midpoint of the age increment.
30 This meant the PSA calculated weighted averages for populations aged 17, 27, 37, .., 97. The
31 final results for the PSA were then calculated as a weighted average across results for
32 people aged 17, 27, 37, ..., 97 using a corresponding age weighting based on ONS
33 population estimates (13).

34 The parameters used in the PSA were intervention effectiveness, smoking status (by age
35 and gender), mortality, comorbidities, utilities, intervention costs and comorbidity costs.

36 **Scenario analysis**

37 In addition, several scenario analyses were carried out to explore the following:

- 38 1. the impact of comparing all interventions to NRT I/s rather than placebo,
- 39 2. the impact of including an additional study e-cigarette study (Hajek et al 2019) in the
40 NMA (see Review K appendices for further information and results),
- 41 3. the impact of allocating the cost of e-cigarettes to the NHS

42

43 **Subgroup analysis**

44 The cost effectiveness of pharmacotherapies for smoking cessation specifically for a
45 population with mental health problems. The characteristics of the mental health subgroup

was informed by the populations included in the updated NMA by Thomas et al. (2020) (6) in NICE evidence review K. This included people with depression, psychiatric disorder, bipolar, schizophrenia and post-traumatic stress disorder. For full details of changes to parameters relevant to mental health populations see full model report.

Exploratory analysis

To address the committee's concerns about possible health harms associated with use of e-cigarettes and the potential for e-cigarettes to promote uptake of smoking in non-smoking populations two analyses were carried out to explore the following:

1. the total amount of QALYs/costs worth of adverse events per person that would make e-cigarettes not cost-effective vs usual care,
2. the trade-off between lifetime costs and QALYs gained in populations who quit smoking due to e-cigarettes and those lost in populations who take up smoking due to e-cigarettes.

Model results

Basecase - full incremental analysis

The full incremental analysis compares the cost-effectiveness of each of the smoking cessation interventions with one-another and to placebo in the general population. All results are obtained as weighted averages of results for populations aged 12 to 100, this representing everybody who could feasibly have been classified as smokers when entering the model.

The base case results for the fully incremental analysis are displayed in Table 14. Bupropion + NRT I/s was the most cost-effective strategy and was dominant versus each of the other interventions having the lowest total healthcare costs (£10,802) and highest lifetime QALYs (15.37) per person, and subsequently the highest net monetary benefit vs. placebo, equal to £5,928 per person.

Table 14: Cost-effectiveness results (per person)

Intervention	RR (mean, rank)	Quitters @ 12 months (per 1,000)	Lifetime costs	Lifetime QALYs	NMB vs. placebo	CE Rank
Placebo	1.00 (11)	98	£11,523	15.11	£0	11
Bupropion	1.73 (10)	170	£11,314	15.18	£1,723	10
NRT I/s	1.83 (9)	180	£11,285	15.19	£1,960	9
Bupropion + NRT I/s	1.93 (8)	190	£11,294	15.20	£2,158	8
Varenicline	2.27 (6)	223	£11,244	15.24	£2,913	7
E-cigarettes	2.25 (7)	221	£11,090	15.24	£3,026	6
Varenicline + NRT I/s	2.58 (5)	254	£11,186	15.27	£3,615	5
Varenicline + bupropion	2.75 (3)	271	£11,122	15.29	£4,031	4

NRT I&s	2.71 (4)	267	£11,035	15.29	£4,035	3
E-cigarettes + NRT I/s	2.93 (2)	288	£10,903	15.31	£4,623	2
Bupropion + NRT I&s	3.51 (1)	345	£10,802	15.37	£5,928	1

RR= relative risk versus placebo

CE = cost-effectiveness

Basecase – pairwise analyses vs placebo

As well as establishing the most cost-effective treatment option, the committee requested that the economic analysis identified the cost-effectiveness of each intervention versus placebo. A full breakdown of the pairwise comparisons is provided in Table 15.

All of the interventions were highly cost-effective, and dominated placebo as they each resulted in healthcare savings and additional QALYs. All of the interventions resulted in substantially more quitters at 12-months, and consequently reductions in the prevalence of smoking related diseases and smoking related mortality.

Table 15: Incremental cost-effectiveness results (per person): Pairwise results vs. placebo

Intervention	RR vs. placebo	Incremental outcomes vs. placebo			ICER
		Quitters @ 12 months (per 1,000)	Lifetime costs	Lifetime QALYs	
Bupropion	1.73	72	-£209	0.07	Dominant
NRT I/s	1.83	82	-£238	0.08	Dominant
Bupropion + NRT I/s	1.93	92	-£229	0.09	Dominant
Varenicline	2.27	125	-£279	0.13	Dominant
E-cigarettes	2.25	123	-£433	0.13	Dominant
Varenicline + NRT I/s	2.58	156	-£337	0.16	Dominant
Varenicline + bupropion	2.75	173	-£401	0.18	Dominant
NRT I&s	2.71	169	-£488	0.18	Dominant
E-cigarettes + NRT I/s	2.93	190	-£620	0.20	Dominant
Bupropion + NRT I&s	3.51	247	-£721	0.26	Dominant

Deterministic sensitivity analysis

Univariate deterministic sensitivity analyses were conducted for several key parameters in the economic model. These included: intervention effectiveness (RR), the probability of cessation at 12-months for placebo; the time horizon; intervention costs; the annual rate of cessation and relapse; the discount rate for costs and QALYs; comorbidity costs; comorbidity disutilities, and applying NHS intervention costs for e-cigarettes.

Applying the lower 95% CI RR values did not affect the pairwise results as each intervention remained cost-effective and dominant (decreased lifetime costs, increased QALYs) versus placebo. However, the DSA affected the fully incremental analysis and there were also substantial changes to the cost-effectiveness ranks. The full results, including those for several additional DSAs are available in the modelling report.

Probabilistic Sensitivity Analysis (PSA)

The results of the PSA, conducted at a cost-effectiveness threshold of £20,000 per QALY are displayed in Table 16. All interventions were highly cost-effective in the pairwise comparison, with each intervention being cost-effective in above 99% of the 3,000 PSA iterations versus placebo.

The PSA results for the fully incremental analysis indicated that bupropion + NRT I/s was cost-effective in 54.3% of iterations. Meanwhile, E-cigarettes + NRT I/s was cost-effective in 22.87% of iterations; varenicline + bupropion was cost-effective in 10.67% of PSA iterations; varenicline + NRT I/s in 4.53% of PSA iterations; NRT I/s was cost-effective in 4.5% of PSA iterations; and e-cigarettes were cost-effective in 3.13% of PSA iterations. Each of the other interventions had a very low probability of cost-effectiveness close or equal to 0%.

Table 16: PSA results for the base case, cost effectiveness threshold = £20,000

Intervention	Probability cost-effective	
	Pairwise analysis (Vs. placebo)	Fully incremental analysis (Vs. all other interventions)
Placebo	N/A	0%
Bupropion	100%	0%
NRT I/s	100%	0%
Bupropion + NRT I/s	100%	0%
Varenicline	100%	0%
E-cigarettes	99.97%	3.13%
Varenicline + NRT I/s	100%	4.53%
Varenicline + bupropion	100%	10.67%
NRT I/s	100%	4.50%
E-cigarettes + NRT I/s	99.90%	22.87%
Bupropion + NRT I/s	99.93%	54.30%

The results of one of the pairwise comparison (for e-cigarettes versus placebo) is displayed in Figure 3. The figure plots PSA results on a cost-effectiveness plane, each point (in red)

represents one PSA iteration. Interventions are cost-effective if their incremental costs and QALYs fall to the south-east of the cost-effectiveness threshold, equal to £20,000 per QALY.

Figure 3: Cost effectiveness plane e-cigarettes versus placebo





Figure 4 displays the results of the fully incremental PSA in a cost-effectiveness acceptability curve (CEAC) for the four interventions with the largest probability of being cost-effective. The CEAC is a graph summarising the impact of uncertainty on the result of an economic evaluation, frequently expressed as an ICER (incremental cost-effectiveness ratio) in relation to possible values of the cost-effectiveness threshold. The graph plots a range of cost-effectiveness thresholds on the horizontal axis against the probability that the intervention will be cost-effective at that threshold on the vertical axis. The CEAC indicates that changes to the cost-effectiveness threshold had a very minimal impact on each intervention's probability of being the most cost-effective treatment option.

Figure 4: Cost effectiveness acceptability curves, fully incremental analysis*



* Figure plots the CEACs for the four interventions with the highest probability of cost-effectiveness. Bupropion, NRT I/s, bupropion + NRT I/s, varenicline, e-cigarettes and varenicline + NRT I/s were not included in the graph as the associated probability of cost-effectiveness was insubstantial (i.e. below 5%).

Scenario analyses

Full incremental analysis excluding placebo

In the scenario analysis placebo was removed and all ten interventions were compared with one-another with NRT I/s acting as the reference category. As with the basecase which included placebo, Bupropion + NRT I/s was the most cost-effective strategy in the scenario analysis. The DSA did not result in any changes to the base case cost-effectiveness results, as bupropion + NRT I/s remained the dominant strategy. Furthermore, each intervention retained the same CE ranking when ordered by NMB.

Applying costs of e-cigarettes to NHS

In the scenario analysis a cost of £55.75 was applied to the NHS. This assumed 48% of costs would be incurred via prescriptions and 52% would be purchased privately OTC. The basecase assumed the cost of e-cigarettes was incurred privately. When including costs for usual care the total costs of: e-cigarettes increased from £82.96 in the base case to £138.71 in the scenario analysis; and e-cigarettes + NRT I/s increased from £131.84 in the base case to £187.59 in the scenario analysis.

The results of the scenario analysis were very similar to the base case analysis. Bupropion + NRT I/s remained the cost-effective strategy. There was a minor change in the results for the e-cigarettes intervention, which became the seventh ranking cost-effective strategy as

opposed to the sixth ranking strategy in the base case analysis (trading positions with varenicline). All other strategies had an identical NMB rank.

Mental health subgroup analysis

Full incremental analysis

The fully incremental analysis identified Bupropion + NRT I/s as the most cost-effective and dominant strategy versus each of the other interventions. This differed from results in the general population where bupropion + NRT I/s was the most cost-effective strategy. Bupropion + NRT I/s had the lowest total healthcare costs (£18,728) and highest lifetime QALYs (12.06) per person, and subsequently the highest net monetary benefit vs. placebo, equal to £6,797 per person. As with the base case analysis, cost-effectiveness was driven by the effectiveness parameters. The RR rank for each intervention directly corresponded with the net monetary benefit rank in the cost-effectiveness analysis (see Table 17). The major difference between the mental health subgroup and the base case analysis were related to the values of lifetime total costs, which substantially increased, and lifetime total QALYs, which substantially decreased.

Table 17 Cost effectiveness results (per person): full incremental analysis for mental health subgroup

Intervention	RR vs. placebo (mean, rank)	Quitters @ 12 months (per 1,000)	Lifetime costs	Lifetime QALYs	NMB vs. placebo	CE Rank
Placebo	1.00 (7)	56	£20,541	11.81	£0	7
Bupropion	1.79 (6)	102	£20,327	11.84	£870	6
NRT I/s	1.89 (5)	106	£20,229	11.84	£981	5
Varenicline	2.29 (4)	128	£20,444	11.84	£1,332	4
NRT I&s	3.97 (3)	223	£19,674	11.86	£3,334	3
Bupropion + NRT I&s	4.24 (2)	237	£19,575	11.94	£3,657	2
Bupropion + NRT I/s	7.00 (1)	392	£18,728	12.06	£6,797	1

RR= relative risk versus placebo

CE= cost-effectiveness

Pairwise results vs placebo

As with the base case analysis (in the general population), each intervention was highly cost-effective versus placebo. All interventions had a dominant ICER as they each resulted in healthcare savings and additional QALYs. All of the interventions resulted in substantially more quitters at 12-months, and consequently reductions in the prevalence of smoking related diseases and smoking related mortality for the mental health subgroup.

Deterministic sensitivity analysis (RR values)

In the DSA for the mental health subgroup the effectiveness rates were set equal to the lower and upper 95% CI RR values. Applying the lower value impacted the cost effectiveness of some interventions and rank order of all interventions included in the analysis. For example, bupropion + NRT I/s became the most cost-effective strategy and bupropion + NRT I/s moved from being most cost-effective to being less effective and cost-effective than placebo. In contrast, applying the upper 95% CI values for the RR parameters resulted in all interventions being highly cost-effective versus placebo. The full results are available in the modelling report.

Probabilistic sensitivity analysis

The results of the PSA for the mental health subgroup are shown in Table 18: all interventions were highly cost effective in the pairwise comparison versus placebo. With the exception of NRT I/s, all other interventions had a probability of over 90% of being cost effective at a threshold of £20,000 per QALY.


The PSA results for the fully incremental analysis indicated that bupropion + NRT I/s was cost-effective in 62% of iterations. Meanwhile, NRT I/s was cost-effective in 23.2% of PSA iterations and bupropion + NRT I/s was cost-effective in 12.2% of PSA iterations. Each of the other interventions had a very low probability of cost-effectiveness close or equal to 0%.

Table 18: PSA results for mental health subgroup, cost effectiveness threshold = £20,000

Intervention	Probability cost-effective	
	Pairwise analysis (Vs. placebo)	Fully incremental analysis (Vs. all other interventions)
Placebo	N/A	0%
Bupropion	92.83%	1.57%
Varenicline	95.23%	0.60%
NRT I/s	95.13%	0.73%
Bupropion + NRT I/s	93.20%	12.27%
NRT I/s	78.83%	23.17%
Bupropion + NRT I/s	96.33%	61.67%

Figure 5 displays the results of the fully incremental PSA in a cost-effectiveness acceptability curve (CEAC) for the three interventions with the largest probability of being cost-effective in the mental health subgroup. As with the base case analysis, the CEAC indicates that changes to the cost-effectiveness threshold had a very minimal impact on each intervention's probability of being the most cost-effective treatment option.

Figure 5: Cost-effectiveness acceptability curves, mental health subgroup, fully incremental analysis*



*Figure plots the CEACs for the three interventions with the highest probability of cost-effectiveness. Bupropion, NRT I/s, and varenicline were not included in the graph as the associated probability of cost-effectiveness was insubstantial (i.e. below 2.5%).

6 Exploratory analyses

7 *E-cigarette health harms*

A threshold analysis was performed to determine the total amount of QALYs/costs worth of adverse events that would be required per person to make e-cigarettes not cost-effective vs. usual care. The results of the threshold analysis are displayed in Figure 6, which depicts the net monetary benefit for E-cigarettes vs. placebo. In each instance, the NMB has been re-estimated to account for safety impacts per person associated with e-cigarettes, and the number of e-cigarette users who have an adverse event. The Figure includes the cost per adverse event in £, which could include NHS treatment costs, or health benefits as monetized QALYs (for example, by using the NICE CE threshold equal to £20,000). For example, E-cigarettes would not be cost-effective if 5% of people who used E-cigarettes experienced an AE, and the net cost per AE was equal to £75,000.

18 **Figure 1: E-cigarettes health harms**

	NMB ¹	Cost per AE per person							
		£500	£1,500	£5,000	£10,000	£25,000	£50,000	£75,000	£100,000
Absolute % of e-cig users with AE	1.00%	£3,020	£3,010	£2,975	£2,925	£2,775	£2,525	£2,275	£2,025
	2.50%	£3,013	£2,988	£2,900	£2,775	£2,400	£1,775	£1,150	£525
	5.00%	£3,000	£2,950	£2,775	£2,525	£1,775	£525	£-725	£-1,975
	7.50%	£2,988	£2,913	£2,650	£2,275	£1,150	£-725	£-2,600	£-4,475
	10.00%	£2,975	£2,875	£2,525	£2,025	£525	£-1,975	£-4,475	£-6,975
	12.50%	£2,963	£2,838	£2,400	£1,775	£-100	£-3,225	£-6,350	£-9,475
	15.00%	£2,950	£2,800	£2,275	£1,525	£-725	£-4,475	£-8,225	£-11,975
	17.50%	£2,938	£2,763	£2,150	£1,275	£-1,350	£-5,725	£-10,100	£-14,475
	20.00%	£2,925	£2,725	£2,025	£1,025	£-1,975	£-6,975	£-11,975	£-16,975
	22.50%	£2,913	£2,688	£1,900	£775	£-2,600	£-8,225	£-13,850	£-19,475
	25.00%	£2,900	£2,650	£1,775	£525	£-3,225	£-9,475	£-15,725	£-21,975

1: Results are displayed as incremental net monetary benefit (NMB) vs. placebo. Any NMB greater than zero indicates that the intervention is cost-effective. The cost-effectiveness threshold was set equal to £20,000.

E-cigarette uptake

A scenario analysis was performed to illustrate the potential gateway impact of e-cigarettes. The scenario analysis investigated the level of smoking uptake due to e-cigarettes in non-smokers that would be required before e-cigarettes were considered to do more harm than good in the UK population. This given the population benefits that e-cigarettes generate due to increasing smoking cessation in current smokers who want to quit in the UK.

The analysis involved two calculations, firstly the total population benefit of e-cigarettes if used for tobacco cessation in current smokers in the UK is approximated. Secondly, the total harm from e-cigarettes in the UK population due to non-smokers taking up smoking due to e-cigarettes is approximated. These values are then summed to identify the net impact of e-cigarettes in the UK population.

The net impact of e-cigarettes is shown in Figure 7. For example, the results indicate that e-cigarettes would still likely have a positive budget impact if: 1.5% or fewer non-smokers (never smokers and ex-smokers) take up e-cigarettes and 20% of this population become regular tobacco smokers due to e-cigarette use; or alternatively, if 5% or fewer non-smokers (never smokers and ex-smokers) took up e-cigarettes and 5% or of this population become regular tobacco smokers due to e-cigarette use.

Figure 7: E-cigarettes uptake analysis

Budget impact (£ millions)		% of new e-cig users who take up smoking								
		1.00%	2.50%	5.00%	7.50%	10.00%	15.00%	20.00%	25.00%	50.00%
% of non-smokers who take up e-cigarettes	1.00%	£4,719	£4,519	£4,185	£3,850	£3,516	£2,848	£2,180	£1,512	£-1,830
	1.50%	£4,652	£4,352	£3,850	£3,349	£2,848	£1,846	£843	£-159	£-5,171
	2.50%	£4,519	£4,017	£3,182	£2,347	£1,512	£-159	£-1,830	£-3,500	£-11,853
	5.00%	£4,185	£3,182	£1,512	£-159	£-1,830	£-5,171	£-8,512	£-11,853	£-28,560
	7.50%	£3,850	£2,347	£-159	£-2,665	£-5,171	£-10,183	£-15,195	£-20,207	£-45,266
	10.00%	£3,516	£1,512	£-1,830	£-5,171	£-8,512	£-15,195	£-21,877	£-28,560	£-61,972
	12.50%	£3,182	£676	£-3,500	£-7,677	£-11,853	£-20,207	£-28,560	£-36,913	£-78,679
	15.00%	£2,848	£-159	£-5,171	£-10,183	£-15,195	£-25,219	£-35,242	£-45,266	£-95,385
	20.00%	£2,180	£-1,830	£-8,512	£-15,195	£-21,877	£-35,242	£-48,607	£-61,972	£-128,798

Summary of the evidence

1 Relative effectiveness at 6 month follow-up

2 Table 19: Evidence summary for relative effectiveness NMA (cessation at 6 months)

3 Full results for the relative effectiveness of various treatments for cessation can be found in Appendix J. The below table summarises the results
 4 from the mileage chart for the full NMA. Results have been reversed where necessary (where A is shown as better than B in the mileage chart, it
 5 has also been reversed to show that B is worse than A in this table).

Cessation at 6 months	Treatments									
	NRT long/short acting	NRT long & short acting	Bupropion	Varenicline	E-cigarette	Bupropion + NRT long/short acting	Bupropion + NRT long & short acting	Varenicline + NRT long/short acting	Varenicline + bupropion	E-cigarette + NRT long/short acting
Treatment* is significantly more effective than:	- Placebo - No drug treatment - Usual care	- Placebo - No drug treatment - Waitlist - Usual care - NRT long/short - Bupropion	- Placebo - No drug treatment - Usual care	- Placebo - No drug treatment - Waitlist - Usual care - NRT long/short - Bupropion	- Placebo - Usual care	- Placebo - No drug treatment - Usual care	- Placebo - No drug treatment - Waitlist - Usual care - Bupropion	- Placebo - No drug treatment - Waitlist - Usual care	- Placebo - No drug treatment - Waitlist - Usual care	- Placebo - No drug treatment - Usual care
Treatment* is significantly less effective than:	- NRT long & short - Varenicline	-	- NRT long & short - Varenicline - Bupropion + NRT long & short	-	-	-	-	-	-	-
An effect was not detected of the treatment* compared with:	- Waitlist - Bupropion - E-cigarette - Bupropion + NRT long/short - Bupropion + NRT	- Varenicline - E-cigarette - Bupropion + NRT long/short - Bupropion + NRT	- Waitlist - NRT long/short - E-cigarette - Bupropion + NRT long/short	- NRT long & short - E-cigarette - Bupropion + NRT long/short - Bupropion + NRT	- No drug treatment - Waitlist - Bupropion - NRT long/short - NRT long & short	- Waitlist - NRT long/short - NRT long & short - Bupropion - Varenicline - E-cigarette	- NRT long/short - NRT long & short - Bupropion - Varenicline - E-cigarette	- NRT long/short - NRT long & short - Bupropion - Varenicline - E-cigarette	- NRT long/short - NRT long & short - Bupropion - Varenicline - E-cigarette	- Waitlist - NRT long/short - NRT long & short - Bupropion - Varenicline - E-cigarette

Cessation at 6 months	Treatments									
	NRT long/short acting	NRT long & short acting	Bupropion	Varenicline	E-cigarette	Bupropion + NRT long/short acting	Bupropion + NRT long & short acting	Varenicline + NRT long/short acting	Varenicline + bupropion	E-cigarette + NRT long/short acting
	long & short • Varenicline + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short	long & short • Varenicline + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short	• Varenicline + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short	long & short • Varenicline + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short	• Varenicline • Bupropion + NRT long/short • Bupropion + NRT long & short • Varenicline + NRT long/short • Varenicline + bupropion • Varenicline + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short	• Bupropion + NRT long & short • Varenicline + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short	• Bupropion + NRT long/short • Varenicline + NRT long/short • Varenicline + bupropion • E-cigarette + NRT long/short	• Bupropion + NRT long/short • Bupropion + NRT long & short • Varenicline + bupropion • E-cigarette + NRT long/short	• Bupropion + NRT long/short • Bupropion + NRT long & short • Varenicline + NRT long/short • E-cigarette + NRT long/short	• Bupropion + NRT long/short • Bupropion + NRT long & short • Varenicline + NRT long/short • Varenicline + bupropion

1 * This refers to the treatment at the head of each column.

2 Mental health subgroup

3 Table 8: Evidence summary for relative effectiveness NMA, mental health subgroup (cessation at 6 months)

4 Full results for the relative effectiveness of various treatments in those with mental health conditions for cessation can be found in Appendix J. The
5 below table summarises the results from the mileage chart for the NMA of studies conducted in populations with mental health conditions. Results
6 have been reversed where necessary (where A is shown as better than B in the mileage chart, it has also been reversed to show that B is worse
7 than A in this table).

Cessation at 6 months	Treatments					
	NRT long/short acting	NRT long & short acting	Bupropion	Varenicline	Bupropion + NRT long & short acting	Bupropion + NRT long / short acting
Treatment* is significantly	• Placebo	-	-	• Placebo	-	• Placebo • Usual care

Cessation at 6 months	Treatments					
	NRT long/short acting	NRT long & short acting	Bupropion	Varenicline	Bupropion + NRT long & short acting	Bupropion + NRT long / short acting
more effective than:						• Bupropion
Treatment* is significantly less effective than:	-	-	• Bupropion + NRT long/short	-	-	-
An effect was not detected of the treatment* compared with:	• No drug treatment • Usual care • Bupropion • Varenicline • Bupropion + NRT long/short • Bupropion + NRT long & short	• Placebo • No drug treatment • Usual care • NRT long/short • NRT long & short • Varenicline • Bupropion + NRT long/short • Bupropion + NRT long & short	• Placebo • No drug treatment • Usual care • NRT long/short • NRT long & short • Varenicline • Bupropion + NRT long/short • Bupropion + NRT long & short	• No drug treatment • Usual care • NRT long/short • NRT long & short • Bupropion • Bupropion + NRT long/short • Bupropion + NRT long & short	• Placebo • No drug treatment • Usual care • NRT long/short • NRT long & short • Bupropion • Varenicline • Bupropion + NRT long & short	• No drug treatment • NRT long/short • NRT long & short • Varenicline • Bupropion + NRT long/short

1 * This refers to the treatment at the head of each column.

1 Adverse events

2 This table is an overview of the results presented in GRADE tables 47 to 49. The GRADE
3 tables contain more information about confidence in the evidence and limitations ([Appendix](#)
4 [E](#)).

5 **Table 9: Evidence summary for adverse events**

Comparison	Summary	Confidence	GRADE profile
E-cigarette vs no drug treatment	The results suggested a clinically important increase in irritability in the e-cigarette group compared with the no drug treatment group. The results suggest a clinically important increase in abnormal dreams, anxiety, dry mouth, fatigue, insomnia, nausea, serious adverse events, skin rash and sleep disorders in the e-cigarette group compared with the no drug treatment group, with high uncertainty. The results suggest no clinically important difference in arrhythmia, headache or withdrawal from the study due to adverse events in the e-cigarette group compared with the no drug treatment group, with high uncertainty. The results suggest no clinically important increase in death (all causes) in the e-cigarette group compared with the no drug treatment group.	Moderate to very low	47
E-cigarette vs NRT	The results suggest a clinically important increase in abnormal dreams, depression, non-fatal MI, non-fatal stroke, pruritus and suicidal ideation in the e-cigarette group compared with the NRT group, with high uncertainty. The results suggest a clinically important decrease in anxiety, headache, insomnia, skin rash, palpitations and transient ischaemic attack in the e-cigarette group compared with the NRT group, with high uncertainty. The results suggest a clinically important increase in serious adverse events and hospital admissions in the e-cigarette group compared with the NRT group, with some uncertainty. The results suggest no clinically important difference in fatigue in the e-cigarette group compared with the NRT group, with high uncertainty. The results suggest no clinically important difference in nausea in the e-cigarette group compared with the NRT group, with some uncertainty.	High to very low	48

Comparison	Summary	Confidence	GRADE profile
	The results suggest no clinically important increase in death (all causes) or cardiovascular death in the e-cigarette group compared with the NRT group.		
E-cigarette vs placebo e-cigarette	The results suggest a clinically important increase in fatigue, insomnia and nausea in the e-cigarette group compared with the placebo e-cigarette group, with high uncertainty. The results suggest a clinically important decrease in non-fatal MI in the e-cigarette group compared with the placebo e-cigarette group, with high uncertainty. The results suggest a clinically important increase in abnormal dreams in the e-cigarette group compared with the placebo e-cigarette group, with some uncertainty. The results suggest no clinically important difference in headache, hospitalisation, non-fatal stroke, palpitations or serious adverse events in the e-cigarette group compared with the placebo e-cigarette group, with high uncertainty. The results suggest no clinically important decrease in death (all causes) or cardiovascular death in the e-cigarette group compared with the placebo e-cigarette group.	Moderate to Low (4 studies in this area)	49

1 Relative effectiveness at short follow-up

2 This table is an overview of the results presented in GRADE tables 50 to 52. The GRADE
3 tables contain more information about confidence in the evidence and limitations ([Appendix](#)
4 [E](#)).

5 Table 10: Evidence summary for short term follow-up (outcome is smoking cessation)

Comparison	Summary	Confidence	GRADE profile
E-cigarette vs placebo e-cigarette	The results suggest no clinically important difference in smoking cessation in the e-cigarette group compared with the placebo e-cigarette group at either 1-3 months or at 3-6 months.	1-3 months: Low (2 studies) 3-6 months: Moderate (2 studies)	50
E-cigarette vs NRT	The results suggest a clinically important increase in smoking cessation in the e-cigarette group compared with the NRT group at 1-3 months.	1-3 months: Moderate (3 studies) 3-6 months: Low (1 study)	51

Comparison	Summary	Confidence	GRADE profile
	The results suggest no clinically important difference in smoking cessation in the e-cigarette group compared with the NRT group at 3-6 months.		
E-cigarette vs no / minimal intervention	The results suggest no clinically important difference in smoking cessation in the e-cigarette group compared with the no / minimal intervention group at 1-3 months. The results suggest a clinically important increase in smoking cessation in the e-cigarette group compared with the no / minimal intervention group at 3-6 months.	1-3 months: Very Low (1 study) 3-6 months: Low (2 studies)	52

1 In all cases, 1-3 months indicates follow-up of more than or equal to one month but less than
2 three months, and 3-6 months indicates follow-up of more than or equal to 3 months but less
3 than 24 weeks. Follow-up of 24 weeks or more is included in the NMA instead of in the short
4 follow-up analysis.

5 Economic evidence statements

6 Annemans (2015) found that re-treatment with varenicline for a smoking cessation was cost-
7 effective compared with re-treatment with bupropion, re-treatment with NRT, re-treatment
8 with placebo and treatment with varenicline followed by re-treatment with placebo. The
9 economic evaluation showed that two quit attempts (2QA) with varenicline dominated all
10 other interventions. Both deterministic sensitivity analyses (DSA) and probabilistic sensitivity
11 analysis (PSA) indicated that the conclusions are robust. For every treatment comparison,
12 the PSA results confirmed that 2QA varenicline was significantly dominated comparators.
13 Due to lack of evidence, it was assumed that NRT and bupropion cessations have equal
14 efficacy for first and second quit attempts. In addition, the author commented that the
15 analysis did not take into account productivity-related costs, likely leading to an
16 underestimation of the economic benefit of 2QA varenicline. The analysis was assessed as
17 partly applicable to the review question, with minor limitations.

18
19 One cost-effectiveness analysis (Athanasakis, 2012) found that a 12-week course of
20 varenicline is cost-effective compared with bupropion (12 weeks), NRT (12 weeks) or
21 unaided cessation. The economic evaluation showed that varenicline (12 weeks) dominated
22 all other interventions. The cost per additional quitter for varenicline, considering only the
23 cost of the smoking cessation strategy, was €2,659 (€1,015) for a lifetime horizon compared
24 with bupropion (NRT). When direct costs were incorporated into the analysis, varenicline
25 was cost saving. The analysis was based on a BENESCO (Markov) model. Probabilistic
26 sensitivity analysis suggests, for an implicit €30,000 threshold, varenicline was cost-effective
27 for 82.3%, 86.6% and 85.2% of the Monte-Carlo iterations vs. bupropion, NRT and unaided
28 cessation, respectively. The author comments that the present analysis would be more
29 favourable if a wider perspective of calculation had been taken into account. The analysis
30 was assessed as partly applicable to the review question, with minor limitations.

31
32 Coward (2014) found that varenicline (12 weeks) was cost-effective compared with NRT with
33 counselling, NRT alone, counselling alone and no program for smoking cessation in patients
34 with Crohn's disease (CD). The economic evaluation showed that varenicline (12 weeks)
35 dominated all other interventions. The cost savings of varenicline (12 weeks) compared with

no program was 16,116,169 CAD\$ over a five year time horizon. Varenicline (12 weeks) remained the most cost-effective strategy until its effectiveness was reduced below 17.7%. Although the model includes health states relating CD, the long-term effects of smoking-related morbidities were not considered. In addition, effectiveness data was taken from multiple sources without the use of meta-analysis. The analysis was assessed as partly applicable to the review question, with major limitations.

One cost-effectiveness analysis (Hagen, 2010) found that varenicline was cost-effective compared with NRT, bupropion and placebo. Results were most sensitive to changes in age, the price of varenicline, average healthcare expenses per person per year and choice of discount rate. However, changes to these parameters did not bring the ICER above the willingness to pay per life year of NOK 500,000. Probabilistic sensitivity analysis showed varenicline was the optimal choice when willingness to pay per life year was above NOK 116,000. Smoking-related morbidities were not included in the model. In addition, annual healthcare cost were assumed the same between smokers and non-smokers. The analysis was assessed as partly applicable to the review question, with minor limitations.

One cost-utility analysis (Hettle, 2012) found that a 12-week treatment of varenicline plus 12 counselling sessions was cost-effective compared with 12 weeks of placebo plus 12 counselling sessions. Three Markov models (BENESCO) were populated using 52-week abstinence rates obtained from a double-blind placebo RCT and cost and utility data from Austria, Germany and Hungary respectively. This analysis was similar to Wilson (2012). The analysis found that from a payer perspective varenicline had an incremental cost-effectiveness ratio per QALY gained of €5,278, €5,867 and €3,183 for Austria, Germany and Hungary respectively. From a societal perspective, varenicline was dominant in all countries. The probabilistic sensitivity analysis found that in all scenarios and countries, varenicline remained cost-effective under a threshold of €12,500 per QALY gained. A minor limitation was that it was unclear if the cost and utility data came from the best sources. The analysis was assessed as partly applicable to the review question since it was set in multiple European countries, but not the UK.

Huber (2018) evaluate the costs, effects and cost-effectiveness of increased reach for smoking cessation interventions in Germany. Current investment interventions included behavioural support, varenicline, bupropion, NRT, and financial incentives. A Markov model (EQUIPTMOD) was populated with efficacy, utility and cost data from Germany. The model established cost-effectiveness for different uptake scenarios where the reach of current investments increased due to an increased number of quit attempts in the population. For scenario 1 uptake attempts were increased by 1% (57,915 total); for scenario 2 intervention uptake was changed to match levels observed in England. Both scenarios were dominant (decreased costs and increased QALYs) vs. current uptake levels in Germany. Secondary outcomes included: returns through reduction in smoking-related health-care costs vs. no intervention for the financial incentive programme (€2.71 per €1 invested), group-based behavioural support (€1.63 per €1 invested) and Varenicline (€1.02 per €1 invested); and ICERs which were dominant for financial incentives, group based behavioural support and varenicline (all vs. no investment). The study was determined to be partly applicable and had major limitations as no uncertainty analysis was conducted around results for the individual interventions.

Kautiainen (2017) found that re-treatment with varenicline for a smoking cessation was cost-effective compared with re-treatment with bupropion, re-treatment with NRT, unaided re-treatment and treatment with varenicline followed by re-treatment with placebo. The economic evaluation showed that two quit attempts (2QA) with varenicline dominated all other interventions. This model was similar to Annemans (2012) but in a Finnish context. Both deterministic sensitivity analyses (DSA) and probabilistic sensitivity analysis (PSA) indicated that the conclusions are robust. Compared with 2QA NRT, 2QA varenicline is

99.9% cost-effective at a willingness to pay threshold of 5,000€ per QALY. It is assumed that the first and second quit attempts for NRT, bupropion and unaided cessation have equal efficacy and that the efficacy estimate for varenicline re-treatment is based on only one RCT. Varenicline retreatment efficacy was investigated in sensitivity analysis. At the lower limit (-20% of base case), 2QA varenicline vs 2QA bupropion gave an ICER of 4,550€/QALY and vs NRT it was 1,584€/QALY with all other comparators dominated. The analysis was assessed as partly applicable to the review question, with minor limitations.

Knight (2012) found that an extended course of varenicline (12 weeks + an additional 12 weeks for those who had remained abstinent), alongside brief counselling, is highly cost-effective compared with 12 weeks of varenicline or bupropion, both with brief counselling, or with brief counselling alone. The economic evaluation showed varenicline (12+12 weeks) compared with varenicline (12 weeks) had an ICER of €1101 per QALY gained over a subject's lifetime. All other interventions were dominated. The analysis was based on a BENESCO (Markov) model. Probabilistic sensitivity analysis suggested an 81.7% likelihood that Varenicline (12+12 weeks) is cost-effective at a willingness to pay of €30,000 per QALY. The author comments that NRT is not considered in the analysis, as it is only available at full cost to the patient. Additionally, the model ignores societal cost that may further improve the cost-effectiveness of the more effective interventions. The analysis was assessed as partially applicable to the review question, with minor limitations.

Li (2019) found that the use of e-cigarettes (EC) to aid smoking cessations was cost-effective compared with nicotine replacement therapy (NRT). The primary analysis was the 12-month cost-effectiveness informed by a self-conducted randomised control trial (RCT) with the secondary analysis a Markov model used to project long-term cost-effectiveness. The economic evaluation of EC compared with NRT gave an incremental cost-effectiveness ratio (ICER) of £1,100 per QALY gained at 12-months and £65 per QALY gained over a lifetime. Probabilistic sensitivity analysis (PSA) estimated an 87% and 85% probability that EC was cost-effective at a £20,000/QALY threshold for 12-months and lifetime horizons, respectively. The lifetime model did not consider the possible long-term effects of using EC on health and personal finance. The author highlights a 35% missing data level from the RCT which makes the analysis less certain. The analysis was assessed as directly applicable to the research question, with minor limitations.

One cost-utility analysis (Linden, 2010) found that a 12-week treatment of varenicline was cost-effective versus both a 7-week treatment of bupropion and unaided cessation. A Markov model was populated using 52-week abstinence rates obtained from numerous studies (including two head to head RCTs of identical study design) and cost and utility data from the Finland. The analysis found that from a Finnish societal perspective varenicline had total cost savings and higher total QALYs than bupropion and unaided cessation, so was dominant. Deterministic sensitivity analysis found that even with major changes of the input values, varenicline remained dominant below the ICER threshold of £30,000 (€33,200) over a lifetime horizon. Probabilistic sensitivity analysis found that, when the willingness-to-pay threshold was €10,000, varenicline was cost-effective compared with bupropion (unaided cessation) 65% (80%) of the time. The study was determined to be partly applicable to the research question since it was set in Finland and had no limitations.

One cost-utility analysis (Lock, 2011) found that a 12-week treatment of varenicline plus weekly counselling sessions and a booklet, was cost-effective versus 12 weeks of placebo with the same co-therapies. A Markov model was populated using 52-week abstinence rates obtained from a double-blind placebo RCT and cost and utility data from the UK. The analysis found that from the NHS's perspective varenicline had an incremental cost-effectiveness ratio per QALY gained of €4478. Probabilistic sensitivity analysis found that at an implicit threshold of €30,000 per QALY gained, varenicline had a high probability of being

cost-effective when compared with placebo. The study was determined to be partly applicable to the research question as the population focused on COPD patients, It had minor limitations since it is unclear whether some of the cost and utility data came from the best sources.

Von Wartburg (2014) found that 12 weeks of varenicline followed by a further 12-week course for successful quitters (varenicline 12+12 weeks) was highly cost-effective compared with standard varenicline treatment (12 weeks only). Both varenicline (12+12 weeks) and varenicline (12 weeks) dominated alternative smoking cessation interventions (NRT and bupropion). The analysis was based on the lifetime BENESCO model using the same quit rates as Knight (2010) and applying costs for a Canadian setting. From the payer perspective varenicline (12+12 weeks) led to an incremental cost per QALY of CAD\$3,758 compared with standard varenicline treatment. For a societal perspective, which included indirect health and productivity costs, varenicline (12 + 12 weeks) was dominant compared with all alternatives. Cost-effectiveness was driven by increased quit rates reducing the number of smoking related comorbidities and smoking related deaths across model's lifetime time horizon. Probabilistic sensitivity analysis (PSA) showed that varenicline (12+12 weeks) had a 95% probability of being cost-effective at a willingness to pay threshold of CAD\$30,000 per QALY compared with varenicline (12 weeks) and 100% compared with the other interventions (from the payer perspective). The analysis was assessed as partly applicable to the review question with minor limitations.

One cost-utility analysis (Wilson, 2012) found that a 12-week treatment of varenicline plus 12 counselling sessions was cost-effective versus 12 weeks of placebo plus 12 counselling sessions. Four Markov models (BENESCO) were populated using 52-week abstinence rates obtained from a double-blind placebo RCT and cost and utility data from Belgium, Spain, Portugal and Italy respectively. This analysis is similar to Hettle (2012). The analysis found that from a payer perspective varenicline had an incremental cost-effectiveness ratio per QALY gained of €6,120, €5,151, €5,357 and €5,433 for Belgium, Spain, Portugal and Italy respectively. From a societal perspective, varenicline was dominant in all countries. The one-way sensitivity analysis determined that assumptions on cost parameters did not exhibit a strong influence on outcomes. It also found time horizon had no significant influence. The probabilistic sensitivity analysis found that all countries had an ICER between willingness to pay thresholds of €4,000 and €10,000 per QALY gained. There were minor limitations: it is unclear if the efficacy, cost and utility data came from the best sources available and whether the efficacy data (UK adapted from a US study) was suitable. The analysis was assessed as partly applicable to the review question since it was set in multiple European countries, but not the UK.

One directly applicable cost-utility analysis with minor limitations found that multiple pharmacotherapies (NRT I/s, NRT I&s, bupropion and varenicline) combined with behaviour support and e-cigarettes combined with behaviour support were dominant (i.e. less costly and more effective than the comparator). The base case results for the fully incremental analysis indicated Bupropion + NRT I&s was the most cost-effective strategy and was dominant versus each of the other interventions having the lowest total healthcare costs (£10,802) and highest lifetime QALYs (15.37) per person, and subsequently the highest net monetary benefit vs. placebo, equal to £5,928 per person. In addition to a series of DSAs and PSAs, several scenario analyses were carried out as well as a subgroup analysis of people with mental health problems. The latter found that all interventions assessed were highly cost effective versus placebo.

1 Harm reduction treatments

2 Review question

3 Are e-cigarettes effective and cost effective for smoking harm reduction?

4 Introduction

5 Electronic cigarettes (e-cigarettes) are a relatively new technology. Their effectiveness for
6 harm reduction in relation to commonly used pharmacotherapies is not certain.

7 The only commonly used treatment for harm reduction in England is NRT. The effectiveness
8 of e-cigarettes, and their relative effectiveness compared with NRT (categorised as either
9 “long- or short-acting NRT” or “long- and short-acting NRT”), is uncertain and may affect
10 patient choice. This review aims to establish whether e-cigarettes are effective and cost
11 effective for harm reduction.

12 PICO table

13 The following table summarises the protocol for this review.

14 **Table 11: PICO inclusion criteria**

Criteria	Detail
Population	Anyone aged 18 and over who smokes and wants to reduce their harm from smoking without stopping completely. Excluded: People who do not smoke Pregnant and breastfeeding women People aged 17 and under People who want to stop using smokeless tobacco but not smoking.
Interventions	E-cigarettes containing nicotine Excluded: Therapies not licensed in the UK. Alternative and complementary therapies. Psychotherapies (unless included as co-treatment with an included smoking therapy). Therapies that are either smoked or contain tobacco.
Comparator	NRT (either single- or multi-mode) No intervention or usual care E-cigarettes without nicotine ('placebo e-cigarette')
Outcomes	Critical outcomes Harm reduction status at longest available follow-up (minimum 6 months). Measured as reduction in validated biochemical measures: • Carbon monoxide in expired air or blood sample • Urinary cotinine • Anabasine and anatabine in urine. Cessation: Smoking status at longest available follow-up (minimum 6 months). Measured as abstinence from smoking (relative risk).

Criteria	Detail
	Where continued abstinence is presented, this is preferred over point-prevalence abstinence. Point prevalence measures will only be used where no continuous measure is reported. Where biochemically validated measures are available (i.e. saliva cotinine / carbon monoxide validation), these will be preferred to self-reported measures. Self-reported measures will only be used where no validated measure is reported. Important outcomes • Reduction in smoking-related symptoms: ◦ Cough ◦ Phlegm ◦ Shortness of breath ◦ Wheezing • Adverse or unintended (positive or negative) effects of e-cigarettes when used for cessation or harm reduction at any time point, including: ◦ Adverse effects such as headaches, nausea, throat irritation or dry mouth. Health-related quality of life of using e-cigarettes for cessation or harm reduction (using validated patient-report measures, for example EQ-5D).

1 Methods and process

2 This evidence review was developed using the methods and process described in
3 [Developing NICE guidelines: the manual](#). Methods specific to this review question are
4 described in the review protocol in appendix A and in the methods chapter.

5 This review addresses an intervention question. Randomised evidence was assessed using
6 the Cochrane Risk of Bias 2.0 tool, according to the NICE Manual. All GRADE ratings start at
7 'high' and are downgraded as appropriate. See appendix F for full GRADE tables.

8 Declarations of interest were recorded according to NICE's 2014 conflicts of interest policy.

9 Protocol deviation

10 The divide between cessation and harm reduction according to the protocol was intention of
11 the participants: cessation studies had participants intending to quit; harm reduction studies
12 had participants not intending to quit, but to reduce harm. The NMA produced by Thomas
13 (2020) for the cessation part of this review used slightly different inclusion criteria, and so
14 included some studies where participants did not intend to quit, but the study was clearly
15 measuring cessation as an outcome. Therefore, *smoking cessation* and *adverse events* from
16 those studies were reported in the cessation part of this review, where they met the other
17 inclusion criteria. It was not anticipated that adverse events for e-cigarettes would be
18 meaningfully different in people intending to stop smoking compared with those intending to
19 reduce their harm, supporting the argument for combining them.

20 Only one study (Caponnetto 2013) reported other harm reduction outcomes of e-cigarettes
21 (reduction in smoking-related symptoms and expired CO). Not enough data was extractable
22 (for example, ranges) to be useful for making recommendations, and therefore this paper
23 was also excluded from the review.

24 Minimal Important Differences (MIDs)

25 The following MIDs were applied to the outcomes in this review.

Table 12: Minimal Important Differences (MIDs) agreed

Outcome	Importance	MID
Smoking cessation	Critical	Statistical significance
Reduction in validated biochemical measures (CO, cotinine etc.)	Critical	Default (RR 0.8-1.25)
Reduction in smoking-related symptoms (cough, phlegm, shortness of breath, wheezing)	Important	Default (RR 0.8-1.25)
Adverse events	Important	Default MIDs
Health-related quality of life (HRQoL) measures	Important	Published MIDs if available for individual measure, otherwise default.

2 Identification of public health evidence

3 Included studies

A single search was used to identify relevant studies for this part of the review. No date limit was applied to the search and studies published in any year were eligible, as this is a new review question. The systematic search was undertaken in July 2019 for studies published in the English language. Website searches were not conducted for this review. Further details on the search strategy are available in appendix B.

After removal of duplicates, 1,233 unique database results were identified. 30 articles were ordered for full-text review. No studies were included in this review. The same search was rerun in November 2019. Ninety-four items were identified. One was requested for full-paper assessment, and none met the inclusion criteria.

A study identified in the surveillance review was already included from the database search. No additional studies from the surveillance reviews were included.

15 Excluded studies

See Appendix G for a full list of excluded studies and the reasons for exclusion.

17 Summary of public health studies included in the evidence review

No studies were included in this review.

19 Economic evidence

A systematic search was carried out to cover the questions in this evidence review (i.e. RQ 6.1a for cessation & RQ6.1b for harm reduction). The search returned 3576 records. Of these records 3409 records were excluded based on information in the title and abstract for both RQ 6.1a and RQ6.1b. Both reviewers assessed all of the records. The level of agreement between the two reviewers was 100%.

The full-text papers of 167 documents were retrieved and assessed. 13 studies were assessed as meeting the eligibility criteria for RQ 6.1a and no studies were assessed as meeting the eligibility criteria for RQ 6.1b. Both reviewers assessed all of the full texts. The level of agreement between the two reviewers was 100%. The excluded references are listed with their reasons for exclusion are listed in Appendix G – Excluded studies. The selection process is shown in Appendix G.

1 Economic model

2 In the absence of effectiveness evidence no economic modelling was undertaken for the
3 review question on tobacco harm reduction (RQ6.1b).

4 Summary of the evidence

5 No evidence was identified.

6 The committee's discussion of the evidence

7 Review questions

8 Note: Expert testimony has been drawn on throughout this discussion section (see Appendix
9 K for full proformas), indicated by (ETX). For example (ET1) refers to Expert Testimony 1.

10 Interpreting the evidence

11 *The outcomes that matter most*

12 1a.: The critical outcome was biochemically validated cessation at 6 months follow-up. Self-
13 reported measures were not accepted. The same outcome was used for assessing
14 effectiveness of e-cigarettes between 1 and 6 months follow-up. Adverse effects and health
15 related quality of life related to use of e-cigarettes were important outcomes. The adverse
16 effects of the other interventions in the review, which have been licensed for use for
17 cessation, are known and have been previously evaluated. The committee agreed that
18 effectiveness of e-cigarettes should be taken account of alongside adverse events, and the
19 benefits and harms considered. Cessation outcomes reported in studies where the aim was
20 harm reduction rather than cessation were included in 1a. rather than 1b. (see [Methods and](#)
21 [process](#) for more information).

22 1b.: Critical outcomes were a reduction in biochemically validated measures of smoking
23 (exhaled CO, urinary cotinine or other commonly used measures) at 6 months. A meaningful
24 reduction in these markers of smoking was interpreted by the committee as indicating a
25 potential reduction in harm sustained from smoking.

26 Important outcomes included a reduction in smoking-related symptoms, which was
27 considered to be an important but less reliable marker of a reduction in harm from smoking.
28 Adverse events and health related quality of life related to e-cigarettes were also important
29 outcomes.

30 *The quality of the evidence*

31 *Harm reduction*

32 No data was identified on harm reduction. The committee agreed with the approach taken for
33 the NMA (1a.), which included both people who intended to quit and people who intended
34 only to reduce their harm from smoking (see [Methods and process](#)). The committee also
35 discussed that the link between harm reduction (temporary abstinence or cutting down
36 numbers of cigarettes per day) and health benefits is still uncertain. Based on this, the
37 committee decided that smoking cessation rather than dual use should be the focus of
38 recommendations, and did not make recommendations about the potential use of e-
39 cigarettes for harm reduction.

1 *Short follow-up*

2 The committee had low confidence in the results for the effectiveness of e-cigarettes at less
3 than 6 month follow-up when compared with placebo e-cigarettes, NRT or no / minimal
4 intervention. A variety of factors contributed to this, as explained below.

5 There was only a small amount of data: six studies were identified with 3,835 participants in
6 total. A maximum of three studies were able to be combined in any single meta-analysis, due
7 to different comparators or follow-up times. This meta-analysis had wide confidence
8 intervals, often including the line of no effect (the MID for this outcome).

9 The data did not appear to be coherent. It is accepted that NRT is effective for cessation.
10 Despite this, e-cigarettes appeared to be more effective than NRT (at 1-3 months) but no
11 better than placebo e-cigarettes at the same time period. This pattern is not observed at later
12 follow-up points, so could be a result of small numbers of participants. It could also be an
13 indicator of the importance of the behavioural element of e-cigarette use (which is present in
14 both nicotine-containing and nicotine-free e-cigarettes).

15 The studies were somewhat heterogeneous: although the committee decided that the studies
16 should be statistically combined, they acknowledged the variations in the studies. One study
17 (Lee 2018) investigated cessation in pre-operative patients who, the committee discussed,
18 might have an increased motivation to quit compared with the those in the other studies.
19 Another study (Halpern 2018) took place in a workplace, and despite having the largest
20 sample size, had very low uptake of any intervention, this may be due to the included
21 participants not having actively chosen to take part in the study. Type of e-cigarette device
22 used may also introduce heterogeneity: studies did not always clearly report e-cigarette
23 generation, but the committee agreed that Bullen (2013) and Lee (2018) would have used
24 first generation e-cigarettes and that these may be less effective due to generally containing
25 lower levels of nicotine and potentially providing a less satisfying experience (see *review L:*
26 *barriers and facilitators to using e-cigarettes*).

27 The committee agreed that although short term cessation outcomes may indicate longer term
28 cessation outcomes, there was not enough good quality evidence at this stage to draw any
29 robust conclusions. They discussed the frequency of relapse to smoking in the initial stages
30 of cessation. Therefore, they decided to consider and make recommendations based on the
31 evidence for cessation at 6 months.

32 *NMA – cessation*

33 *Behavioural interventions*

34 The committee discussed the fact that a large majority of the studies included in the NMA
35 investigated the drug intervention as an adjunct to a behavioural intervention which was
36 present in both intervention and control arms. The results should therefore be interpreted as
37 the effect of the intervention in combination with behavioural support. They also noted that
38 the behavioural element of the included studies varied widely from minimal contact (brief
39 advice or short telephone calls) to intensive courses of behavioural counselling.

40 Using an NMA assumes that the included studies are similar in terms of factors that may
41 interact with the intervention effects, this is the same assumption that is made when
42 undertaking a pairwise meta-analysis. For the majority of the studies in this review the
43 intervention included a pharmacotherapy or e-cigarette and a behavioural aspect to the
44 intervention and the control arm included the same behavioural aspect. The nodes have
45 therefore been categorised by the pharmacotherapy or e-cigarette intervention as the
46 behavioural aspect was in all arms. The committee acknowledged that in a minority of
47 studies included in the NMA, there was an imbalance in how intense the behavioural
48 intervention was between arms. In most of these cases the arm receiving the intervention
49 under investigation (pharmacotherapy or e-cigarettes) also received a more intensive

behavioural intervention than the comparator arm, but the inverse also occurred. For this small number of studies this could result in an overestimation of the intervention effect in assuming that all of any effect seen was due to the pharmacotherapy or e-cigarette aspect of the intervention, while a more intensive behavioural intervention in this arm may have interacted causing the resultant effect. This is a limitation of the NMA, as the NMA attributed the effect of *intervention under investigation plus behavioural elements* to *intervention under investigation* alone (see Appendix I and J and table 16 for full explanation). The committee discussed and agreed that they did not consider that this affected any particular interventions more than other interventions in a way which was likely to impact the results of the NMA, the studies would remain as part of the NMA. There were also inconsistency checks completed as part of the quality assurance on the NMA, further details on these can be found in Appendix J.

Characteristics of included studies

The committee considered the characteristics of the included studies. The committee noted that a large number of studies (59/192) were considered to be at high risk of bias, which resulted in serious risk of bias for the full NMA in GRADE. They noted that this was often due to studies not blinding participants or personnel to the allocated treatments. They discussed that although blinding reduces bias, it may be very difficult to achieve in these studies, and therefore took this into account when interpreting the results.

The committee discussed the overall number of participants in the NMA. They noted that they may have expected to see a larger number of participants ($n = 92,067$) bearing in mind the accepted critical importance of the smoking cessation, and the length of time it has been researched. This implied the relative paucity of studies investigating bioverified outcomes to 6 months.

The committee discussed that the results for interventions investigated by fewer studies should be interpreted with some caution as they rely on few sources of data. Some interventions were included in a large number of studies (for example NRT long/short acting [$n = 116$]). where others – mainly combinations of treatments – appeared infrequently (for example bupropion + NRT long & short acting [$n = 2$], varenicline + bupropion [$n = 2$] and e-cigarette + NRT long/short acting [$n = 2$]). This concern is somewhat reduced in the NMA, where estimates are less sensitive to any one source of data, however the committee agreed that the evidence was not certain enough to recommend specific combinations of treatments.

Confidence in the NMA was reduced by the risk of bias and by inconsistency indicated by the better fit of a random effects model for between studies. The committee agreed that although the overall the confidence in the results of the full NMA was low, recommendations could be made due to the large amount of data for this cessation outcome and strong association between the outcome at 6 months and a longer-term behavioural change.

Mental health subgroup NMA

This subgroup included studies taking place in populations with mental illness. Mental illness includes both common mental disorders (CMD), for example anxiety and depression, and severe mental illness (SMI) for example schizophrenia. Most of the included studies took place in people with SMI. The subgroup NMA was small, with only 13 studies included. This may be in part attributable to many studies in groups with mental illness tailoring the intervention to the needs and context of the individuals, resulting in not being able to classify studies in a way that allowed their inclusion in the NMA. This smaller NMA had wider confidence intervals and was not able to differentiate effectiveness of active treatments from each other. The NMA was judged to have serious imprecision in GRADE. There was very serious risk of bias in the NMA, due to 6/13 studies having high risk of bias. The NMA was also downgraded for inconsistency (for the same reasons as the full NMA, above). This resulted in very low confidence in the results of the network.

1 The committee discussed these limitations, and whether they would expect the treatments to
 2 act differently for a population with mental illness compared with the general population.
 3 They noted that there has historically been a focus on groups with mental illness as different
 4 from the general population; either requiring different approaches or the view that the mental
 5 illness should be addressed or treated before – or instead of – their smoking. The committee
 6 agreed that this is not an appropriate approach due to the severity of the impact smoking has
 7 on people with mental health conditions. People with SMI in particular may have a life
 8 expectancy 20 years lower than that in the general population, part of which is attributable to
 9 smoking. The committee further noted that although smoking rates have substantially
 10 decreased in the general population, for those with mental health conditions rates have
 11 remained stagnant, indicating an increasing health inequality which needs addressing. The
 12 committee also discussed that beliefs that have been held in the past (such as that people
 13 with mental health conditions often do not want to quit, or that quitting will be detrimental to
 14 their mental health) are increasingly being challenged by new research and should not form
 15 the basis for decisions about offering cessation treatment (ET4).

16 The committee agreed that there should be a considerable focus on stopping smoking for
 17 those with mental health conditions. They agreed that interventions that work for the general
 18 population are also likely to work, and should be provided in the same way, and equitably, for
 19 people with mental illness. Therefore, the committee did not use this subgroup NMA to make
 20 recommendations. Instead, they combined their experience of smoking cessation in people
 21 with mental illness with the results of the full NMA, an analysis in which there were fewer
 22 concerns about quality and generally higher confidence in the findings.

23 *Adverse events*

24 Of the 9 studies which reported on adverse events of e-cigarettes, 5 were at high risk of bias.
 25 The main concern was a lack of blinding of participants and personnel, where comparators
 26 were noticeably different from each other. The committee discussed that where the
 27 comparator arm was an active intervention like NRT – in which case blinding was often not
 28 carried out – participants might reasonably expect adverse events from either intervention.
 29 However, lack of blinding of personnel could be more problematic and could bias results in
 30 favour of the new treatment under investigation.

31 The committee also noted that one study (Cravo 2016) was funded by Fontem ventures, a
 32 tobacco organisation (see [NICE's statement on engagement with tobacco industry organisations](#)). The study was included in line with NICE's methods for dealing with data
 33 from tobacco organisations. This study provided the only data for most outcomes comparing
 34 e-cigarettes to no drug treatment (continued smoking), with the exception of nausea which
 35 was also contributed to by Carpenter (2017). Results from Cravo (2016) were similar to
 36 results from the other studies, which had very low precision meaning there was no clinically
 37 important difference in most adverse events between e-cigarette and the comparator.
 38

39 The committee discussed the fact that the low event rates and widespread imprecision seen
 40 in the adverse events outcomes may be attributed to studies not being powered for these
 41 outcomes (primary outcomes were effectiveness). Although adverse event outcomes were
 42 difficult to draw conclusions from, the committee did further discuss them when making
 43 recommendations about e-cigarettes – see benefits and harms section below for detail.

44 **Benefits and harms**

45 *Effect sizes*

46 The committee discussed the effect sizes seen in the evidence, noting that the absolute
 47 cessation rates in many of the studies appear to be quite low, though this was something that
 48 tallied with their experience. The committee discussed that even a small increase in
 49 cessation has a public health impact. They discussed the complex nature of tobacco

1 addiction, noting that addiction to smoking includes both physical as well as behavioural and
2 psychological aspects and can therefore be very strong.

3 *Technical discussion of NMA results*

4 The committee discussed the four comparator treatments (placebo, no drug treatment,
5 waitlist, usual care), and how to interpret effects in relation to these. They noted that the
6 placebo node was comprised of placebo versions of all included treatments. This means that
7 the estimate for *treatment vs placebo* is not comparing the treatment to only the placebo
8 version of itself, but to all placebos. The usual care arm was discussed, and the committee
9 noted that this is likely to include a wide range of interventions due to the varied settings and
10 countries that the studies took place in, they discussed that usual care in the UK may be very
11 different to the usual care in non-UK based studies. In both cases, they agreed that this did
12 not reduce their certainty in the usefulness of those estimates but was borne in mind for their
13 interpretation.

14 The committee discussed that NMA results may be different from pairwise results of the
15 same comparison. The NMA used a random effects model, this averages the heterogeneity
16 from all the results and applies that average. If the result has higher heterogeneity in the
17 NMA, the NMA result will have wider credible intervals, potentially changing the conclusion
18 about whether an intervention is effective against a given comparator. Where a result has
19 lower heterogeneity in the NMA, the credible intervals will narrow. Credible intervals are also
20 narrowed where the addition of indirect evidence increases precision of the effect estimate.

21 *Choosing a treatment for cessation*

22 The committee had agreed that there was no plausible reason for any of the active
23 interventions to act differently for a population with mental health conditions. Expert
24 testimony (ET4) highlighted that the same issues, both in terms of addiction to smoking and
25 attitudes towards the various treatments, are likely to be present for both the general
26 population and for people with mental health conditions, and that persistent beliefs that
27 people with mental illness are not interested in quitting or that quitting interferes with
28 recovery are false. The remainder of this discussion draws on the full NMA and applies to
29 both the general population and those with mental illness unless otherwise specified.

30 The committee agreed that the evidence supported doing something over doing nothing.
31 They strongly agreed that people interested in stopping smoking should be given a choice of
32 treatments, and that the relative effectiveness presented in this review should not be a
33 reason to narrow or restrict the range of cessation treatments available through stop smoking
34 support. They agreed that the provision of information on the potential benefits and harms of
35 each option was crucial to facilitate discussion and ensure informed choice. The same
36 treatment may work differently for different people depending on the nature of their addiction,
37 their previous experience of products, previous cessation attempts, what they value about
38 smoking and other lifestyle factors. The committee decided that these factors should all be
39 taken into account alongside effectiveness, and that all recommendations about cessation
40 treatments should be centred around making sure individuals have the information to feel
41 empowered to make their own choice. This includes information on any cost that the
42 individual might incur; how the product works, how best to use the products, what is currently
43 known about adverse events and long-term harms of each intervention; and information on
44 the difference between the continued use of nicotine and continuing to smoke.

45 The committee did not consider it appropriate to rank each individual treatment in the
46 recommendations – individual factors and preferences are likely to play a large role which
47 may supersede small differences in effectiveness. The committee discussed their experience
48 of individuals wanting to incorporate research evidence or the practitioner's expertise into
49 their decision-making, and for this reason the committee decided to use the NMA results to
50 identify what interventions were likely to be most and least effective.

- 1 They also discussed that as many of the included studies are unblinded, whether there may
 2 have been some impact on the effectiveness of participants knowing that they were receiving
 3 a combination treatment. As discussed previously the committee noted that many initial and
 4 subsequent attempts to stop smoking are often not successful. They discussed the
 5 importance of providing different options to encourage a further quit attempt.
- 6 The committee discussed the combination treatments and noted that many of these are not
 7 currently used in practice. This is because in their experience, there are concerns over
 8 adherence to multiple interventions given that it is difficult for people who want to quit
 9 smoking to adhere to a single intervention. The committee were also concerned that there
 10 may be difficulty in obtaining prescriptions for multiple products. Also the committee
 11 commented that, based on the NMA and their experience, the effectiveness of the
 12 combinations appears to be attributable to the NRT component.
- 13 The committee agreed that while the combination of bupropion + NRT long / short acting was
 14 the most cost-effective option, this combination was not significantly better than NRT alone in
 15 the effectiveness analyses. The committee also acknowledged that this combination has
 16 been used in the past but this is no longer common practice in many stop smoking services.
- 17
- 18
- 19 For the combination of e-cigarette + NRT long/short the committee discussed the limited
 20 evidence available (2 studies) and noted that this is a combination of a medically licensed
 21 and unlicensed products. They further discussed the similarities of how they are used by
 22 those seeking to stop smoking. Thus they agreed that they would not recommend this
 23 combination treatment.
- 24 The committee expressed caution regarding the use of combination varenicline + bupropion,
 25 they noted that this is not used in practice and that there may be uncertainties about the
 26 combined side effects or interactions. There were only 2 studies that investigated this
 27 combination (compared with varenicline) and the committee agreed that they would not
 28 recommend this combination treatment.
- 29 The combination of different forms of NRT (short acting and long acting) and different
 30 methods of delivery was shown to be effective and so the committee recommended these as
 31 an option for smoking cessation.
- 32 Overall, as the other combinations showed similar effectiveness to the individual
 33 interventions alone, the committee recommended the use of individual treatment options and
 34 this specific combination of short and long acting NRT options.
- 35 The committee discussed and agreed that varenicline and NRT long and short acting were
 36 likely to be the most effective pharmacotherapies which are licensed for cessation, and
 37 bupropion and long acting or short acting NRT may also be helpful for achieving cessation
 38 from smoking but may be less effective treatments. The committee noted that bupropion is
 39 not often used in practice, despite being investigated by 44 included studies.
- 40
- 41 The committee further discussed and agreed that e-cigarettes may be similarly effective to
 42 varenicline or NRT long and short acting, however they are not medically-licensed and no
 43 long-term health effects data are available, specifically in relation to harms. Some committee
 44 members suggested that e-cigarettes can be thought of as a type of short acting NRT in
 45 terms of how they deliver nicotine, but not medically-licensed for smoking cessation. The
 46 committee discussed and agreed that although there was more uncertainty around the effect
 47 of e-cigarettes, possibly due to the small number of studies,, they were still effective. They
 48 further noted that as there are ongoing e-cigarette studies and that future additional evidence

1 in this area may alter the findings of the NMA. There were many more studies for the other
 2 cessation interventions. They also discussed that it is not clear in some of the studies which
 3 generation of e-cigarettes was being used noting that the older generations of e-cigarettes
 4 may have been less helpful for smoking cessation as the nicotine levels in these were lower.
 5 The increasing evidence being published can be seen during the reruns searching during the
 6 development of this guideline which identified a further four studies for inclusion in relation to
 7 the use of e-cigarettes for smoking cessation. The committee noted that there was a recent
 8 UK based e-cigarette study that did not meet the inclusion criteria as these criteria specified
 9 biochemically validated cessation at 6 months follow up. This study considered e-cigarettes
 10 and behavioural intervention compared with NRT long/short acting and behavioural
 11 intervention in 886 participants. The cessation outcomes were bioverified at 3 and 12 months,
 12 the outcomes at 6 months were self-report. A sensitivity analysis was undertaken that
 13 included this additional UK e-cigarette study (Hajek, 2019). This involved the running of an
 14 NMA that included the Hajek (2019) study to consider whether additional studies on e-
 15 cigarettes have the potential to further impact on the findings of this analysis. findings of this
 16 sensitivity analysis (see Appendix J) did show differences in the NMA outcomes, further
 17 supporting the view that e-cigarettes are an effective option for smoking cessation.
 18 Therefore, it is important that further research is undertaken regarding the use of e-cigarettes
 19 for smoking cessation.

20 Based on committee expertise and evidence from the qualitative review of barriers and
 21 facilitators to e-cigarettes (review [L]), the committee discussed the fact that many people
 22 who choose to quit smoking using NRT or e-cigarettes are concerned about the continued
 23 use of nicotine. The committee agreed that it was important for people to understand the
 24 importance of stopping smoking, and to be reassured that nicotine is not the major cause of
 25 damage to people's health from smoking. The committee noted that for NRT to be effective
 26 for cessation, people must use it in a way that ensures they get enough nicotine. Nicotine-
 27 containing e-cigarettes may present more of a challenge in terms of knowing how to match
 28 the level of nicotine, particularly as different types or generations may facilitate differing
 29 intake, and e-liquid is available in many different nicotine strengths. Seeking advice from a
 30 health practitioner may help as they may be able to obtain up to date information from PHE,
 31 or from the NCSCT training materials on e-cigarettes.

32 The committee were aware of concerns about the use of varenicline by people with mental
 33 illness. They agreed it was important that practitioners were aware that there appears to be
 34 no increased risk of neuropsychiatric effects in people who use varenicline (see the
 35 [Summary of Product Characteristics for CHAMPIX](#) [emc, 2019] and the [Royal College of](#)
 36 [Psychiatrists' position statement](#) [2018] for more information). Expert testimony (ET4)
 37 highlighted that people with mental health conditions are disproportionately burdened by
 38 smoking and the resulting adverse health effects. The committee emphasised the
 39 importance, supported by expert testimony (ET4), of addressing smoking in this group by
 40 making all effective interventions available for use (while acknowledging that bupropion is an
 41 antidepressant which needs consideration when prescribed to certain subgroups). They
 42 agreed that varenicline should be available for those with mental illness in the same way as
 43 for the general population. Expert testimony (ET4) put forward that smoking cessation
 44 support should be a core part of mental health care provision rather than an optional
 45 element. Committee agreed the importance of supporting smoking cessation in this group.
 46 They considered that this should be explored alongside other support provided and
 47 discussed a possible role for dedicated stop smoking advisers as part of the mental health
 48 service.

49 **Cost effectiveness and resource use**

50 The committee considered evidence from 13 published cost effectiveness analyses. They
 51 noted 12 were assessed as partly applicable and 1 as directly applicable, 11 had minor
 52 limitations and 2 had potentially serious limitations. They observed that 12 studies assessed
 53 varenicline and 1 study assessed e-cigarettes.

One study (Lock 2011), which included a UK population, found 12-weeks of varenicline plus weekly counselling sessions and a booklet was cost-effective vs. 12 weeks of placebo with same co-therapies in a population with COPD. The remaining 11 non-UK studies of varenicline differed by course length. Seven studies established cost-effectiveness for a standard length course of varenicline vs. comparators including bupropion, NRT, placebo. Two studies established cost-effectiveness of varenicline for multiple quit attempts vs. varenicline for single quit attempt (& bupropion & NRT for multiple quit) and 2 studies established cost-effectiveness for an extended course of (12 weeks + 12 weeks for quitters) vs. standard 12 weeks course of varenicline, bupropion and NRT.

The committee agreed the evidence was comprehensive and robust in showing varenicline is cost-effective vs. bupropion, NRT, placebo and unaided cessation. However, they were mindful that four studies were informed by efficacy data from a single RCT.

The committee noted the results were consistent across multiple countries and considered it reasonable to assume non-UK results are applicable. They also noted multiple and extended courses of varenicline are likely to be cost-effective vs. shorter varenicline courses including for multiple quit attempts and extended courses to prevent relapse.

One UK study (Li 2019) found e-cigarettes were cost effective compared with nicotine replacement therapy. The finding was associated with a high level of certainty at 12 months (87%) and across a lifetime horizon (85%) using a cost effectiveness threshold of £20,000/QALY. Whilst the committee accepted the results of the study they were mindful the model did not consider the possible long-term effects of using e-cigarettes on health and personal finance and noted the high level of missing data (35%) from the RCT.

The committee discussed whether the main drivers were cost of treatment, effectiveness and difference in health care costs of the lifetime. They agreed the evidence pointed to intervention effectiveness as the main driver and as opposed to the cost of the intervention. The committee agreed that unless there are very small differences in effect sizes or very large differences in intervention in general economic models will identify most effective interventions as cost effective because the long term benefits of stopping smoking are so pronounced.

Economic model

General population

The committee discussed the results from the de novo economic model which assessed ten pharmaceutical interventions using evidence from the network meta analysis reported in this review (Evidence review K). In the basecase analysis which included the cost of the interventions to the NHS, the committee observed that bupropion, NRT I/s and I&s, varenicline, bupropion + NRT I/s, varenicline + NRT I/s, varenicline + bupropion and bupropion + NRT I&s were all dominant meaning they were more effective and less costly than the comparator.

The committee noted e-cigarettes only or combined with NRT I/s were dominant (more effective and less costly than the comparator) and this finding applied irrespective of whether the costs were assumed to be incurred over the counter (i.e. £0.00 cost to the NHS) or by the NHS (scenario analysis). They also noted that including an additional study of e-cigarettes (Hajek et al 2019) in the network meta-analysis impacted the results of the economic analysis such that E-cigarettes + NRT I/s became the most cost-effective strategy. The inclusion also impacted the NMB rankings with e-cigarettes moving from rank six in the base case analysis to the third rank in the scenario analysis (see Appendix J for results). As indicated above, the committee were mindful that the evidence base on this topic is still emerging and that future studies may change the conclusions. However, based on the evidence available to date the committee agreed e-cigarettes should be included in the list of cost-effective interventions recommended for smoking cessation.

1 The committee observed across all base case and deterministic scenarios, that when any
2 intervention was more effective than placebo, it was also cost-effective. They also observed
3 the PSA identified very low levels of uncertainty regarding the cost-effectiveness of each
4 intervention versus placebo.

5 The committee noted the results assume pharmacological interventions are delivered
6 alongside behaviour support because the estimates of effectiveness are from studies which
7 included behaviour support in the intervention and comparator arms. They discussed the
8 timing of the benefits and agreed that whilst some of these can take 10 to 15 years to accrue
9 others may accrue in a relatively short timescale such as myocardial infarction which showed
10 a decline in incidence just 1 year after the smoking ban was introduced.

11 The committee considered the findings of the full incremental analyses which showed
12 bupropion + NRT I&s was the most cost-effective intervention strategy having the lowest
13 healthcare costs and highest lifetime QALYs per person. When ordered by NMB they
14 observed the cost effectiveness ranking of each intervention remained the same with or
15 without the inclusion of the placebo. They also noted the incremental findings were
16 associated with high levels of uncertainty. For example, in the PSA bupropion + NRT I&s was
17 cost-effective in 54% of PSA iterations but was not the most cost-effective strategy in the
18 remaining 46% of iterations. Given the uncertainty and limited number of studies for some of
19 the interventions the committee agreed there was no convincing evidence to sequence the
20 recommendations for interventions based on their individual rankings.

21 The committee agreed the economic model is likely to have underestimated the benefits of
22 smoking cessation as many other outcomes were not included such as impact on other
23 smoking related diseases, co-morbidities and associated costs, benefits to local authorities
24 and public sector more widely as well as benefits to employers through reduced sickness
25 absence and increase productivity and financial benefits to individuals who quit smoking.

26 ***Mental health subgroup***

27 The economic model was also used to assess the cost effectiveness of six
28 pharmacotherapies for the sub-population with mental health problems. Using evidence from
29 the network meta-analysis the basecase analysis for this subgroup showed that NRT (I/s and
30 I&s), bupropion, varenicline, and bupropion + NRT (I/s and I&s) were all cost effective versus
31 the comparator. As with the basecase for the general population all interventions for the
32 mental health subgroup were dominant resulting in more QALYs than the comparator and
33 healthcare savings.

34 The committee noted that in the DSA when the effectiveness rates were set to equal the
35 lower 95% CI three interventions - NRT I&s, bupropion + NRT I/s and bupropion - moved
36 from being cost effective to being less effective and more costly than the comparator. The
37 other interventions remained cost effective. However, in the PSA which considers the
38 uncertainty in the value of multiple parameters in the model, five of the interventions had a
39 probability of >90% of being cost effective versus the comparator at a threshold of
40 £20,000/QALY. Only NRT I&s had a lower probability (79%) which the committee considered
41 sufficient evidence to support including it among the interventions recommended for the
42 subgroup with mental health problems.

43 ***E-cigarette health harms and uptake***

44 The committee had concerns regarding the cost effectiveness of e-cigarettes as there is
45 currently no evidence to indicate whether they are safe over the long term. To address their
46 concerns an exploratory threshold analysis was carried out to determine the level of adverse
47 events at which e-cigarettes would not be cost effective compared with usual care. The
48 committee noted the analysis suggested e-cigarettes would need to cause a very high
49 number of adverse outcomes before they were considered not to be cost-effective versus
50 placebo. For example, e-cigarettes would not be cost effective if more than 10% of people

1 who used them experienced an adverse event, and the net cost per adverse event was equal
 2 to £25,000 which is similar to the 5-year treatment costs for stroke (NICE CG92).

3 The committee were also concerned that e-cigarettes might promote smoking uptake by
 4 acting as a gateway to tobacco smoking in non-smoking populations. The results of the
 5 exploratory analysis indicated that e-cigarettes would have a net positive impact on health
 6 and healthcare resources if acting as a gateway to tobacco smoking in up to 0.25% on the
 7 non-smoking UK population. This value is equivalent to 2.5% of non-smokers taking up e-
 8 cigarettes and up to 10% of this population subsequently taking up tobacco smoking. Based
 9 on the evidence seen by the committee, some members agreed it would be useful to include
 10 research recommendation on whether the use of e-cigarettes increases the chance of a non-
 11 smoker taking up cigarettes.

12 **Overall discussion of evidence across multiple reviews**

13 **Gaps in the evidence**

14 The committee noted that smoking prevalence is not distributed equally throughout society. A
 15 range of inequalities were identified in the Equality Impact Assessment (EIA), including
 16 inequalities by socioeconomic status, sexual orientation, and mental illness. Published
 17 evidence to address these inequalities was limited, and the committee concluded that there
 18 was not enough evidence to make recommendations for specific groups. They highlighted
 19 this as a gap in the evidence that could be addressed with expert testimony. Expert
 20 testimony provided to the committee on these inequalities is relevant to multiple reviews and
 21 is detailed in full in this review (Appendix K). It is referenced throughout the committee
 22 discussion where it has been drawn on in decision-making.

23 The Medicines and Healthcare products Regulatory Agency (MHRA) provided expert
 24 testimony on e-cigarettes and the Yellow Card Scheme, including current information on
 25 adverse events and monitoring.

26 **Implications of recommending e-cigarettes**

27 This section on the implications of recommending e-cigarettes covers discussion that the
 28 committee had in relation to a number of e-cigarette reviews:

- 29 • Reviews F and G: e-cigarettes and young people
- 30 • Review K: cessation and harm reduction treatments
- 31 • Review L: barriers and facilitators to using e-cigarettes for cessation or harm reduction
- 32 • Review M: long-term health effects of e-cigarettes.

33 The committee have made recommendations that all e-cigarette use (including both nicotine-
 34 containing e-cigarettes and e-cigarettes without nicotine) should be discouraged in children,
 35 young people and young adults who do not smoke, and that the products should be clearly
 36 differentiated from tobacco products. It is also recommended that nicotine-containing e-
 37 cigarettes are discussed with people interested in stopping smoking. To support this the
 38 committee has made recommendations about the advice that people providing stop smoking
 39 support should give people about e-cigarettes, in order that people can make informed
 40 decisions The committee have also recommended that nicotine-containing products are
 41 included as options for sale in secondary care settings (for example in hospital shops).

42 ***Use by young people***

43 Evidence on e-cigarette use by children, young people and young adults is presented in
 44 reviews F and G.

45 The committee discussed the implications of making recommendations about e-cigarettes as
 46 an effective intervention for smoking cessation. The committee were aware of the wider

1 international discussions about the use of e-cigarettes by children, young people and young
 2 adults who do not smoke (see *reviews F and G: e-cigarettes and young people* for a full
 3 discussion of the identified evidence). The included studies showed an association between
 4 use of e-cigarettes and ever smoking in the future. The committee noted that a small
 5 proportion of children, young people and young adults who have never smoked use e-
 6 cigarettes, and therefore might be exposed to this increased risk of trying smoking in the
 7 future. The committee discussed that the size of the risk of taking up smoking following e-
 8 cigarette use is somewhat uncertain as many of the studies have considerable limitations.
 9 They also discussed that it is possible that people moving from e-cigarettes to smoking might
 10 have been at higher risk for smoking for other reasons (for example, peer or family smoking).

11 There is no benefit to never-smokers using e-cigarettes and because the harm of smoking is
 12 so great, the committee agreed there was justification to strongly discourage use of e-
 13 cigarettes in these groups. The current review indicates that e-cigarettes are likely to be
 14 effective for cessation, and so the committee agreed that children, young people and young
 15 adults should not be told that e-cigarettes are to be avoided by all people at all times, and
 16 that e-cigarettes should be clearly differentiated from tobacco products. They agreed that the
 17 emphasis should be placed on discouraging use of e-cigarettes among never smokers.

18 ***Long-term health effects and safety of e-cigarettes***

19 Evidence on long-term health effects of e-cigarettes is presented in review M.

20 A very small amount of evidence which was at high risk of bias was identified from database
 21 searches, and no new evidence was identified through the call for evidence process (see
 22 *review M: long-term health effects of e-cigarettes* for the full discussion on the evidence). The
 23 committee were concerned about the lack of evidence about harms in comparison with
 24 licensed treatments and recommended that research should be conducted. They noted that
 25 possible long-term outcomes may take decades to emerge and will require carefully planned
 26 studies to reliably identify them.

27 The committee agreed that the severity of smoking harms was so high that it was important
 28 to discuss e-cigarettes further as an option despite the lack of evidence on any long-term
 29 health effects. They noted the importance of weighing up harms and benefits of using e-
 30 cigarettes in relation to the alternatives:

- 31 • Cessation using licensed treatments: The committee heard expert testimony (ET1) that
 32 gave the view that for some e-cigarettes have become the preferred smoking cessation
 33 aid, exceeding licensed products. While the committee emphasised that licensed products
 34 offer much greater certainty about side effects and harms, they recognised evidence (see
 35 *review L: barriers and facilitators to e-cigarettes*) that many people found using e-
 36 cigarettes convenient and a more satisfying experience compared with NRT. These
 37 factors may contribute to their effectiveness and may be particularly important for people
 38 who have attempted to stop smoking unsuccessfully using licensed products in the past.
- 39 • Continued smoking: For many people who smoke, the alternative to using e-cigarettes
 40 might be continued smoking. The extensive harms of smoking are well known, and it is
 41 considered unlikely that use of e-cigarettes could cause similar levels of harm. The
 42 committee noted and discussed the evidence reviews produced annually by PHE, the
 43 most recent of which states that “vaping regulated nicotine products has a small fraction of
 44 the risks of smoking, but this does not mean it is safe” ([PHE 2020](#), p.10). Evidence from
 45 studies to support this was not found for review M, but the committee drew on their
 46 knowledge of the components of e-cigarettes compared with tobacco cigarettes to agree
 47 that vaping is likely to be less harmful than smoking.

48 The committee also discussed the development of events around e-cigarettes in the US
 49 reported on by the [CDC \(2019\)](#) and others, and the UK response to these. They noted that
 50 the latest findings suggest that the events (which included lung injury and death) have been
 51 linked to vaping tetrahydrocannabinol (THC) and vitamin E acetate oil. These compounds
 52 are not permitted in e-cigarettes in the UK. E-cigarettes are more tightly regulated in the UK

than in the US, and nicotine-containing e-cigarettes are regulated through the Tobacco and Related Products Regulations 2016 (TRPR). Although the MHRA has received reports of 4 deaths which were suspected as being related to vaping through its Yellow Card Scheme, 2 of the deaths happened before the implementation of TRPR and PHE states that in all the deaths the connection with nicotine-containing e-cigarettes has not yet been established ([PHE 2020](#)).

In order to address the potential risk posed by using e-cigarettes which contain harmful compounds not permitted in the UK, the committee noted that e-cigarettes should not be customised by adding components or mixing e-liquids. The committee agreed the importance of providing those thinking about using e-cigarettes to stop smoking with clear and up-to-date information. This recommendation is also supported by evidence from *review L: barriers and facilitators to using e-cigarettes*, which found that people had concerns about how to use e-cigarettes safely and whether contents were properly regulated.

The committee heard expert testimony directly from the MHRA about the monitoring of e-cigarettes through the [Yellow Card Scheme](#) (ET5). Signalling evidence collected through the Scheme is preliminary and, although it has not raised any particular concerns relating to e-cigarettes, it relies on voluntary reporting. The committee chose to recommend that health professionals ask those using e-cigarettes about any possible adverse effects or safety concerns with their use, and report these using the Yellow Card Scheme to support the growing evidence base. This supports advice from the MHRA on how healthcare professionals can be vigilant for suspected adverse reactions associated with the use of e-cigarettes ([MHRA 2020](#)). The committee also heard about the need to work with trading standards to ensure that only e-cigarette devices which have been notified to the MHRA are in circulation.

The committee recognised that while most of the other recommended treatments are usually used for a defined period, and stopped within a number of months, people using e-cigarettes to stop smoking may be more likely to use them for longer. A view from an Expert testimony (ET1) highlighted that some groups tending to use e-cigarettes for longer periods after cessation had been more dependent on tobacco, and so longer use of the devices after a quit may have been necessary to prevent relapse. The committee discussed that e-cigarettes may need to be used for as long as is necessary to prevent relapse. They emphasised that this practice made it especially important to give people up to date information on long-term harms, which are currently not known (see review M: long-term health effects of e-cigarettes for more details about evidence on long-term harms, and about the call for evidence NICE conducted in this area).

The committee discussed that the size of the population that could benefit from using the devices – and the size of the benefit that could be delivered – warranted recommending e-cigarettes as an option for cessation, alongside continued monitoring and evidence gathering. The committee noted that the recommendations take place in a context in which e-cigarettes and related advertising are tightly regulated, and suspected adverse reactions are being monitored.

Adverse events of e-cigarettes

The committee agreed that considering adverse events of e-cigarettes was important (the adverse effects of the other treatments in this review, which have been licensed for use for cessation, are well-known). Possible adverse events of all treatments should be communicated to people looking to quit. The committee highlighted that adverse events should be discussed with emphasis on the very considerable health benefits of stopping smoking. They agreed that many of the adverse event outcomes recorded for e-cigarettes may be linked with stopping smoking, and so may occur as a result of cessation regardless of the method used. The committee considered this as likely to be the case in the single significant result for adverse events: significantly increased irritability in those using e-cigarettes compared with no drug treatment (continued smoking) (see *Summary of the*

evidence). They added that this was feasible even when nicotine containing therapies were used for cessation, as many people do not match their previous levels of nicotine consumption.

The committee discussed serious adverse events (SAE) in detail. This outcome was reported for e-cigarettes when compared with no drug treatment, NRT and placebo e-cigarettes. None of these comparisons showed e-cigarettes to result in significantly more events. In addition, the committee noted the diverse range of events included in this outcome, including hospitalisation and knee surgery. Based on this information and that the studies were not powered to detect adverse event outcomes, the committee were not confident that the outcomes could be attributed to the intervention. They considered most of the adverse events to be outweighed by the significant and well documented benefits of stopping smoking.

See also section in the economic discussion around adverse events and cost effectiveness.

Making e-cigarettes accessible

The committee discussed the method of provision for e-cigarettes. They recognised that e-cigarettes are categorised as appliances rather than medicines. This means that they can only be prescribed if they are listed in part IX of the [NHS Electronic Drug Tariff](#). E-cigarettes are not currently listed in the tariff. This means that e-cigarettes must be provided by other means. The committee chose to recommend that commissioners and providers of stop smoking support make e-cigarettes accessible along with the other evidence-based interventions. Expert testimony (ET4) identified that the cost of e-cigarette devices may be prohibitive for some groups, particularly disadvantaged groups or those with mental health conditions. The committee discussed that there are various ways that e-cigarettes could be made more accessible, and that schemes already exist in some local areas that are trialing these. For example, stop smoking support could focus on being 'e-cigarette friendly' by ensuring that support (for example, behavioural support) is still provided to people using e-cigarettes as part of a quit attempt and providing evidence-based advice about e-cigarettes; e-cigarettes could be offered for sale in some health settings, or the devices and / or e-liquid could be offered free of charge or through a voucher scheme for a set period of time.

The reviews in this guideline did not look at evidence about the most effective ways of making e-cigarettes accessible for cessation. The committee agreed that decisions about how to make e-cigarettes accessible should be made at a local level dependent on how stop smoking services and other relevant settings are set up and link together. They discussed the fact that this area may develop over the lifetime of this guideline.

Recommendations supported by this evidence review

This evidence review supports recommendations 1.12.1 to 1.12.6, 1.12.13 to 1.12.17, 1.14.19, 1.22.1 to 1.22.2, 1.22.14, and the research recommendations on health effects of e-cigarettes, stop-smoking interventions for under-served groups, support for people with mental health conditions to stop smoking, e-cigarettes for harm reduction, use of e-cigarettes (amount and frequency), and e-cigarette flavours. Other evidence supporting these recommendations can be found in the evidence reviews on barriers and facilitators to e-cigarettes (review L), long-term health effects of e cigarettes (review M), smoking relapse prevention (review N) and tailored interventions for those with mental health conditions (review O).

1 References for cessation and harm reduction treatments

- 2 Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for
3 smoking cessation in African Americans: a randomized controlled trial. *JAMA*.
4 2002;288(4):468-74.
- 5 Ahluwalia JS, Okuyemi K, Nollen N, Choi WS, Kaur H, Pulvers K, et al. The effects of
6 nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design.
7 *Addiction*. 2006;101(6):883-91.
- 8 Andrews JO, Mueller M, Dooley M, Newman SD, Magwood GS, Tingen MS. Effect of a
9 smoking cessation intervention for women in subsidized neighborhoods: A randomized
10 controlled trial. *Prev Med*. 2016;90:170-6.
- 11 Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. Effects of
12 varenicline on smoking cessation in adults with stably treated current or past major
13 depression: a randomized trial. *Ann Intern Med*. 2013;159(6):390-400.
- 14 Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al.
15 Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers
16 with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-
17 controlled clinical trial. *Lancet*. 2016;387(10037):2507-20.
- 18 Areechon W, Punnotok J. Smoking Cessation through the Use of Nicotine Chewing Gum - a
19 Double-Blind Trial in Thailand. *Clinical Therapeutics*. 1988;10(2):183-6.
- 20 Ashare Rebecca L, Thompson Morgan, Serrano Katrina, Leone Frank, Metzger David, Frank
21 Ian, Gross Robert, Hole Anita, Mounzer Karam, Collman Ronald G, Wileyto E Paul, and
22 Schnoll Robert (2019) Placebo-controlled randomized clinical trial testing the efficacy and
23 safety of varenicline for smokers with HIV. *Drug and alcohol dependence* 200, 26-33
- 24 Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of
25 bupropion and predictors of successful outcome in a sample of French smokers: a
26 randomized placebo-controlled trial. *Addiction*. 2004;99(9):1206-18.
- 27 Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Jr., Gong J, et al. Varenicline versus
28 transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.
29 *Thorax*. 2008;63(8):717-24.
- 30 Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, et al. A randomized controlled
31 trial of a smoking cessation intervention among people with a psychotic disorder. *American*
32 *Journal of Psychiatry*. 2006;163(11):1934-42.
- 33 Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, et al. Effects of Nicotine Patch
34 vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26
35 Weeks: A Randomized Clinical Trial. *JAMA*. 2016;315(4):371-9.
- 36 Baldassarri SR, Bernstein SL, Chupp GL, Slade MD, Fucito LM, Toll BA. Electronic
37 cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: A
38 pilot study. *Addict Behav*. 2018;80:1-5.

- 1 Binnie VI, McHugh S, Jenkins W, Borland W, Macpherson LM. A randomised controlled trial
2 of a smoking cessation intervention delivered by dental hygienists: a feasibility study. BMC
3 Oral Health. 2007;7:5.
- 4 Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as
5 an aid in smoking cessation. Eur Respir J. 1997;10(7):1585-90.
- 6 Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray
7 with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ.
8 1999;318(7179):285-8.
- 9 Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects of
10 varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-
11 controlled study. Clin Ther. 2011;33(4):465-77.
- 12 Bonevski B, Twyman L, Paul C, D'Este C, West R, Siahpush M, et al. Smoking cessation
13 intervention delivered by social service organisations for a diverse population of Australian
14 disadvantaged smokers: A pragmatic randomised controlled trial. Prev Med. 2018;112:38-44.
- 15 Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic
16 cigarettes for smoking cessation: A randomised controlled trial. The Lancet.
17 2013;382(9905):1629-37.
- 18 Caldwell BO, Adamson SJ, Crane J. Combination rapid-acting nicotine mouth spray and
19 nicotine patch therapy in smoking cessation. Nicotine Tob Res. 2014;16(10):1356-64.
- 20 Caldwell BO, Crane J. Combination Nicotine Metered Dose Inhaler and Nicotine Patch for
21 Smoking Cessation: A Randomized Controlled Trial. Nicotine Tob Res. 2016;18(10):1944-51.
- 22 Campbell IA. Comparison of 4 Methods of Smoking Withdrawal in Patients with Smoking
23 Related Diseases. British Medical Journal. 1983;286(6365):595-7.
- 24 Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency
25 and Safety of an eElectronic cigarette (ECLAT) as tobacco cigarettes substitute: a
26 prospective 12-month randomized control design study. PLoS One. 2013;8(6):e66317.
- 27 Carpenter MJ, Heckman BW, Wahlquist AE, Wagener TL, Goniewicz ML, Gray KM, et al. A
28 Naturalistic, Randomized Pilot Trial of E-Cigarettes: Uptake, Exposure, and Behavioral
29 Effects. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1795-803.
- 30 Carson KV, Smith BJ, Brinn MP, Peters MJ, Fitridge R, Koblar SA, et al. Safety of varenicline
31 tartrate and counseling versus counseling alone for smoking cessation: a randomized
32 controlled trial for inpatients (STOP study). Nicotine Tob Res. 2014;16(11):1495-502.
- 33 Chan SS, Leung DY, Abdullah AS, Wong VT, Hedley AJ, Lam TH. A randomized controlled
34 trial of a smoking reduction plus nicotine replacement therapy intervention for smokers not
35 willing to quit smoking. Addiction. 2011;106(6):1155-63.
- 36 Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, et al. Varenicline
37 for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled
38 study. J Clin Psychiatry. 2014;75(7):765-72.

- 1 Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W, Van Vunakis H. Behavior therapy and
2 the transdermal nicotine patch: effects on cessation outcome, affect, and coping. *J Consult*
3 *Clin Psychol.* 1996;64(2):314-23.
- 4 Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of
5 varenicline and bupropion sustained-release use plus intensive smoking cessation
6 counseling on prolonged abstinence from smoking and on depression, negative affect, and
7 other symptoms of nicotine withdrawal. *JAMA Psychiatry.* 2013;70(5):522-33.
- 8 Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, et al. An RCT
9 with the combination of varenicline and bupropion for smoking cessation: clinical implications
10 for front line use. *Addiction.* 2018.
- 11 Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, et al.
12 Gender differences in smoking cessation in a placebo-controlled trial of bupropion with
13 behavioral counseling. *Nicotine Tob Res.* 2004;6(1):27-37.
- 14 Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinberg HR, Oncken CA. Concurrent brief
15 versus intensive smoking intervention during alcohol dependence treatment. *Psychol Addict*
16 *Behav.* 2007;21(4):570-5.
- 17 Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, et al. Smoking
18 cessation during alcohol treatment: a randomized trial of combination nicotine patch plus
19 nicotine gum. *Addiction.* 2009;104(9):1588-96.
- 20 Cooper TV, Klesges RC, Debon MW, Zbikowski SM, Johnson KC, Clemens LH. A placebo
21 controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on
22 cessation rates and postcessation weight gain in women. *Addict Behav.* 2005;30(1):61-75.
- 23 Cooperman NA, Lu SE, Richter KP, Bernstein SL, Williams JM. Pilot Study of a Tailored
24 Smoking Cessation Intervention for Individuals in Treatment for Opioid Dependence. *Nicotine*
25 *Tob Res.* 2018;20(9):1152-6.
- 26 Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of
27 bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse.
28 *Addiction.* 2007;102(8):1292-302.
- 29 Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for
30 smoking cessation in African American light smokers: a randomized controlled trial. *J Natl*
31 *Cancer Inst.* 2012;104(4):290-8.
- 32 Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craige S, et al. A randomised, parallel
33 group study to evaluate the safety profile of an electronic vapour product over 12 weeks.
34 *Regul Toxicol Pharmacol.* 2016;81 Suppl 1:S1-S14.
- 35 Cummins SE, Gamst AC, Brandstein K, Seymann GB, Klonoff-Cohen H, Kirby CA, et al.
36 Helping Hospitalized Smokers: A Factorial RCT of Nicotine Patches and Counseling. *Am J*
37 *Prev Med.* 2016;51(4):578-86.

- 1 Cunningham JA, Kushnir V, Selby P, Tyndale RF, Zawertailo L, Leatherdale ST. Effect of
2 Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers: A Randomized
3 Clinical Trial. *JAMA Intern Med.* 2016;176(2):184-90.
- 4 Dalsgareth OJ, Hansen NC, Soes-Petersen U, Evald T, Hoegholm A, Barber J, et al. A
5 multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion
6 hydrochloride sustained-release tablets as an aid to smoking cessation in hospital
7 employees. *Nicotine Tob Res.* 2004;6(1):55-61.
- 8 Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, et al. Effect of
9 Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation
10 Therapy - a Randomized, Placebo-Controlled, Double-Blind-Study. *Archives of Internal*
11 *Medicine.* 1991;151(4):749-52.
- 12 Daughton D, Susman J, Sitorius M, Belenky S, Millatmal T, Nowak R, et al. Transdermal
13 nicotine therapy and primary care. Importance of counseling, demographic, and participant
14 selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation
15 Trial Group. *Arch Fam Med.* 1998;7(5):425-30.
- 16 Dautzenberg B, Ruff F, Vaucher M, Maillon P, Jacob N, Kienzler JL, et al. First
17 demonstration of the good efficacy/safety ratio of Nicotinell® 1mg Lozenge (NL 1mg), a new
18 form of nicotine substitution, by randomised clinical trial. *European Respiratory Journal.*
19 2001;18 Suppl 33:12s.
- 20 de Dios MA, Anderson BJ, Stanton C, Audet DA, Stein M. Project Impact: a
21 pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino
22 light smokers. *J Subst Abuse Treat.* 2012;43(3):322-30.
- 23 Dogar O, Zahid R, Mansoor S, Kanaan M, Ahluwalia JS, Jawad M, et al. Varenicline versus
24 placebo for waterpipe smoking cessation: a double-blind randomized controlled trial.
25 *Addiction.* 2018;113(12):2290-9.
- 26 Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination
27 varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a
28 randomized trial. *JAMA.* 2014;311(2):155-63.
- 29 Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline
30 on smoking cessation through smoking reduction: a randomized clinical trial. *JAMA.*
31 2015;313(7):687-94.
- 32 Ebbert J, Croghan I, Hurt R, Schroeder D, Hays J. Varenicline for smoking cessation in light
33 smokers 2017; 18(10):[2031-5 pp.]. Available from:
34 <http://onlinelibrary.wiley.com/doi/10.1002/coc.1400>
- 35 Ehrensam RE, Buhler A, Muller P, Mauli D, Schumacher PM, Howald H, et al. [Weaning of
36 young smokers using a transdermal nicotine patch]. *Schweiz Rundsch Med Prax.*
37 1991;80(7):145-50.
- 38 Eisenberg MJ, Grandi SM, Gervais A, O'Loughlin J, Paradis G, Rinfret S, et al. Bupropion for
39 smoking cessation in patients hospitalized with acute myocardial infarction: a randomized,
40 placebo-controlled trial. *J Am Coll Cardiol.* 2013;61(5):524-

- 1 Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for Smoking
2 Cessation in Hospitalized Patients With Acute Coronary Syndrome. *Circulation*.
3 2016;133(1):21-30.
- 4 Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added
5 to cognitive behavioral therapy for smoking cessation in schizophrenia. *Nicotine Tob Res*.
6 2001;3(4):397-403.
- 7 Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, et al.
8 A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation
9 in schizophrenia. *J Clin Psychopharmacol*. 2005;25(3):218-25.
- 10 Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, et al. A 12-week double-
11 blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement
12 therapy for smoking cessation or reduction in schizophrenia. *J Clin Psychopharmacol*.
13 2007;27(4):380-6.
- 14 Fagerstrom KO. A comparison of psychological and pharmacological treatment in smoking
15 cessation. *J Behav Med*. 1982;5(3):343-51.
- 16 Fernandez Arias IG, Garcia-Vera MP, Sanz J. The more psychology, the better: The efficacy
17 of smoking cessation treatment using intensive cognitive-behavioral therapy versus a
18 combination of nicotine patches plus intensive or less intensive cognitive-behavioral therapy:
19 First prize of the 20th "Rafael Burgaleta" Applied Psychology Awards 2013. *Clinica y Salud*.
20 2014;25(1):1-10.
- 21 Ferry LH, Robbins AS, Scariati PD, Masterson A, Abbey DE, Burchette RJ. Enhancement of
22 smoking cessation using the antidepressant bupropion hydrochloride [abstract 2670].
23 *Circulation*. 1992;86(4 Suppl 1):I-671.
- 24 Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the
25 clinical effectiveness of the nicotine patch with different counseling treatments. *Chest*.
26 1994;105(2):524-33.
- 27 Fossati R, Apolone G, Negri E, Compagnoni A, La Vecchia C, Mangano S, et al. A double-
28 blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary
29 care. *Arch Intern Med*. 2007;167(16):1791-7.
- 30 George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, et al. A
31 placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in
32 schizophrenia. *Biol Psychiatry*. 2008;63(11):1092-6.
- 33 Gifford EV, Kohlenberg BS, Hayes SC, Antonuccio DO, Piasecki MM, Rasmussen-Hall ML,
34 et al. Acceptance-based treatment for smoking cessation. *Behavior Therapy*.
35 2004;35(4):689-705.
- 36 Glavas D, Rumboldt Z. [Smoking cessation using the transdermal nicotine system]. *Lijec*
37 *Vjesn*. 2003;125(1-2):8-12.
- 38 GlaxoSmithKline. Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in
39 Smoking Cessation. <https://ClinicalTrials.gov/show/NCT00985985>; 2009.

- 1 Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, et al. Bupropion SR
2 as an aid to smoking cessation in smokers treated previously with bupropion: a randomized
3 placebo-controlled study. *Clin Pharmacol Ther.* 2001;69(6):438-44.
- 4 Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an
5 alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion
6 and placebo for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):47-55.
- 7 Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, et al. Retreatment with
8 varenicline for smoking cessation in smokers who have previously taken varenicline: a
9 randomized, placebo-controlled trial. *Clin Pharmacol Ther.* 2014;96(3):390-6.
- 10 Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated
11 treatment with transdermal nicotine for relapsed smokers. *BMJ.* 1995;311(7001):363-6.
- 12 Gross J, Johnson J, Sigler L, Stitzer ML. Dose effects of nicotine gum. *Addict Behav.*
13 1995;20(3):371-81.
- 14 Haggstram FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC. A
15 controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking
16 cessation: preliminary results. *Pulm Pharmacol Ther.* 2006;19(3):205-9.
- 17 Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A Randomized
18 Trial of E-Cigarettes versus Nicotine-Replacement Therapy. *N Engl J Med.* 2019;380(7):629-
19 37.
- 20 Hall SM, Tunstall C, Rugg D, Jones RT, Benowitz N. Nicotine gum and behavioral treatment
21 in smoking cessation. *J Consult Clin Psychol.* 1985;53(2):256-8.
- 22 Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, Jones RT. Nicotine gum and behavioral
23 treatment: a placebo controlled trial. *J Consult Clin Psychol.* 1987;55(4):603-5.
- 24 Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological
25 intervention and antidepressant treatment in smoking cessation. *Arch Gen Psychiatry.*
26 2002;59(10):930-6.
- 27 Hall SM, Tsoh JY, Prochaska JJ, Eisendrath S, Rossi JS, Redding CA, et al. Treatment for
28 cigarette smoking among depressed mental health outpatients: a randomized clinical trial.
29 *Am J Public Health.* 2006;96(10):1808-14.
- 30 Halpern SD, Harhay MO, Saulsgiver K, Brophy C, Troxel AB, Volpp KG. A Pragmatic Trial of
31 E-Cigarettes, Incentives, and Drugs for Smoking Cessation. *N Engl J Med.*
32 2018;378(24):2302-10.
- 33 Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine
34 replacement treatment in hospital patients also given advice and support. *Thorax.*
35 2002;57(8):715-8.
- 36 Hanioka T, Ojima M, Tanaka H, Naito M, Hamajima N, Matsuse R. Intensive smoking-
37 cessation intervention in the dental setting. *J Dent Res.* 2010;89(1):66-70.

- 1 Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN. Nicotine gum and self-help
2 manuals in smoking cessation: an evaluation in a medical context. *Addict Behav.*
3 1988;13(4):319-30.
- 4 Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, et al. Effects of
5 sustained-release bupropion among persons interested in reducing but not quitting smoking.
6 *Am J Med.* 2004;116(3):151-7.
- 7 Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter
8 nicotine patch therapy for smoking cessation: results from randomized, double-blind,
9 placebo-controlled, and open label trials. *Am J Public Health.* 1999;89(11):1701-7.
- 10 Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom KO. Nicotine gum, 2 and
11 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior
12 modification support program. *Chest.* 1995;108(2):447-51.
- 13 Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion
14 sustained-release for smoking cessation in patients with chronic posttraumatic stress
15 disorder. *J Clin Psychopharmacol.* 2001;21(1):94-8.
- 16 Heydari G, Talischi F, Tafti SF, Masjedi MR. Quitting smoking with varenicline: parallel,
17 randomised efficacy trial in Iran. *Int J Tuberc Lung Dis.* 2012;16(2):268-72.
- 18 Heydari G, Talischi F, Batmanghelidj E, Pajoo M, Boroomand A, Zamani M, et al. Dual
19 addictions, parallel treatments: Nicotine replacement therapy for patients receiving
20 methadone treatment in the Islamic Republic of Iran 2013. Available from:
21 <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/288/CN-00911288/frame.html>.
- 22 Hjalmarson AI. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-
23 controlled, double-blind study. *JAMA.* 1984;252(20):2835-8.
- 24 Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking
25 cessation. A randomized, placebo-controlled, double-blind study. *Arch Intern Med.*
26 1994;154(22):2567-72.
- 27 Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O. The nicotine inhaler in smoking cessation.
28 *Arch Intern Med.* 1997;157(15):1721-8.
- 29 Holliday Richard, Preshaw Philip M, Ryan Vicky, Sniehotta Falko F, McDonald Suzanne,
30 Bauld Linda, and McColl Elaine (2019) A feasibility study with embedded pilot randomised
31 controlled trial and process evaluation of electronic cigarettes for smoking cessation in
32 patients with periodontitis. *Pilot and feasibility studies* 5, 74
- 33 Holt S, Timu-Parata C, Ryder-Lewis S, Weatherall M, Beasley R. Efficacy of bupropion in the
34 indigenous Maori population in New Zealand. *Thorax.* 2005;60(2):120-3.
- 35 Horst W, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to
36 maintain smoking cessation in persons with schizophrenia. *Neuropsychiatr Dis Treat.*
37 2005;1(4):349-55.

- 1 Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al.
2 Are higher doses of nicotine replacement more effective for smoking cessation? *Nicotine Tob*
3 *Res.* 1999;1(2):169-74.
- 4 Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. Efficacy of nicotine patch in
5 smokers with a history of alcoholism. *Alcohol Clin Exp Res.* 2003;27(6):946-54.
- 6 Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of
7 varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized
8 placebo-controlled trial. *Nicotine Tob Res.* 2011;13(10):955-64.
- 9 Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. Nicotine-Replacement Therapy with
10 Use of a Transdermal Nicotine Patch - a Randomized Double-Blind Placebo-Controlled Trial.
11 *Mayo Clinic Proceedings.* 1990;65(12):1529-37.
- 12 Jensen EJ, Schmidt E, Pedersen B, Dahl R. The effect of nicotine, silver acetate, and
13 placebo chewing gum on the cessation of smoking. The influence of smoking type and
14 nicotine dependence. *Int J Addict.* 1991;26(11):1223-31.
- 15 Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A
16 controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking
17 cessation. *N Engl J Med.* 1999;340(9):685-91.
- 18 Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus
19 delayed smoking intervention for patients in alcohol dependence treatment. *J Stud Alcohol.*
20 2004;65(6):681-91.
- 21 Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers
22 with a history of alcohol dependence: 36-week outcomes. *J Subst Abuse Treat.*
23 2006;30(3):213-7.
- 24 Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, et al. Incremental efficacy
25 of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent
26 history of alcohol dependence: results from a randomized, double-blind, placebo-controlled
27 study. *Drug Alcohol Depend.* 2011;118(2-3):111-8.
- 28 Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach
29 combining nicotine gum with self-guided behavioral treatments for smoking relapse
30 prevention. *J Consult Clin Psychol.* 1990;58(1):85-92.
- 31 Killen JD, Fortmann SP, Davis L, Varady A. Nicotine patch and self-help video for cigarette
32 smoking cessation. *J Consult Clin Psychol.* 1997;65(4):663-72.
- 33 Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from
34 higher dose nicotine patch therapy? *Experimental and Clinical Psychopharmacology.*
35 1999;7(3):226-33.
- 36 Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al.
37 Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for
38 smoking cessation: a randomized clinical trial. *JAMA.* 2014;312(2):155-61.

- 1 Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch
2 and gum in smoking cessation: a placebo-controlled clinical trial. *Prev Med.* 1995;24(1):41-7.
- 3 Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for
4 perioperative smoking cessation: a pilot randomized trial. *PeerJ.* 2018;6:e5609.
- 5 Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. Efficacy of the nicotine inhaler
6 as an adjunct to smoking cessation. *American Journal of Health Behavior.* 1996;20(5):364-
7 71.
- 8 Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al.
9 Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a
10 randomized trial. *Ann Intern Med.* 2004;140(6):426-33.
- 11 Lerman C, Schnoll RA, Hawk LW, Jr., Cinciripini P, George TP, Wileyto EP, et al. Use of the
12 nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or
13 varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.
14 *Lancet Respir Med.* 2015;3(2):131-8.
- 15 Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, et al. Bupropion and
16 cognitive behavioral therapy for weight-concerned women smokers. *Arch Intern Med.*
17 2010;170(6):543-50.
- 18 Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB. Transdermal nicotine
19 replacement for hospitalized patients: a randomized clinical trial. *Prev Med.* 1998;27(2):296-
20 303.
- 21 Llivina TS, Tuya DM, Quintana JG, Torres CI, Barrera EC, Saez CM, et al. Smoking
22 Cessation - Effectiveness of Nicotine Containing Chewing Gum - a Double-Blind Trial.
23 *Medicina Clinica.* 1988;90(16):646-50.
- 24 Malcolm RE, Sillett RW, Turner JA, Ball KP. The use of nicotine chewing gum as an aid to
25 stopping smoking. *Psychopharmacology (Berl).* 1980;70(3):295-6.
- 26 Masiero M, Lucchiari C, Mazzocco K, Veronesi G, Maisonneuve P, Jemos C, et al. E-
27 cigarettes May Support Smokers With High Smoking-Related Risk Awareness to Stop
28 Smoking in the Short Run: Preliminary Results by Randomized Controlled Trial. *Nicotine Tob*
29 *Res.* 2019;21(1):119-26.
- 30 McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A
31 randomized controlled clinical trial of bupropion SR and individual smoking cessation
32 counseling. *Nicotine Tob Res.* 2008;10(4):717-29.
- 33 Mori T STYGNMHT. A clinical trial of nicotine chewing gum for smoking cessation [abstract
34 428]. 1992.
- 35 Myles PS, Leslie K, Angliss M, Mezzavia P, Lee L. Effectiveness of bupropion as an aid to
36 stopping smoking before elective surgery: a randomised controlled trial. *Anaesthesia.*
37 2004;59(11):1053-8.

- 1 Nahvi S, Ning Y, Segal KS, Richter KP, Arnsten JH. Varenicline efficacy and safety among
2 methadone maintained smokers: a randomized placebo-controlled trial. *Addiction*.
3 2014;109(9):1554-63.
- 4 Nakamura M, J. S, A. O, M. M, A. M, S. E. Effect of nicotine chewing gun in smoking
5 cessation classes. *The Global War*. 1990:665–7.
- 6 Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and
7 tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a
8 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for
9 smoking cessation in Japanese smokers. *Clin Ther*. 2007;29(6):1040-56.
- 10 Niaura R, Goldstein MG, Abrams DB. Matching high- and low-dependence smokers to self-
11 help treatment with or without nicotine replacement. *Prev Med*. 1994;23(1):70-7.
- 12 Niaura R, Abrams DB, Shadel WG, Rohsenow DJ, Monti PM, Sirota AD. Cue exposure
13 treatment for smoking relapse prevention: a controlled clinical trial. *Addiction*.
14 1999;94(5):685-95.
- 15 Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. The efficacy and
16 safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers:
17 a randomized controlled trial. *Curr Med Res Opin*. 2008;24(7):1931-41.
- 18 Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking
19 cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results
20 from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
21 *Arch Intern Med*. 2006;166(15):1561-8.
- 22 Nides M, Danielsson T, Saunders F, Perfekt R, Kapikian R, Solla J, et al. Efficacy and safety
23 of a nicotine mouth spray for smoking cessation; a randomized, multicenter, controlled study
24 in a naturalistic setting. *Nicotine Tob Res*. 2018;18:18.
- 25 Okuyemi KS, James AS, Mayo MS, Nollen N, Catley D, Choi WS, et al. Pathways to health:
26 a cluster randomized trial of nicotine gum and motivational interviewing for smoking
27 cessation in low-income housing. *Health Educ Behav*. 2007;34(1):43-54.
- 28 Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-
29 controlled study of transdermal nicotine patch for smoking cessation. *J Formos Med Assoc*.
30 1998;97(8):547-51.
- 31 Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of
32 bupropion alone and in combination with nicotine gum. *Nicotine Tob Res*. 2007;9(9):947-54.
- 33 Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized
34 placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen*
35 *Psychiatry*. 2009;66(11):1253-62.
- 36 Pirie PL, McBride CM, Hellerstedt W, Jeffery RW, Hatsukami D, Allen S, et al. Smoking
37 cessation in women concerned about weight. *Am J Public Health*. 1992;82(9):1238-43.

- 1 Puska P, Korhonen HJ, Vartiainen E, Urjanheimo EL, Gustavsson G, Westin A. Combined
2 use of nicotine patch and gum compared with gum alone in smoking cessation - a clinical
3 trial in North Karelia. *Tobacco Control*. 1995;4(3):231-5.
- 4 Quilez Garcia C, Hernando Arizaleta L, Rubio Diaz A, Granero Fernandez EJ, Vila Coll MA,
5 Estruch Riba J. [Double-blind study of the efficacy of nicotine chewing gum for smoking
6 cessation in the primary care setting]. *Aten Primaria*. 1989;6(10):719-26.
- 7 Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine
8 patches: a randomized controlled trial study in smoking cessation. *BMC Med*.
9 2014;12(172):172.
- 10 Ratner PA, Johnson JL, Richardson CG, Bottorff JL, Moffat B, Mackay M, et al. Efficacy of a
11 smoking-cessation intervention for elective-surgical patients. *Res Nurs Health*.
12 2004;27(3):148-61.
- 13 Reid MS, Fallon B, Sonne S, Flammino F, Nunes EV, Jiang H, et al. Smoking cessation
14 treatment in community-based substance abuse rehabilitation programs. *J Subst Abuse*
15 *Treat*. 2008;35(1):68-77.
- 16 Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A
17 randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit
18 dates. *Nicotine Tob Res*. 2012;14(3):343-50.
- 19 Richmond RL, Makinson RJ, Kehoe LA, Giugni AA, Webster IW. One-year evaluation of
20 three smoking cessation interventions administered by general practitioners. *Addict Behav*.
21 1993;18(2):187-99.
- 22 Richmond RL, Harris K, Dealmeidaneto A. The Transdermal Nicotine Patch - Results of a
23 Randomized Placebo-Controlled Trial. *Medical Journal of Australia*. 1994;161(2):130-&.
- 24 Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of
25 varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.
26 *Circulation*. 2010;121(2):221-9.
- 27 Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, et al. Varenicline versus
28 nicotine patch with brief advice for smokers with substance use disorders with or without
29 depression: effects on smoking, substance use and depressive symptoms. *Addiction*.
30 2017;112(10):1808-20.
- 31 Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to
32 precessation nicotine patch. *Am J Psychiatry*. 2013;170(8):860-7.
- 33 Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-Hour Transdermal Nicotine Patch
34 in a Medical-Practice Setting, without Intensive Group-Counseling. *Archives of Internal*
35 *Medicine*. 1993;153(16):1881-90.
- 36 Schmitz JM, Stotts AL, Mooney ME, Delaune KA, Moeller GF. Bupropion and cognitive-
37 behavioral therapy for smoking cessation in women. *Nicotine Tob Res*. 2007;9(6):699-709.

- 1 Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in
2 smoking cessation: a placebo-controlled, double-blind trial. *Addict Behav.* 1983;8(3):253-61.
- 3 Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, et al. Efficacy of a
4 nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. *Addiction.*
5 1995;90(12):1671-82.
- 6 Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine
7 inhaler in smoking cessation: a double-blind, placebo-controlled trial. *Addiction.*
8 1996;91(9):1293-306.
- 9 Schnoll RA, Martinez E, Tatum KL, Weber DM, Kuzla N, Glass M, et al. A bupropion smoking
10 cessation clinical trial for cancer patients. *Cancer Causes Control.* 2010;21(6):811-20.
- 11 Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness
12 of extended-duration transdermal nicotine therapy: a randomized trial. *Ann Intern Med.*
13 2010;152(3):144-51.
- 14 Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, et al. Nicotine patch vs.
15 nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community
16 Clinical Oncology Program. *Drug Alcohol Depend.* 2010;107(2-3):237-43.
- 17 Segnan N, Ponti A, Battista RN, Senore C, Rosso S, Shapiro SH, et al. A randomized trial of
18 smoking cessation interventions in general practice in Italy. *Cancer Causes Control.*
19 1991;2(4):239-46.
- 20 Selma Bozkurt Z, Serkan Z, Esra K, Esra Aydin S. Comparison of the effectiveness of
21 varenicline, extended-release bupropion and nicotine replacement therapy on the success
22 and the maintenance of a smoking cessation program. *Klinik Psikofarmakoloji Bulteni-*
23 *Bulletin of Clinical Psychopharmacology.* 2013;23(3):224-30.
- 24 Sharma SK, Mohan A, Singh AD, Mishra H, Jhanjee S, Pandey RM, et al. Impact of nicotine
25 replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change
26 counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised
27 controlled trial. *Sci Rep.* 2018;8(1):8828.
- 28 Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine
29 gum: a randomized controlled trial. *Am J Prev Med.* 2009;36(2):96-104 e1.
- 30 Shiffman Saul, Scholl Sarah M, Mao Jason, Ferguson Stuart G, Hedeker Donald, Primack
31 Brian, and Tindle Hilary A (2019) Using nicotine gum to assist non-daily smokers in quitting:
32 A randomized clinical trial. *Nicotine & tobacco research : official journal of the Society for*
33 *Research on Nicotine and Tobacco.*
- 34 Siddiqi K, Khan A, Ahmad M, Dogar O, Kanaan M, Newell JN, et al. Action to stop smoking
35 in suspected tuberculosis (ASSIST) in Pakistan: a cluster randomized, controlled trial. *Ann*
36 *Intern Med.* 2013;158(9):667-75.
- 37 Simon JA, Duncan C, Huggins J, Solkowitz S, Carmody TP. Sustained-release bupropion for
38 hospital-based smoking cessation: a randomized trial. *Nicotine Tob Res.* 2009;11(6):663-9.

- 1 SMK20001: A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized,
2 Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN
3 (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to
4 Smoking Cessation.
- 5 Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Dose
6 effects and predictors of outcome in a randomized trial of transdermal nicotine patches in
7 general practice. *Addiction*. 1995;90(1):31-42.
- 8 Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking
9 cessation among methadone-maintained smokers: a randomized clinical trial. *Drug Alcohol*
10 *Depend*. 2013;133(2):486-93.
- 11 Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-
12 combination pharmacotherapy for medically ill smokers: a randomized trial. *Ann Intern Med*.
13 2009;150(7):447-54.
- 14 Stockings EA, Bowman JA, Baker AL, Terry M, Clancy R, Wye PM, et al. 2014 world
15 congress abstracts, 3-6 december 2014, melbourne, australia. *Asia Pac J Clin Oncol*.
16 2014;10 Suppl 9:1-263.
- 17 Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, et al. Randomized
18 Controlled Trial of Nasal Nicotine Spray in Smoking Cessation. *Lancet*. 1992;340(8815):324-
19 9.
- 20 Swanson NA, Burroughs CC, Long MA, Lee RW. Controlled trial for smoking cessation in a
21 navy shipboard population using nicotine patch, sustained-release bupropion, or both.
22 *Military Medicine*. 2003;168(10):830-4.
- 23 Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in
24 patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled,
25 randomised trial. *Lancet*. 2001;357(9268):1571-5.
- 26 Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on
27 smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.
28 *Chest*. 2011;139(3):591-9.
- 29 Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a
30 nicotine inhaler for smoking cessation. *JAMA*. 1993;269(10):1268-71.
- 31 Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher
32 dosage nicotine patches increase one-year smoking cessation rates: results from the
33 European CEASE trial. Collaborative European Anti-Smoking Evaluation. *European*
34 *Respiratory Society*. *Eur Respir J*. 1999;13(2):238-46.
- 35 Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a
36 lung clinic. *Eur Respir J*. 2000;16(4):717-22.
- 37 Tonnesen P, Tonstad S, Hjalmarson A, Leborgy F, Van Spiegel PI, Hider A, et al. A
38 multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for
39 smoking cessation. *J Intern Med*. 2003;254(2):184-92.

- 1 Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with
2 COPD using nicotine sublingual tablets and behavioral support. *Chest*. 2006;130(2):334-42.
- 3 Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in
4 smoking cessation: a randomised, double-blind trial. *Eur Respir J*. 2012;40(3):548-54.
- 5 Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR
6 for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised
7 study. *Eur Heart J*. 2003;24(10):946-55.
- 8 Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of
9 maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
10 *JAMA*. 2006;296(1):64-71.
- 11 Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Jr., et al. A randomized,
12 placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor
13 partial agonist, as a new therapy for smoking cessation in Asian smokers. *Clin Ther*.
14 2007;29(6):1027-39.
- 15 Tseng TY, Ostroff JS, Campo A, Gerard M, Kirchner T, Rotrosen J, et al. A Randomized Trial
16 Comparing the Effect of Nicotine Versus Placebo Electronic Cigarettes on Smoking
17 Reduction Among Young Adult Smokers. *Nicotine Tob Res*. 2016;18(10):1937-43.
- 18 Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, dual-form nicotine replacement
19 therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized
20 controlled trial. *BMC Med*. 2016;14(80):80.
- 21 Uyar M, Filiz A, Bayram N, Elbek O, Herken H, Topcu A, et al. A randomized trial of smoking
22 cessation. Medication versus motivation. *Saudi Med J*. 2007;28(6):922-6.
- 23 Vial RJ, Jones TE, Ruffin RE, Gilbert AL. Smoking cessation program using nicotine patches
24 linking hospital to the community. *Journal of Pharmacy Practice and Research*.
25 2002;32(1):57-62.
- 26 Wagena EJ, Knipschild PG, Huibers MJH, Wouters EFM, Schayck CPR. Efficacy of
27 bupropion and nortriptyline for smoking cessation among people who are at risk for or have
28 chronic obstructive pulmonary disease: Results from a randomized, placebo-controlled trial.
29 *Nicotine & Tobacco Research*. 2005;7(4):683-4.
- 30 Walker Natalie, Parag Varsha, Verbiest Marjolein, Laking George, Laugesen Murray, and
31 Bullen Christopher (2019) Nicotine patches used in combination with e-cigarettes (with and
32 without nicotine) for smoking cessation: a pragmatic, randomised trial. *The Lancet*.
33 *Respiratory medicine*.
- 34 Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical
35 evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction*. 2000;95(8):1161-
36 71.
- 37 Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking
38 cessation: a placebo-controlled, randomized study. *Respirology*. 2009;14(3):384-92.

- 1 Westergaard CG, Porsbjerg C, Backer V. The effect of Varenicline on smoking cessation in a
2 group of young asthma patients. *Respir Med*. 2015;109(11):1416-22.
- 3 Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized
4 trial with telephone counseling. *Arch Intern Med*. 1993;153(16):1917-23.
- 5 Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, et al. A
6 randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of
7 varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. *J*
8 *Clin Psychiatry*. 2012;73(5):654-60.
- 9 Winhusen TM, Brigham GS, Kropp F, Lindblad R, Gardin JG, 2nd, Penn P, et al. A
10 randomized trial of concurrent smoking-cessation and substance use disorder treatment in
11 stimulant-dependent smokers. *J Clin Psychiatry*. 2014;75(4):336-43.
- 12 Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of
13 naltrexone for smoking cessation. *Addiction*. 1999;94(8):1227-37.
- 14 Zellweger JP, Boelcskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ. Bupropion SR vs
15 placebo for smoking cessation in health care professionals. *Am J Health Behav*.
16 2005;29(3):240-9.
- 17 Zernig G, Wallner R, Grohs U, Kriechbaum N, Kemmler G, Saria A. A randomized trial of
18 short psychotherapy versus sustained-release bupropion for smoking cessation. *Addiction*.
19 2008;103(12):2024-31.
- 20 ZYB40005: The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking
21 reduction leading to cessation among smokers unwilling and unable to quit smoking.

22

